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Polyomaviruses (PyVs) are ubiquitous DNA viruses that are not generally associated with 
pathogenicity.  However, in immunosuppressed populations, PyVs can cause diseases, including 
BK Virus associated nephropathy, hemorrhagic cystitis and progressive multifocal 
leukoencephalopathy.  There is currently no PyV specific inhibitor for these diseases.  Because 
all PyVs express a conserved large T antigen (TAg) that is essential for viral replication, I 
hypothesized that inhibitors of the model TAg from Simian Virus 40 (SV40) would inhibit the 
replication of PyVs in general.  TAg has multiple essential activities, but my work focused on the 
ATPase activity of TAg, which provides the helicase activity during viral replication.  Two high 
throughput screens were performed on purified TAg to identify inhibitors of TAg ATPase 
activity.  In the first screen, a quinaldine red screen of the MS2000 library of commercially 
available compounds identified the FDA approved compounds bithionol and hexachlorophene as 
inhibitors of the ATPase activity of TAg.  The structure activity relationship of these bisphenols 
was refined, and the results suggested that inhibition of TAg was unique to these compounds, 
and is not a general feature of bisphenols.  The compounds also inhibited SV40 DNA replication 
and infection, and are the most potent SV40 inhibitors reported.  Surprisingly, bithionol and 
hexachlorophene inhibit replication of the clinically relevant PyV BK Virus (BKV), but not to 
the same extent. 
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In the second screen, which employed the ADP Hunter assay and the NIH Molecular 
Libraries Probe Centers Network (MLPCN) compound library, three scaffolds of interest were 
identified.  However, all three had limited potency when characterized in other in vitro assays.  
Chemical refinement of these scaffolds identified another bisphenol that inhibits TAg activity 
and TAg dependent DNA replication in vitro.  Unfortunately, the known cytotoxicity of this 
compound limits its use as a therapeutic.  Although I have not yet identified a PyV specific 
inhibitor that would be a suitable therapeutic, this work supports my overall hypothesis: small 
molecules that inhibit the ATPase activity of TAg reduce viral DNA replication, and viral 
infection. My work has also provided valuable insights to design future screens to identify 
inhibitors of PyV replication. 
 
 vi 
TABLE OF CONTENTS 
PREFACE ................................................................................................................................. XIV 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 THE BIOLOGY OF POLYOMAVIRUSES ..................................................... 1 
1.1.1 Life cycle ........................................................................................................... 2 
1.1.2 Early region ...................................................................................................... 6 
1.1.3 Late region........................................................................................................ 7 
1.1.4 The family of Polyomaviruses ........................................................................ 8 
1.2 POLYOMAVIRUSES AS TOOLS IN MOLECULAR BIOLOGY ............. 12 
1.2.1 Characterization of cellular transformation and tumorigenesis ............... 13 
1.2.2 Insights in viral and eukaryotic DNA replication ...................................... 15 
1.2.3 Other activities essential for functional TAg expression: Splicing and 
Nuclear Localization .................................................................................................. 18 
1.3 LARGE T ANTIGEN ........................................................................................ 19 
1.3.1 J domain and molecular chaperone activity ............................................... 32 
1.3.2 Binding and inactivating the Rb family ....................................................... 33 
1.3.3 DNA binding domain..................................................................................... 34 
1.3.4 AAA+ ATPase and associated activities ...................................................... 35 
1.3.5 Binding and misregulation of p53 ................................................................ 37 
 vii 
1.3.6 Host range domain......................................................................................... 38 
1.3.7 Differences between TAgs ............................................................................. 39 
1.4 POLYOMAVIRUSES AND HUMAN DISEASE ........................................... 40 
1.4.1 Disease in immunocompetent patients ......................................................... 41 
1.4.1.1 SV40...................................................................................................... 41 
1.4.1.2 Other PyVs........................................................................................... 42 
1.4.2 Known disease in immunosuppressed patients ........................................... 42 
1.4.2.1 BKV ...................................................................................................... 43 
1.4.2.2 JCV ....................................................................................................... 44 
1.4.2.3 MCPyV ................................................................................................. 45 
1.4.2.4 TSV ....................................................................................................... 46 
1.4.2.5 Current treatment options for PyV-related diseases ....................... 46 
1.4.3 Linking recently discovered PyVs to disease .............................................. 49 
1.5 PERSPECTIVES ............................................................................................... 50 
1.6 DISSERTATION OVERVIEW ....................................................................... 51 
2.0 HIGH THROUGHPUT SCREENING IDENTIFIES BISPHENOL 
INHIBITORS OF POLYOMAVIRUS REPLICATION. ....................................................... 53 
2.1 INTRODUCTION ............................................................................................. 53 
2.2 MATERIALS AND METHODS ...................................................................... 56 
2.2.1 Materials ......................................................................................................... 56 
2.2.2 A high throughput screen to identify inhibitors of TAg ATPase activity ....  
  ......................................................................................................................... 57 
2.2.3 Biochemical and kinetic assays to assess TAg activity ............................... 58 
 viii 
2.2.4 Viral replication and cell culture assays ...................................................... 61 
2.2.5 In silico chemical similarity searches ........................................................... 65 
2.3 RESULTS ........................................................................................................... 66 
2.3.1 Identification of bisphenols that inhibit TAg ATP hydrolysis .................. 66 
2.3.2 A structure-activity relationship for bisphenol-like TAg ATPase 
inhibitors ..................................................................................................................... 74 
2.3.3 Bithionol and hexachlorophene have off target effects on hsp70 and p97 ...  
  ......................................................................................................................... 77 
2.3.4 Bithionol and hexachlorophene inhibit SV40 replication .......................... 80 
2.3.5 Bithionol and hexachlorophene inhibit BKV replication .......................... 94 
2.4 DISCUSSION ................................................................................................... 100 
3.0 HIGH THROUGHPUT SCREENING IDENTIFIES A BISPHENOL 
INHIBITOR OF SV40 LARGE T-ANTIGEN ATPASE ACTIVITY. ................................ 106 
3.1 INTRODUCTION ........................................................................................... 106 
3.2 MATERIALS AND METHODS .................................................................... 109 
3.2.1 Recombinant TAg expression and purification ........................................ 109 
3.2.2 Expression and purification of PAb419 from hybridoma cells ............... 110 
3.2.3 Screening Assay Validation Conditions ..................................................... 111 
3.2.4 Pilot and Primary Assay Conditions .......................................................... 112 
3.2.5 Counter-Screens for cytotoxicity and assay interference ........................ 113 
3.2.6 DNA replication assays ............................................................................... 113 
3.2.7 Cell Culture .................................................................................................. 114 
3.2.8 Preparation of SV40 .................................................................................... 114 
 ix 
3.2.9 Cytoprotection assays .................................................................................. 115 
3.2.10 Compound handling for the HTS effort ................................................... 115 
3.2.11 Data acquisition and analysis .................................................................... 115 
3.2.12 Compound acquisition and/or synthesis ................................................... 116 
3.3 RESULTS ......................................................................................................... 117 
3.3.1 Improving TAg purification protocol ........................................................ 117 
3.3.2 Primary Assay Development and Validation ............................................ 122 
3.3.3 Pilot and Primary Screening ...................................................................... 125 
3.3.4 Assay Hit Characterization by Secondary Assays .................................... 128 
3.3.5 Analog design and syntheses ....................................................................... 132 
3.4 DISCUSSION ................................................................................................... 136 
4.0 CONCLUSIONS AND PERSPECTIVES ............................................................. 140 
4.1 COMPARISON OF THE SCREENING METHODS USED AND OTHER 
APPLICATIONS OF THIS APPROACH ..................................................................... 141 
4.2 FURTHER UTILITY FOR THE GENERATED SCREENING DATA .... 144 
4.3 APPLICATIONS OF THE IDENTIFIED POLYOMAVIRUS INHIBITORS 
  ........................................................................................................................... 146 
4.4 REFINEMENT OF THE HYPOTHESIS: INHIBITORS OF SV40 TAG 
MAY INHIBIT REPLICATION OF OTHER PYVS, BUT WITH DIFFERENT 
POTENCIES ..................................................................................................................... 151 
4.5 RECOMMENDATIONS FOR FURTHER IDENTIFICATION OF PYV 
INHIBITORS AND THERAPEUTICS .......................................................................... 153 
4.6 SUMMARY AND CONCLUSIONS .............................................................. 156 
 x 
APPENDIX A ............................................................................................................................ 157 
APPENDIX B ............................................................................................................................ 164 
BIBLIOGRAPHY ..................................................................................................................... 170 
 xi 
 LIST OF TABLES 
 
Table 1.  Viral proteins encoded by SV40 and their functions. ...................................................... 5 
Table 2. Percent identity by pairwise alignment of full length TAgs and specific domains. ....... 20 
Table 3.  Summary of reported SV40 TAg interacting proteins and their predicted functions. ... 24 
Table 4.  Commonly used therapeutics and the dosages for PyV-related diseases. ..................... 47 
Table 5.  MI50 and Therapeutic index for bithionol and hexachlorophene. .................................. 85 
Table 6. Bithionol and hexachlorophene change the Km of TAg ATP hydrolysis. ...................... 93 
Table 7.  Titers of BKV stocks as determined by immunofluorescence. ..................................... 97 
Table 8.  Notes from TAg purification during optimization. ...................................................... 121 
Table 9.  Summary of the TAg ATPase HTS assay pilot validation and primary screen. ......... 126 
Table 10. A structure activity relationship for bisphenol A and analogues. ............................... 135 
Table 11.  Summary of hit coincidence of TAg ATPase inhibitors............................................ 138 
 xii 
LIST OF FIGURES 
 
Figure 1. Genome map of SV40. .................................................................................................... 3 
Figure 2. Alignment of the clinically relevant TAgs, displayed by domain. ................................ 22 
Figure 3.  Domain map of TAg and crystal structures of three domains. ..................................... 31 
Figure 4. Development of a high throughput screen for TAg ATPase inhibitors......................... 69 
Figure 5. A high throughput screen identifies inhibitors of TAg ATPase activity. ...................... 72 
Figure 6. Chloranil cause TAg aggregation in vitro ..................................................................... 73 
Figure 7. A structure activity relationship for the action of select bisphenols and bisphenol-like 
compounds for inhibition of TAg ATPase activity....................................................................... 76 
Figure 8. Bithionol and hexachlorophene are more potent inhibitors of hsp70 activity than 
MAL2-11B. ................................................................................................................................... 78 
Figure 9. Bithionol stimulates p97 ATPase activity while hexachlorophene inhibits p97. .......... 80 
Figure 10.  Bithionol and hexachlorophene inhibit SV40 replication. ......................................... 82 
Figure 11.  Bithionol and hexachlorophene do not inhibit DNA replication in vitro. .................. 84 
Figure 12. Expression of soluble TAg is decreased during treatment with bithionol and 
hexachlorophene. .......................................................................................................................... 87 
Figure 13. Limited proteolysis indicates bithionol and hexachlorophene do not cause TAg 
unfolding. ...................................................................................................................................... 90 
 xiii 
Figure 14. Example of Lineweaver Burk analysis of TAg with ATP and ADP. .......................... 92 
Figure 15. BKV TAg can be detected by immunofluorescence. .................................................. 95 
Figure 16. BKV DNA replication is inhibited by bithionol and hexachlorophene. ..................... 99 
Figure 17. Modifications to TAg purification protocol improve yield. ...................................... 120 
Figure 18. Comparison of assay sensitivity using the malachite green and ADP Hunter endpoint 
methods. ...................................................................................................................................... 124 
Figure 19. Compounds confirmed as active against SV40 TAg ATPase activity in a biochemical 
assay. ........................................................................................................................................... 129 
Figure 20. Specificity for TAg is demonstrated by TAg dependent in vitro DNA replication 
assays. ......................................................................................................................................... 130 
Figure 21. All three scaffolds inhibit TAg dependent in vitro DNA replication at high 
concentration, but to varying effects. .......................................................................................... 131 
Figure 22. Cytoprotection and cytotoxicity of TAg inhibitors. .................................................. 134 
Figure 23.  Stimulation of hsp70 ATPase activity is dependent on the TAg J domain in a single 
turnover ATPase assay. ............................................................................................................... 159 
Figure 24. MAL2-11B inhibits SV40 DNA replication. ............................................................ 161 
Figure 25. MAL2-11B reduces TAg expression without inducing apoptosis. ........................... 163 
Figure 26. Effect of MAL2-11B and the tetrazol derivative on TAg and BKV replication. ...... 167 
 xiv 
PREFACE 
This dissertation could not have come together without the enormous support and 
encouragement of my colleagues, friends and family.  I would need another 200 pages to 
quantify their many and splendid contributions to this process, and without listing you each by 
name, please accept my gratitude. 
 
I would like to first acknowledge the contributions of my boss and mentor Dr. Jeff 
Brodsky.  His role in my research and training has shaped both my experience and development 
as a graduate student and scientist.  His critical insights have strengthened this dissertation and 
helped me become a more competent writer.  I cannot thank him enough for the flexibility to 
develop many different aspects both of this project, but also my career at Pitt, including the 
unparalleled opportunity to design and teach my own course.  My experience in the Brodsky lab 
has given me the training I need for lifelong success for which I cannot express enough gratitude. 
Jeff designed a project that took advantage of the collaborative nature of our department, 
and as a result, I benefitted from the knowledge and experience of Dr. Jim Pipas and his lab.  
Jim’s influence on my research and education has given me both the passion and expertise to 
succeed in this endeavor.  He has also granted me the essential opportunity to share in his lab 
meeting, which proved to be an essential venue for training and developing the important 
relationships that helped me through innumerable challenges.  Without the expertise and 
 xv 
institutional memory of both Paul Cantalupo and Mayte Saenz Robles, this work would no doubt 
have languished.  Abhilasha Rathi and Nicole Seneca helped me to design formative experiments 
and provided essential feedback on this dissertation.  I am so grateful to the past and present 
members of the lab for their reagents, protocols or feedback over the years. 
Another unparalleled benefit of working in the Brodsky lab was the chance to work with 
his crew of fantastic scientists.  Alex Ireland, an undergraduate, has worked with me since 2007 
and provided some essential experiments discussed below.  Thank goodness I had him to share 
my TAg woes with and that he was so forgiving of my laissez faire attitude towards 
organization.  Thanks to World’s Greatest Lab Manager, Jen Goeckeler, I never fully understood 
the designs that keep the lab up and running.  The post-docs in the lab, Annette Chiang, Chris 
Guerriero, Patrick Needham, and especially Teresa Buck and Cristy Gelling, have provided 
insights, cookies and cocktails as needed.  Karen Hecht kept me in school and taught me to love 
gin, for which I am forever indebted.  My fellow graduate students, Sarah Grubb, Alex Kolb, Joe 
Tran, Stacy Hrizo and Shruthi Vembar have been encouraging and helped to celebrate both the 
milestones and setbacks.  I must particularly acknowledge the mentorship of Christine Wright 
who provided the groundwork for this dissertation, pounds of protocols and troubleshooting by 
phone or email.  Many thanks to the past and present members of the lab for their technical and 
emotional contributions. 
My family has always had every confidence in my success, which has proven an essential 
source of strength.  Many thanks to my parents and grandparents for never questioning that this 
is where I belong, and for encouraging me to excel.  I can’t begin to acknowledge the unending 
support from my husband, Matt, who has juggled every aspect of these last 5 years with patience 
and compassion, kept me fed and from getting evicted. I must also express my deepest gratitude 
 xvi 
and affection my modern family, Shaoshu Jiang, Jessi Board and Wade Znosko for their joyous 
distractions and being such important people in my life.   
I’d like to express my gratitude for the supportive community that developed as a result 
of the Women in Science Careers (WISC) meetings for encouraging my professional 
development.  I also want to thank the co-op members of the Union Project for providing an 
encouraging learning environment that gave me the patience to return to the bench after comps.  
My sincere thanks to Dr. Space for encouraging me to use my own definition of success.  I 
would also like to acknowledge the Silversun Pickups, Ratatat, and RjD2, without whom, this 
dissertation could not have been written.  Finally, I must express my gratitude for the wonderful 
Pitt Libraries for providing many of the resources used in this document. 
  1 
1.0  INTRODUCTION 
When the work described in this dissertation was initiated in 2007, there was sufficient evidence 
that the diseases caused by the polyomaviruses BK Virus (BKV) and JC Virus (JCV) were in 
need of anti-virals.  Fortunately, more than half a century of work studying Simian Virus 40 
(SV40), the model polyomavirus, presented us with the necessary molecular and cellular tools 
to approach this need aggressively using high throughput techniques.  During this time, an 
additional 7 human polyomaviruses have been described, some of which have been shown to 
cause disease.  Therefore, what we know about polyomavirus biology has become increasingly 
relevant, and future investigations of these viruses may give us new insight into the basic 
biology that drives the replication of disease-associated polyomaviruses. 
1.1 THE BIOLOGY OF POLYOMAVIRUSES 
Polyomaviruses (PyVs) are small, double-stranded DNA viruses (Cole, 1996; Fanning et al., 
2009; Pipas, 2009).  On average, the circular genome is just over 5kB (Dulbecco and Vogt, 
1963), physically constraining the genetic material carried by the virus.  The genome is 
generally divided into an early and late region, with a regulatory region in between.  The early 
region is responsible for preparing the cellular environment for viral replication and for initation 
of replication. Given the small size of the virus, viral replication relies heavily on host proteins, 
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which are redirected for this purpose by the early proteins. PyVs are also ecologically diverse.  
They infect many different host species, and cause a variety of pathologies depending on the 
host.  Given the recent characterization of several new PyVs, what is known about this family is 
based on the study of a few model viruses, and may not prove to be true of all PyVs. 
1.1.1 Life cycle 
PyVs target non-dividing host cells, primarily epithelial or fibroblastic cells (Cole, 
1996).  Host cell specificity of PyVs starts with the viral receptor; each virus is thought to 
recognize a specific ganglioside structure, although some PyVs have been shown to bind 
specifically to sialic acid (Gilbert and Benjamin, 2004; Low et al., 2006; Neu et al., 2009; Tsai 
et al., 2003).  Once attached at the plasma membrane, the virus enters the cell either by caveolae 
mediated entry (Eash et al., 2004; Jiang et al., 2009b; Pelkmans et al., 2001), or in the case of 
JCV, clathrin dependent transport (Pho et al., 2000).  The virus is next trafficked from a 
caveosome directly to the endoplasmic reticulum (ER).  The mechanisms that drive this sorting 
event are unclear and it is surprising that the virus never colocalizes with the Golgi (Jiang et al., 
2009b; Norkin and Kuksin, 2005; Pelkmans et al., 2001).  Once in the ER, protein disulfide 
isomerases and other factors required for the ER Associated Degradation (ERAD) pathway 
partially unfold the heavily disulfide-bonded capsid proteins and the virus is transported to the 
cytoplasm (Jiang et al., 2009b; Magnuson et al., 2005; Schelhaas et al., 2007; Walczak and Tsai, 
2011).  Through an unknown mechanism, the partially unfolded virion enters the nucleus where 
expression of the early proteins begins.   
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Figure 1. Genome map of SV40. 
This map is based on genome NC_001669, and prepared in The Gene Construction Kit (West 
Lebanon, NH).  The genomic organization of SV40 is common among PyVs.  The SV40 genome is 5243 
bases.  The early and late regions are transcribed in opposite directions from the ori (denoted in black, at 
nucleotides 5211-31).  The early message is alternatively spliced to form the small t (5163-4639) or large T 
antigen (5163-4918 spliced to 4571-2691).  The late message is polycistronic; the first ORF is the agnogene 
(335-523).  Downstream on this same RNA are the genes encoding VP2, VP3 and VP4 as in-frame messages 
with alternative starts (527-1620, 562-1620 and 1243-1620), and VP1 and an ORF from a separate reading 
frame (1499-2593).  At the end of the late message, the SVmiRNAs are encoded (2861-2782).  See text for 
additional details. 
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As shown in Figure 1, PyVs have a deceptively simple genome yet a highly complex 
regulatory gene network.  These events are described in detail below (section 1.1.2), but in 
brief, the early proteins are responsible for making the non-dividing host competent for viral 
replication while initating and then blocking DNA damage and other immune responses (see 
Table 1).  In turn, expression of the late genes, including the capsid proteins, decreases 
expression of early proteins, and may be responsible for virion exit by lysis (Daniels et al., 
2007; Sullivan et al., 2005).  Assembly of the virion around the viral minichromosome occurs in 
the nucleus just before cell lysis.  Overall, the complete life cycle of polyomaviruses can range 
from a few days to weeks.  
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Table 1.  Viral proteins encoded by SV40 and their functions. 
Adapted from Fields Virology (Shah, 1996).  The known functions of these SV40 proteins are known 
and assumed to be the same for other PyVs.  However, especially in avian PyVs, the names VP4 or 
Agnoprotein B indicate a different ORF that is also thought to be a virulence factor. 
 
 
Protein Molecular 
Weight (kDa) 
Function 
Early 
Large T 
Antigen 
80 Modifies cellular environment to favor conditions for viral 
replication through interactions with host proteins, including 
hsp, Rb and p53.  Initates viral replication.  Acts as the viral 
helicase during replication, and promotes transactivation of 
many other factors. 
Small t 
Antigen 
20 Modifies cellular environment via interactions with PP2A.  
Important for efficient viral replication. 
Late 
Agnoprotein 8 unknown 
VP1 40 Major capsid protein 
VP2 37 Minor capsid protein 
VP3 26 Minor capsid protein 
VP4  Supports efficient capsid formation and lysis (Daniels et al., 
2007) 
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1.1.2 Early region 
The early region of polyomaviruses encodes the tumor, or t, antigen proteins.  All 
polyomaviruses express a large tumor (“T”) Antigen (TAg), and a small tumor antigen (tAg), 
which are splice variants of the same transcript (Figure 1).  Some PyVs also express a middle 
tumor antigen (mTAg), or in the case of JCV, the very small tumor (t’) antigens (Simmons et 
al., 1979; Trowbridge and Frisque, 1995). The N-terminal J domain-containing exon (see 
section 1.2.3) is shared in common between all T/t antigens (Cole, 1996; Shah, 1996). In some 
cell types, the virus can enter and express these early genes, but is unable to express late 
proteins or assemble virions.  These non-permissive infections can lead to cellular 
transformation, which will be further described in section 1.2.1.   
The activity of TAg is both conserved and essential for viral replication (see section 
1.3). TAg drives replication of the viral genome, and manipulates the host cell environment by 
altering the activity of many cellular proteins (refer to Table 3 in section 1.3), including the 
tumor suppressors Rb and p53 (see sections 1.3.2 and 1.3.5, respectively).  In SV40, tAg binds 
protein phosphatase 2A (PP2A) (Pallas et al., 1990; Yu et al., 2001), whose targets include 
components in the MAPK pathway.  Specifically, tAg disrupts formation of the PP2A 
heterotrimer, altering the substrate specificity of PP2A with many downstream consequences, 
including stabilization of c-myc and transition to S phase (Sablina and Hahn, 2008; Sontag et 
al., 1993; Yeh et al., 2004). These activities are essential for transformation of some human cell 
lines (Hahn et al., 2002).  Studies of tAg or mTAg from MPyV have greatly informed our 
understanding of these signaling pathways, as well as the role of PP2A as a tumor suppressor 
(Schaffhausen and Roberts, 2009).  
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1.1.3 Late region 
The major products of the late region of the polyomavirus are the capsid proteins, VP1, VP2 
and VP3 (Table 1 and Figure 1).  The late region of polyomaviridae is more divergent than the 
early region (Gaynor et al., 2007; van der Meijden et al., 2010), which is predicted to prevent 
detection by the host immune system and determine cell type specificity.  This is supported by 
the fact that multiple PyVs can infect a single host, suggesting that infection with one PyV does 
not provide seroprotection against other PyVs (Kantola et al., 2010; Kean et al., 2009).  A 
polycistronic message expresses VP2 and VP3 (Fiers et al., 1978; Reddy et al., 1978), which 
share a common C Terminus (Figure 1), and some PyVs express a VP4 that aids in efficient cell 
lysis and viral release (Daniels et al., 2007).  
The X-ray crystal structure of the whole virion has been solved for several 
polyomaviruses (Liddington et al., 1991; Stehle et al., 1996; Stehle et al., 1994).  The major 
capsid protein, VP1, forms pentamers and hexamers that are coordinated by a combination of 
inter- and intramolecular interactions to form the stable icosahedral virion.  Specifically, 
disulfide bonds form between the pentamers, which must be disrupted during viral entry for 
productive infection (as noted in section 1.1.1) (Walczak and Tsai, 2011).  Although each 
pentamer associates with one copy of either VP2 or VP3, which may aid in viral entry (Chen et 
al., 1998), characterization of neutralizing monoclonal antibodies first suggested that VP1 is 
responsible for receptor recognition (Anders and Consigli, 1983).  There is also evidence that 
the capsid proteins elicit host responses during entry, such as PARP and Akt activation, which 
are manipulated later during expression of the early genes (Butin-Israeli et al., 2010; Gordon-
Shaag et al., 2003).  The virion is more than just a coat for DNA; it has been shown that VP 
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proteins 1-3 bind to DNA, facilitating capsid packing and viral maturation (Clever et al., 1993; 
Mukherjee et al., 2010; Soussi, 1986; Tsukamoto et al., 2007). 
The late region of some PyVs produces two additional transcripts, an agnoprotein and 
microRNAs (SVmiRNA).  The agnogene was first predicted from a preliminary sequence 
analysis (Dhar et al., 1977), and the agnoprotein was confirmed to bind both single and double 
stranded DNA (Jay et al., 1981).  The agnoprotein is associated with viral nucleoproteins, but 
not the mature virion (Jackson and Chalkley, 1981).  The agnoprotein also promotes viral 
assembly and maturation, and although its role is poorly understood, it is conserved among the 
PyVs in which it is expressed (Khalili et al., 2005).   
In 2005, viral microRNAs in SV40 were discovered to degrade early gene transcripts 
late in infection (Sullivan et al., 2005).  Carefully regulating expression of early genes removes 
viral antigens from detection by cytotoxic T cells (Sullivan et al., 2005).  Analogous 
microRNAs have been confirmed in other members of the polyomaviridae (Grundhoff and 
Sullivan, 2011). 
1.1.4 The family of Polyomaviruses 
Since the first PyV was discovered in mice (MPyV) (Gross, 1953), PyVs have been detected in 
a number of hosts, including many mammals and birds.  In addition to its small size, all PyVs 
contain a similar genomic organization and express the hallmark TAg (Figure 1).  Before the 
discovery of human PyVs, the MPyV, Murine Pneumotropic Virus, Rabbit Polyomavirus and 
Hamster Polyomavirus were all shown to infect rodents (Graffi et al., 1968; Hartley and Rowe, 
1964; Kilham, 1952).  Recently, the International Committee on the Taxonomy of Viruses 
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(ICTV) has proposed dividing the growing genera of polyomaviridae into three genera, 
Avipolyomaviridae, Wukipolyomaviridae and the Orthopolyomaviridae (Johne et al., 2011).   
The best known non-human primate PyV, SV40, was originally described as a non-
filterable agent from African Green Monkey cell culture which, when injected in hamsters, 
caused tumors (Eddy et al., 1961; Sweet and Hilleman, 1960).  Because these cell cultures had 
been used in the production of the Salk Polio vaccine, and this virus was not inactivated by the 
formalin treatment that inactivated other viruses in the culture (Provost and Hilleman, 1979), 
significant effort focused on characterizing this virus and its role in transformation (See section 
1.1.2). At this time, the virus was actually called Simian Vaculoating virus for causing this 
distinctive cytopathic effect (Sweet and Hilleman, 1960), and was classified as part of the 
Papovaviridae, a designation that included Papillomavirus, MPyV (then called simply 
Polyomavirus) and the Simian Vaculoating virus (Cole, 1996).  Although known to transform a 
variety of cell lines, infection with SV40 has not been shown to cause human disease (section 
1.4.1.1).  However, SV40 replicated relatively quickly and so was adapted to develop molecular 
tools.  It has also become the type species and model virus of this family. The early history of 
SV40 was recounted recently (Levine, 2009).   
Several additional non-human primate polyomaviruses have been characterized, 
including the Lymphotropic Virus (LPV), which is known to infect only B-lymphoblasts of the 
African Green Monkey (zur Hausen and Gissmann, 1979).  Approximately 30% of the human 
population express antibodies against this virus (Brade et al., 1981; Kean et al., 2009; Takemoto 
and Segawa, 1983).   The ICTV also recognizes two orangutan viruses (Bornean Orangutan 
Virus and Sumatran Orangutan Virus), Sea Lion Virus, Bat Virus and Bovine Polyomaviruses 
among the members of the diverse family polyomaviruses (Johne et al., 2011).  
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The discovery of Avian Polyomavirus (APyV), originally called Budgerigar Fledgling 
Disease Virus, has increased interest in finding and treating PyVs in birds (Muller and Nitschke, 
1986).  Outbreaks of APyV can cause acute death in Psittacine birds, which is a concern for 
breeders (Katoh et al., 2010).  Birds can be vaccinated against APyV after the fledgling stage, 
but this leaves the youngest birds at risk (Ritchie et al., 1998a; Ritchie et al., 1998b).  Similarly, 
Goose Hemorrhagic Polyomavirus (GHPyV) is highly pathogenic in birds, and preliminary 
evidence suggests that both the Crow Polyomavirus and Canary Polyomavirus are pathogenic as 
well (Johne et al., 2006).  These avian viruses tend to cause acute inflammatory disease in 
immunocompetent hosts (Halami et al., 2010; Johne and Muller, 2007).  Unlike most 
polyomaviruses, there is no evidence that these avian viruses can transform cell lines (Halami et 
al., 2010).   
In 1971, the first two human polyomaviruses, BKV and JCV, were discovered 
separately as disease causing agents in two immunosuppressed patients.  BKV was isolated 
from a kidney transplant patient who was demonstrating features of what is now called 
Polyomavirus Associated Nephropathy (PVAN), including viruria, detection of viral inclusion 
by biopsy and poor renal function (Gardner et al., 1971).  JCV was isolated post-mortem from 
an AIDS patient with progressive multifocal leukoencephalopathy (PML), which is 
characterized by palsy, neurodegeneration and acute demyelination of the white matter (Padgett 
et al., 1971).  Since their initial discovery, both viruses have been shown to be quite common in 
the population and maintain a lifelong infection; 70-80% of the all people carry them (Kean and 
Garcea, 2009; Kean et al., 2009).  However, BKV and JCV are not generally associated with 
disease in immunocompetent patients (Kean and Garcea, 2009; Kean et al., 2009).  
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In contrast, Merkel Cell Polyomavirus (MCPyV) was isolated from sequences found 
integrated into Merkel Cell carcinomas, which is a rare but fatal form of skin cancer associated 
with immunosuppression (Feng et al., 2008; Shuda et al., 2008).  Although closely related to 
each other, WU Virus (WUV) and KI Virus (KIV) were discovered independently from acute 
respiratory tract infection patient samples (Allander et al., 2007; Gaynor et al., 2007).  Evidence 
does not support either virus causing respiratory illness (Wattier et al., 2008).  Rather, both 
viruses show a wide distribution, both geographically and demographically, and estimates of 
seropositivity range from 1%-65% of the population (Bialasiewicz et al., 2010; Bialasiewicz et 
al., 2007; Dang et al., 2011; Furuse et al., 2010; Kean et al., 2009; Zhao et al., 2010).  In an 
effort to characterize the distributions of MCPyV, the Buck lab recently identified two new 
polyomaviruses, most closely related by sequence to WUV and KIV, Human Polyomavirus 6 
and Human Polyomavirus 7, by sequencing viral genomes on healthy human foreheads 
(Schowalter et al., 2010).  The authors proposed that the ancestral PyV may have been a skin 
virus, which took advantage of the frequent turnover of skin cells to replicate.  While this 
hypothesis does not fully explain how polyomaviruses became so adept at replicating in non-
dividing host cells, it is consistent with the virus’s ability to maintain a lifelong association with 
its host.  
In further support for a skin tropism, polyomavirus-like particles were also identified in 
the rare skin condition trichodysplasia spinulosa, a type of dysplasia unique among some 
transplant patients (Haycox et al., 1999; Wyatt et al., 2005).  This virus was recently identified 
by sequencing and characterized as Trichodysplasia Spinulosa Polyomavirus (TSV) (van der 
Meijden et al., 2010).  The very recent discovery of a Human Polyomavirus (HPyV9) with 
greater homology to the primate LPV may explain the previously detected high levels of human 
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seropositivity to LPV (Scuda et al., 2011).  The detection of HPyV9 sequences in patients who 
were immunosuppressed for a variety of reasons does not preclude future disease association.  
Together, as virus discovery techniques improve, the family of PyVs will likely continue 
to grow.  Because many of the recently characterized viruses cannot yet be replicated in cell 
culture, the majority of what is known about these viruses is based on studies of the model 
virus, SV40.   
1.2 POLYOMAVIRUSES AS TOOLS IN MOLECULAR BIOLOGY 
PyVs have long provided a model to study viral biology and to some extent have driven the last 
half-century of molecular biology.  The first virus identified in this family, MPyV, was isolated 
from a murine leukemia model, and gave the family the name “polyoma” for the many small 
tumors that were induced in rodents (Gross, 1953).  As described above, SV40 was isolated 
from the monkey cell cultures used to culture the Salk Polio vaccine (Sweet and Hilleman, 
1960).  SV40 was also shown to induce tumors in rodents, and has proven to be an excellent 
model for tumorigenesis (see section 1.2.1). Because SV40 was discovered under such 
conspicuous conditions, it has catalyzed the development of new techniques and served as a 
means to ask a variety of biological questions.  The utility of the PyV for developing tools and 
testing hypotheses is evidenced by the seven Nobel Laureates who credit a PyV in their 
development as scientists or award winning work (Berg, 2004; Dulbecco, 1975; Hartwell, 2001; 
Montagnier, 2008; Nathans, 1978; Tonegawa, 1987; zur Hausen, 2008).  Here, I will highlight 
some of the major contributions to molecular biology from research on SV40, several of which 
have proved important for my dissertation work. 
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1.2.1 Characterization of cellular transformation and tumorigenesis 
SV40 was first observed as a non-filterable agent that induced tumors in infected rodents (Sweet 
and Hilleman, 1960), and this observation laid the ground work to use SV40 as a model system 
for tumorigenesis. Following the description of SV40 causing tumors in hamsters, SV40 was 
quickly shown to cause a variety of tumors in other rodents, including hamsters (Ashkenazi and 
Melnick, 1963; Black and Rowe, 1963, 1964; Eddy et al., 1961; Gerber and Kirschstein, 1962; 
Kirschstein and Gerber, 1962; Rabson and Kirschstein, 1962; Vogt and Dulbecco, 1960).  Both 
SV40 and MPyV were also shown to transform a variety of human and rodent cells and tissues 
in culture (Black and Rowe, 1963; Jensen et al., 1963; Koprowski et al., 1963; Ponten et al., 
1963; Shein and Enders, 1962; Shein et al., 1962; Shein et al., 1963; Todaro and Green, 1966; 
Todaro et al., 1966).   Assays were developed to further refine this transforming activity, and 
were used to show that PyV transformed cells lines are immortal, grow in low serum or 
independent of anchorage, and lose contact inhibition, which allows for formation of foci; they 
also induce tumors in mice, all of which are hallmarks of transformation (Aaronson and Todaro, 
1968; Chiang et al., 1985; Damania and Pipas, 2009; Macpherson and Montagnier, 1964; Pipas, 
2009; Smith et al., 1971; Todaro and Green, 1964).   
Characterization of the transformed phenotype showed that a variety of host cell 
functions were altered in a carefully regulated manner (Oda and Dulbecco, 1968b).  Enzymes 
such as DNA and RNA polymerases and kinases become activated (Frearson et al., 1966; Kit et 
al., 1967).  Consequently, both cellular and viral DNAs, as well as mRNAs are synthesized 
(Dulbecco et al., 1965; Gershon et al., 1965; Hartwell et al., 1965; Oda and Dulbecco, 1968a, 
b).  The demonstration that viral DNA carried the transforming ability of the virus focused the 
search for the cellular transforming factor (Crawford et al., 1964).  Later work showed that 
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DNA fragments of the early region were required for transformation, and that temperature 
sensitive mutants of the A gene could confer a temperature sensitive transformation phenotype 
to various rodent cell lines (Abrahams et al., 1975; Brockman, 1978; Brugge and Butel, 1975; 
Kimura and Dulbecco, 1973; Kimura and Itagaki, 1975; Martin and Chou, 1975; Osborn and 
Weber, 1975; Tegtmeyer, 1972). 
At this time, the focus of the field moved toward teasing out the role of the early region 
in transformation.  Transformation by PyV is a relatively rare event, and is not an essential part 
of PyV replication or biology.  Todaro and Green showed that one in 103 infections leads to 
transformation and that this rate increased in cells from Fanconi anemia patients, who have 
defective DNA damage repair (Todaro and Green, 1966; Todaro et al., 1966).  In addition, the 
Koprowski group showed that while initially transformed human cells still produced some level 
of viral progeny, cells that survive crisis and are immortalized no longer produce infectious 
virus.  These data suggest that there is no evolutionary advantage to viral transformation 
(Girardi et al., 1965).  Interestingly, these immortalized cells did continue to produce what was 
known as the Complement Fixing Antigen, eponymous for the assay that was used to detect low 
levels of the virus, but later called the Tumor Antigen (TAg) (Girardi et al., 1965; Habel et al., 
1965; Westphal and Dulbecco, 1968).  Attempts to purify this antigen from tumors took 
advantage of its localization to nuclei and the complement fixing activity (Gilden et al., 1965; 
Lazarus et al., 1967; Sever, 1962).  It was not until 1977 that mutagenesis (using techniques 
described in section 1.2.2) and immunoprecipitation experiments showed that the TAg was not 
an induced product of the host cell but was virally encoded by the early region (Rundell et al., 
1977). Interestingly, in MPyV, transformation requires the activity of mTAg (Carmichael et al., 
1984; Schaffhausen and Roberts, 2009; Templeton and Eckhart, 1984).    
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Studies of SV40 TAg then helped identify and characterize the major cellular tumor 
supressors, as well as elucidate the pathways necessary for immortalization and transformation.  
This is in part because the small genome of the PyV does not provide the functions required for 
viral replication.  Rather, TAg manipulates the host cell environment to induce S phase and 
DNA replication while activating and blocking a DNA damage response (see section 1.3).  As 
detailed below, TAg interacts with the tumor supressors Rb and p53, and the N-terminal J 
domain is further required for TAg mediated transformation (sections 1.3.2, 1.3.5 and 1.3.1, 
respectively).  Additional host proteins have been shown to play a role in transformation, 
including the target of tAg and the MAPK pathway, PP2A (Hahn et al., 1999; Hahn et al., 
2002).  It is important to note, though, that virus-induced transformation is thought to occur as a 
result of a non-permissive infection, indicating that the activities that are essential for viral 
replication may lead to transformation when misregulated.  This perspective has driven the use 
of the tumor virus model for understanding more general aspects of cancer. 
1.2.2 Insights in viral and eukaryotic DNA replication 
Viral replication requires replication of the viral genome, which in many virus systems 
is an extraordinarily complex event.  Fortunately, the small genome of SV40 has made it a 
facile model to define how DNA architecture is established and to understand the molecular 
requirements for DNA replication.  With the identification of restriction enzymes from H. 
influenzae (HindII/III), SV40 was the first complete genome mapped (Danna and Nathans, 
1971; Danna et al., 1973).  This allowed early investigators to assign functions to specific 
regions of the genome, including defining the coding sequences and regions essential for viral 
replication (Khoury et al., 1973; Scott et al., 1976).   With a crude map available, the race to 
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sequence the genome of SV40 resulted in one of the earliest whole genome sequences (Fiers et 
al., 1978; Reddy et al., 1978).  This detailed knowledge also provided the tools for the first 
example of site-specific mutagenesis, which involved nicking the DNA, excising one template 
strand, and treating the gap with a mutagen.  The gap was then repaired by polymerase, thus 
introducing the mutation (Shortle and Nathans, 1978). Mutagenesis of this genome directed the 
initial description of the required sequence of the viral origin of replication, ori (Shortle and 
Nathans, 1979).  
The small size of the viral minichromosome also made SV40 an ideal model for early 
characterization of the structural features of chromatin.  Although not the first to recognize that 
histones bind DNA, the Chambon lab championed the use of SV40 to characterize the 
relationship between histones and DNA.  Confirming their earlier results with DNA from other 
organisms (Oudet et al., 1975), they showed that SV40 DNA was associated with histones, and 
obtained electron microscopy (EM) images that supported the “Beads and Bridge” model of 
nucleosome structure (Germond et al., 1975).  By proteinase treating the purified chromatin, 
these researchers also showed that the interaction between histones and DNA is responsible for 
DNA supercoiling.  Refining these observations with a combination of EM and electrophoresis, 
the Chambon and Griffith labs then suggested that ~200bp are protected by the nucleosome, 
while the “bridging” DNA is of varying lengths (Bellard et al., 1976; Griffith, 1975).   EM was 
also used to test the stability of the protein-DNA complexes, confirming that the ionic histone-
DNA interactions are not sequence specific (Bellard et al., 1976). 
SV40 also provided an early in vitro system to characterize eukaryotic DNA replication 
(Li and Kelly, 1984), which has been important for the work discussed in this dissertation.  
Because TAg manipulates host cell factors to replicate viral DNA, the proteins that are 
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necessary for viral DNA replication in vitro are also essential for eukaryotic DNA replication.  
In the original DNA replication system, monkey kidney cell lysate, an ATP regenerating 
system, and a plasmid with a viral ori were mixed, and the incorporation of a radiolabeled 
nucleotide into the synthesized DNA was measured.  Later, more refined systems replaced 
lysate with purified components until the 10 essential proteins required for replication were 
identified (Waga and Stillman, 1994); only four of these proteins are required for initiation of 
replication.  TAg binds to the pol α-primase (Murakami et al., 1986), either topoisomerase  I or 
II (Yang et al., 1987),  and RPA (Fairman and Stillman, 1988; Wobbe et al., 1987; Wold and 
Kelly, 1988).  The activity of TAg and these three proteins is sufficient to initiate DNA 
replication as indicated by template unwinding and production of short DNA fragments, but full 
length copies of the DNA template were not produced.  With the addition of PCNA (Prelich et 
al., 1987), activator I (or RF-C) (Lee et al., 1989; Tsurimoto et al., 1989), and pol δ (Lee et al., 
1989; So and Downey, 1988; Tsurimoto et al., 1990; Weinberg and Kelly, 1989) the 
holoenzyme of pol δ is assembled, and a more processive polymerase activity was evident (Lee 
and Hurwitz, 1990; Tsurimoto and Stillman, 1989).  This system also provided evidence for 
polymerase switching: pol α acted as a primase and pol δ functioned as the elongation 
polymerase, for the first time explaining the distinct biological functions of the multiple 
polymerases.  However, many nicked circular DNA products were produced, due to a failure to 
remove RNA primers or ligate the generated Okazaki fragments.  Subsequent isolation and 
addition of the final three components, the 5’-3’ exonuclease MF-1 (or FEN-1), RNase H and 
DNA ligase I, together function to remove the primers and ligate the DNA fragments (Waga et 
al., 1994; Waga and Stillman, 1994).  This purified in vitro system is fully competent to 
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replicate unnicked circular DNA products (Fanning and Zhao, 2009; Waga et al., 1994; Waga 
and Stillman, 1994).   
1.2.3 Other activities essential for functional TAg expression: Splicing and Nuclear 
Localization 
Two other activities of the early region are also essential for viral replication, namely the 
splicing of the early transcript and the localization of TAg to the nucleus. Evidence from the 
first sequence of the early region of SV40 suggested that large and small t antigens were splice 
variants (Fiers et al., 1978; Reddy et al., 1978), which prompted the use of the early transcript as 
a model of alternative splicing (Berk and Sharp, 1978).  The Alternative Splicing Factor (ASF) 
was one of the early trans-acting factors shown to regulate the exon inclusion of the SV40 early 
transcript (Ge and Manley, 1990).   
TAg must localize to the nucleus to recruit the host factors necessary for viral 
replication; mutations in the nuclear localization sequence (NLS) are defective for viral 
replication (Peden and Pipas, 1985).  Analysis of the SV40 early sequences also helped identify 
one of the first minimal NLS motifs.  While previous work had begun to show that some 
regions of proteins facilitated their nuclear localization, some TAg mutants that failed to 
localize to the nucleus were also described (Kalderon et al., 1984a; Lanford and Butel, 1984).  
Specifically, the Smith lab defined the NLS of TAg by characterizing a panel of TAg internal 
deletion mutants which failed to localize to the nucleus (Kalderon et al., 1984b).  By appending 
β-gal to distinct TAg sequences, these investigators could artificially localize the majority of β-
gal to the nucleus.  The NLS sequence is a string of mostly basic amino acids, starting at residue 
126 (PPKKKRKV).  Mutations in any one of these residues shifts the population of TAg from 
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predominantly nuclear to being predominantly cytoplasmic (Smith et al., 1985).  While similar 
basic regions are found on other nuclear proteins, the TAg NLS is shorter and shows a more 
potent localization effect compared to other NLS sequences identified.  As such, it can easily be 
added to other proteins to modulate their localization (Smith et al., 1985; Yoneda et al., 1987).   
1.3 LARGE T ANTIGEN 
As the major early protein expressed by PyVs (Table 1), TAg encodes several activities and is 
responsible for changes to the cellular environment as well as for recruitment of essential host 
factors during viral replication.  Indeed, the common features of TAg represent a shared 
solution to the challenge of replicating DNA in a non-dividing host without eliciting a defensive 
host cell response.  To this end, TAg has several essential and independently folded domains: an 
N terminal J domain (1.3.1), an ori binding domain (OBD) (1.3.3) and a AAA+ ATPase domain 
(AAA+) (1.3.4).   In addition to these domains, other essential and conserved TAg activities, 
binding Rb and p53, are described below (1.3.2 and 1.3.5).  This 708 amino acid protein of 
SV40 is the best characterized TAg of the polyomaviridae.  The high degree of sequence 
homology (see Table 2 and Figure 1) and the essential nature of these activities leads to a 
hypothesis that much of what we know about SV40 TAg will be true for other T antigens, 
although these activities have not yet been confirmed for all PyVs.  Consistent with this view, 
the sequence conservation between TAgs is greater in the folded, functional domains in contrast 
to the less conserved linker regions (Table 2).  
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Table 2. Percent identity by pairwise alignment of full length TAgs and specific domains. 
Pairwise alignments were done in Jalview and are reported as percent amino acid identity 
(Waterhouse et al., 2009).  The alignments for each domain were based on the predicted SV40 domain 
boundaries, which are indicated.  The alignments were performed with the following accession numbers 
P03070 (SV40), P03072 (JCV), P03071 (BKV), B6DVW7 (MCPyV) and E2ESL8 (TSV). 
 
 
Comparison Full Length 
Protein 
J domain 
(aa1-82) 
OBD 
(131-246) 
AAA+ 
(259-627) 
SV40 to JCV 72.6 81.7 81.0 74.8 
SV40 to BKV 74.0 81.7 84.3 77.5 
SV40 to MCPyV 39.6 40.2 53.7 47.4 
SV40 to TSV 43.4 45.1 47.9 48.2 
TSV to MCPyV 43.9 42.2 55.7 54.4 
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Figure 2. Alignment of the clinically relevant TAgs, displayed by domain. 
Alignments were done in Jalview (Waterhouse et al., 2009). The alignments were performed with 
the following accession numbers P03070 (SV40), P03072 (JCV), P03071 (BKV), B6DVW7 (MCPyV) and 
E2ESL8 (TSV).  Relative shades of blue indicate percentage shared identity: the darkest shade of blue 
indicates identity shared by all 5 viruses at that position, the lightest shade indicates that the identity is 
shared by only 3 of the viruses.  A) Alignment of the J domain, based on the first 82 aa of SV40 TAg.  This 
alignment highlights the insertion in the MCPyV J domain.  B) Alignment of the Rb binding domain, 
showing conservation of the LXCXE motif.  C) Alignment of the DNA binding domain, based on aa 130-251 
of SV40 TAg.  D) Alignment of the AAA+ ATPase domain.  In this alignment, the Walker A motif (red box, 
SV40 TAg aa425-433) is highly conserved within the family, but both the Walker B (yellow box, SV40 TAg 
aa 467-474) and arganine finger motifs (green box, SV40 TAg aa 537-541) are less conserved between the 
TAgs and canonical AAA+ proteins (Koonin, 1993).   
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SV40 TAg interacts with a wide variety of host proteins to exert major and more nuanced 
effects on the host cell environment.  A summary of the known TAg-protein interactions and the 
predicted function of the interaction is described in Table 2, highlighting the diversity and 
breadth of these interactions. Although my goal is to consider the importance of these 
interactions in normal virus replication, it is clear that many of these host-virus interactions have 
unintended consequences in the absence of a lytic infection.  For example, TAg is capable of 
inhibiting the DNA damage response while encouraging DNA replication and endoreduplication.  
In addition, many of the proteins listed are known to be misregulated in cancer, including Fbw7 
(Tan et al., 2008), AP-2 (Pellikainen and Kosma, 2007) and Bub1 (Williams et al., 2007).  Such 
interactions have been used both to understand the role of the targeted protein in cancer, as well 
as to understand the roles of tumor suppressors in viral replication.  It is of note that Table 2 does 
not include genetic interactions that influence protein expression patterns (Abend et al., 2010; 
Rathi et al., 2010; Rathi et al., 2009), DNA interactions (Bharucha et al., 1994; Montenarh and 
Henning, 1982; Tegtmeyer et al., 1983) or membrane affinity (Butel et al., 1989; Klockmann and 
Deppert, 1983; Lange-Mutschler and Henning, 1984), although many of each have been 
described.  The remainder of this section will be dedicated to describing the specific roles of the 
major folding domains and activities of TAg both during infection and transformation.   
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Table 3.  Summary of reported SV40 TAg interacting proteins and their predicted functions. 
Interactors are organized by the general roles during viral replication, including DNA replication, cell cycle regulation, transactivation, 
modification of the DNA damage response, localization or unknown functions.  Accession numbers from the NCBI Protein Database are included to 
minimize confusion regarding nomeclature, and were determined based on the species and details of the interaction noted in the reference column. 
 
 
Binding 
Partner: 
Accession 
Number 
Protein Function Binding Site 
(aa) 
Viral Function Evidence References 
DNA replication 
Pol-prim: 
2KEB_A 
 
RNA primase for 
DNA replication 
425 and AAA+ 
domain (259-
627) 
Initiates lagging strand 
DNA replication 
Interaction mapped to p68 
subunit of pol-prim, NMR 
structure  
(Huang et al., 2010; 
Murakami et al., 1986) 
PCNA: 
P12004 
 
Processivity factor 
for pol δ/ε 
  Replication of viral 
genome 
Co-purified in replicating 
fractions of human cell 
lysates 
(Prelich et al., 1987) 
RF-C: 
NP_001191676 
Loads PCNA onto 
DNA 
  Replication of viral 
genome 
Purified RF-C required for 
reconstituted DNA 
replication assay 
(Lee et al., 1989; 
Tsurimoto and 
Stillman, 1989) 
Pol δ DNA polymerase   Replication of viral 
genome 
Cofractionation 
experiments indicate this 
is a PCNA dependent 
interaction 
(Lee et al., 1989; So 
and Downey, 1988; 
Tsurimoto et al., 1990; 
Weinberg and Kelly, 
1989) 
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Topo I or II: 
AAI36298, 
P11388  
 
 
Topoisomerase, 
involved in DNA 
supercoiling 
83-106 and 612, 
616, 617, and 
621 
Facilitates initiation of 
DNA replication by 
relaxing DNA 
Mutational analysis of 
TAg disrupts Topo I 
binding and activity, 
purified Topo II required 
for reconstituted DNA 
replication assay  
(Ishimi et al., 1992; 
Khopde and Simmons, 
2008; Roy et al., 2003; 
Wold et al., 1989; 
Yang et al., 1987) 
MF-1 
Fen-1: 
CAG38799 
5’-3’ exonuclease   Replication of viral 
genome, required for 
Okazaki fragment 
processing 
Purified MF1 required for 
reconstituted DNA 
replication assay 
(Waga et al., 1994; 
Waga and Stillman, 
1994) 
RNase H     Replication of viral 
genome, required for 
Okazaki fragment 
processing 
Purified RNase H required 
for reconstituted DNA 
replication assay 
(Waga et al., 1994; 
Waga and Stillman, 
1994) 
DNA ligase I: 
AAA59518 
  
Ligates Okazaki 
fragments 
  Replication of viral 
genome, required for 
Okazaki fragment 
processing 
Purified DNA ligase 
required for reconstituted 
DNA replication assay 
(Waga et al., 1994; 
Waga and Stillman, 
1994) 
RPA: 
AAA58350  
  
Stabilizes ssDNA 
during replication 
 64-249 As part of the viral 
replisome, stabilizes viral 
ssDNA during unwinding 
TAg specific monoclonal 
antibodies prevent 
interaction 
(Melendy and Stillman, 
1993; Weisshart et al., 
1998) 
Cell cycle regulation 
Hsc70 
AAK17898 
  
Molecular 
chaperone 
1-82, 
specifically 
HPD motif at 
42-44 
Assembles virion and 
releases E2F from Rb 
Mapped by mutational 
analysis and reporter 
assays, loss of J domain 
interaction results in 
decreased viral replication 
and transformation 
(Chromy et al., 2006; 
Chromy et al., 2003; 
Sawai et al., 1994; 
Srinivasan et al., 1997; 
Sullivan et al., 2000) 
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pRb, p107, 
p130: 
AAA69808  
P28749  
Q08999 
Inhibits E2F until 
initiation of S 
phase 
LXCXE Motif,   
102-107 
  
  
By disrupting the Rb-
E2F interaction, TAg 
activates transition to S 
phase 
pRb-TAg co-crystal 
structure 
(Amin et al., 1994; 
DeCaprio et al., 1988; 
Kim et al., 2001) 
cdc2:  
AAI07751 
Cell cycle 
regulator and 
kinase 
Phosphorylates 
Thr124 
Enhances ori binding Mutant lacking Thr124 is 
not phosphorylated 
(McVey et al., 1989) 
Fbw7: 
NP_361014 
NP_060785 
NP_001013433 
Substrate 
recognition for the 
SCFFbw7  
ubiquitination 
complex 
Interaction 
occurs via 
phosphorylation 
at Thr701 
TAg acts as a 
competitive inhibitor for 
the Ub-ligase, preventing 
ubiquitination and 
degradation of substrates 
such as cyclin E and 
other cdks 
TAg co-
immunoprecipitates with 
all three Fbw7 isoforms 
(Welcker and Clurman, 
2005) 
Transactivation 
TFIIB: 
NP_001505 
Transcription 
factor, member of 
the RNA pol II 
pre-initiation 
complex 
133-249 Transactivation of the 
late promoter 
Truncation mutants of 
TAg used to map 
recombinant TFIIB 
interaction by pull-down 
(Johnston et al., 1996) 
Sp1 Transcriptional 
activator protein  
133-249 Transactivation of the 
late promoter. May 
promote TAg binding to 
ori 
Truncation mutants of 
TAg used to map 
recombinant Sp1 
interaction by pull-down, 
Sp1 isoform is unclear 
(Johnston et al., 1996) 
RNA pol II RNA polymerase 
essential for 
transcription 
133-249 Transactivation of the 
late promoter 
Truncation mutants of 
TAg used to map RNA 
pol II interaction by pull-
down, specific subunits 
interacting are unclear 
(Johnston et al., 1996) 
IRS1: Insulin receptor, 107 (k1 mutant) Mediates activation of IRS1 is required for TAg (DeAngelis et al., 2006; 
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NP_005535 
  
tyrosine kinase 
transducer, which 
signals  increased 
Glut4 expression 
Akt, required for 
transformation 
dependent transformation Yu and Alwine, 2008) 
TBP: 
P20226  
  
TATA Binding 
protein, subunit of 
SL-1, TFIID and 
TFIIIB 
181-205 In combination with 
other transcription 
factors, essential for 
activation of polymerase, 
may inhibit DNA 
replication 
Truncation mutants of 
TAg used to map 
recombinant TBP 
interaction by pull-down 
(Herbig et al., 1999; 
Johnston et al., 1996; 
Zhai et al., 1997) 
SL1 complex-
TAF1110, 
TAF148: 
Q15573 
Q15572  
  
Transcription 
factor involved in 
target selectivity, 
subunit of SL-1 
1-538 Co-activates transcription 
of ribosomal RNA, 
recruits RNA pol II 
Radiolabeled co-
immunoprecipitations 
with truncated TAg 
mutants map the 
interaction domain of TAg 
with TAF1110, TAF148 
but not TAF163 complex 
(Mazzarelli et al., 1995; 
Zhai et al., 1997) 
TEFI 
NP_068780 
Transcription 
factor 
133-249  May be involved in 
early-to-late transcription 
transition 
Truncation mutants of 
both interacting partners 
used to map TAg 
interaction domain to 
TEF1 TEA domain by 
pull-down 
(Berger et al., 1996) 
c-Jun and c-
Jun-related 
protein 
Part of the AP-1 
transcription 
factor, which 
targets genes 
required for cell 
cycle control 
  Repression of the Po 
promoter, and Po 
expression (a 
glycoprotein in the 
myelinated plasma 
membrane), possibly 
contributing to 
demyelination 
TAg, c-Jun and c-Jun-
related protein (identity 
unclear) co-
immunoprecipitated and 
both bind Po promoter in 
vitro 
(Bharucha et al., 1994) 
AP2: 
P05549 
Transcription 
factor, targets 
  Inhibits AP2 mediated 
transcription 
TAg changes the AP2 
sedimentation 
(Mitchell et al., 1987) 
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  genes required for 
cell cycle control 
Modification of the DNA damage response 
Bub1 
O08901 
 
Mitotic checkpoint 
kinase 
89-97 Misregulates DNA 
damage response to 
promote viral replication 
Identified by yeast two 
hybrid interaction, 
confirmed by co-
immunoprecipitation from 
3T3 cells.  TAg mutant 
Δ89-97 fails to interact 
(Cotsiki et al., 2004; 
Hein et al., 2009) 
ATM: 
Q13315 
  
DNA damage 
response and 
kinase 
Phosphorylates 
Ser120 
Phosphorylates Ser-120, 
which is thought to 
inhibit TAg.  However 
ATM is required for 
efficient viral replication 
Truncation mutants of 
TAg used to map the 
specific phosphorylation 
site in an in vitro ATM 
kinase assay 
(Shi et al., 2005) 
Nbs1: 
BAA28616  
  
Required for 
dsDNA break 
repair via MRN 
complex 
147-259 Promotes 
endoreduplication 
TAg co-
immunoprecipitates the 
entire MRN complex, 
truncation mutants used to 
identify both the region of 
Nbs1 and TAg responsible 
(Wu et al., 2004) 
TACC2: 
O95359 
  
May organize 
microtubules at the 
centrosome 
250-708 Inhibition of TACC2 
inhibits microtubule 
assembly 
Interaction identified by 
yeast two hybrid, 
confirmed by co-
immunoprecipitation, 
results in mitotic defects 
that can be rescued by 
TACC2 overexpression 
(Tei et al., 2009) 
p53: 
P04637  
  
Monitors DNA 
damage, provides 
a G1-S checkpoint 
351-450 and 
533-627 
Prevents DNA damage 
response, promotes 
transition to S phase 
Interaction confirmed by 
crystal structure 
(Lilyestrom et al., 
2006) 
Localization  
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Importin 58/97: 
NP_942021 
NP_058759 
 
Regulating protein 
entry into the 
nucleus 
NLS-126-135 Imports TAg into the 
nucleus 
Interaction showed by 
ligand-Western blot, and 
confirmed by phenotype 
using TAg mutants in 
NLS, and CKII and DNA-
PK phosphorylation sites 
(Hubner et al., 1997; 
Xiao et al., 1997) 
casein kinase II 
(CKII): 
P19139  
 
Serine/threonine 
kinase with a 
variety of targets, 
including Wnt 
signaling and 
DNA damage 
Phosphorylates 
Ser112 
Leads to phosphorylation 
which enhances 
interaction with importin, 
supports cell  
transformation 
In vitro assays with TAg 
peptides indicate that 
CKII (presumed both 
subunits) specifically 
phosphorylates the TAg 
sequence, and that this 
increases affinity for 
importin. 
(Gotz et al., 1995; 
Hubner et al., 1997; 
Xiao et al., 1997) 
Tubulin: 
NP_001074440 
 
Structural polymer Requires p53 Possibly regulates 
intracellular trafficking   
Co-immunoprecipitates 
with TAg and p53 in a 
complex that is dependent 
on the presence of both.   
(Maxwell et al., 1991) 
double-stranded 
DNA dependent 
protein kinase 
(DNA-PK) 
P78527  
Involved in DNA 
damage repair 
Phosphorylates 
Ser120, 665, 
and 667 
Phosphorylates Ser120, 
enhancing nuclear import 
via CKII phosphorylation 
and importin interaction 
In vitro reactions show 
DNA-PK phosphorylates 
TAg at the same sites, 
which are phosphorylated 
in vivo.  Phosphorylation 
at Ser120 mediates the 
rate of nuclear import. 
(Chen et al., 1991; 
Xiao et al., 1997) 
Chromatin Nucleoprotein 
complex 
comprised of 
histone and non-
histone proteins 
bound to DNA 
  May be involved in 
several processes during 
infection and viral 
replication 
Filter binding assays used 
to show affinity for both 
DNA and chromatin, 
localization experiments 
confirm a protein-protein 
interaction. 
(Hinzpeter and 
Deppert, 1987; Persico-
DiLauro et al., 1977) 
Unknown function 
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SCF –like 
ubiquitination 
complex 
including Cul7, 
Fbw6/Fbx29/Fb
xw8 and 
Rbx1/Roc1  
NP_079887 
NP_796163 
XP_358324,  
NP_766309, 
NP_062686  
 
E3 ubiquitin ligase 98-102 Required for 
transforming MEFs, role 
unclear 
Co-immunoprecipitates 
with TAg.  TAg mutants 
that do not co-
immunoprecipitate the 
Cul7 Fbw6 Rbx1/Roc1 
complex are 
transformation defective. 
(Ali et al., 2004) 
CBP/ p300/ 
p400: 
NP_001020603 
NP_808489 
Q8CHI8 
Histone acetyl 
transferases 
Proposed via 
p53 
Role during infection 
unclear 
Co-immunoprecipitates 
with TAg.  CBP acetylates 
K697, which stabilizes 
TAg. 
(Avantaggiati et al., 
1996; Eckner et al., 
1996; Lill et al., 1997; 
Shimazu et al., 2006; 
Srinivasan et al., 1997) 
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Figure 3.  Domain map of TAg and crystal structures of three domains. 
A) The domain map highlights the major features conserved between polyomaviruses based on SV40 
TAg, including the folded domains depicted in green in B-D, the Rb binding sequence (LXCXE), a nuclear 
localization sequence (NLS) and p53 binding sites (aa 351-450 and 533-627).  Not all TAgs have a host range 
domain, and the length of linker sequences between domains is different in many of the human 
polyomaviruses. Structures have been solved for the independently folding domains, which are displayed in 
green.  B) The J domain (green) bound to the pocket domain of Rb (which is denoted in blue) (PDB: 1GH6) 
(Kim et al., 2001).  C) The DNA Binding domain displayed as a dimer (PDB: 2IPR) (Bochkareva et al., 2006).  
D) The AAA+ domain, displayed as a monomer (PDB: 1N25) (Li et al., 2003). Structures are not to scale. 
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1.3.1 J domain and molecular chaperone activity 
J domains stimulate the ATPase activity of the Heat Shock Protein of 70kDa (hsp70) molecular 
chaperones and are generally involved in processes such as protein folding or unfolding (Craig et 
al., 2006; Walsh et al., 2004).  The J domain derives its name from the classical co-chaperone 
activity described by the E.coli protein DNAJ, which binds to and stimulates a bacterial hsp70, 
DNAK (Liberek et al., 1991; Mayer and Bukau, 2005).  Although the family of hsp70s is known 
to respond to heat shock, the hsc70 is constitutively expressed in unstressed cells (Gething and 
Sambrook, 1992).  Early reports had shown that TAg interacts with hsc70 (Sawai and Butel, 
1989); however, because this protein functions as a general peptide binding protein, it was not 
clear whether the hsc70 interaction was biologically relevant.   
The N terminal J domain of TAg (aa 1-82) (Figure 2) was first described in 1997 in three 
concurrent studies (Campbell et al., 1997; Kelley and Georgopoulos, 1997; Srinivasan et al., 
1997). First, it was shown that chimeric proteins including the J domain of TAg could 
complement DNAJ mutants in a bacteriophage plaque assay (Kelley and Georgopoulos, 1997).  
Second, it was demonstrated that point mutants in the J domain abolished the interaction with 
hsp70, and that this interaction was necessary for efficient DNA replication in culture (Campbell 
et al., 1997; Peden and Pipas, 1992).  Interestingly, the J domain is not required for in vitro DNA 
replication assay described in section 1.2.2 (Weisshart et al., 1996), suggesting some 
fundamental distinctions between the in vitro and in vivo assays (see section 4.3).  Third, the 
Pipas lab found that deletions or point mutations in the J domain compromise cellular 
transformation.  Moreover, a truncation mutant of TAg lacking the endogenous ATPase activity 
stimulated the ATPase activity of hsc70 and stimulated the ability of hsc70 to release an 
unfolded peptide, both of which are hallmarks of DNAJ-like activity.  This study further 
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established that transformation deficient mutants incapable of binding the tumor suppressor Rb 
(section 1.3.2) cannot be rescued by J domain mutants.  These data both established that hsc70 
activity was essential for transformation and suggested that the J domain must act in cis with Rb-
binding activity (Srinivasan et al., 1997).  Based on the collective data, it was proposed that TAg 
uses hsc70 to disrupt the Rb-E2F complex, which is essential for moving the cell into S phase 
(Ahuja et al., 2005; Brodsky and Pipas, 1998).  This hypothesis is further supported by the 
cocrystal structure of the J domain and Rb pocket domain (Figure 3), which confirmed that the 
Rb-E2F complex is positioned in proximity to hsc70 (Kim et al., 2001).  The structure also 
confirmed that the first 82aa of TAg would form a 4 helical bundle, which all J domains possess, 
although the fourth helix is longer than typical J domain. 
Other work has since shown that the activity of the J domain is essential for additional 
activities during viral infection.  For example, the Garcea lab demonstrated that the J domain 
promotes both assembly and disassembly of the capsid in vitro, suggesting an important role for 
host chaperones in viral entry and exit (Chromy et al., 2006; Chromy et al., 2003).  More 
recently, work in our lab confirmed that small molecules that target J domain stimulation of 
hsc70 activity inhibit viral replication in a cell culture system (Wright et al., 2009).  Because 
molecular chaperones play dynamic roles in a variety of cellular processes, the J domain may 
represent a viable drug target for a variety of diseases (see section 1.4). 
1.3.2 Binding and inactivating the Rb family 
TAgs share a highly conserved Rb binding motif (LxCxE) (Figure 2), which is essential for 
transformation (DeCaprio, 2009; Kalderon and Smith, 1984; White and Khalili, 2006).  The 
retinoblastoma susceptibility gene, Rb, was first identified following a genetic study suggesting 
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that childhood retinoblastoma has a hereditary component (Knudson, 1971).  This gene was later 
shown to be mutated in retinoblastoma tumors, suggesting that loss of Rb function promotes 
cancer (Friend et al., 1986; Fung et al., 1987; Horowitz et al., 1989; Lee et al., 1987).  The 
Livingston lab then demonstrated that TAg binds to the retinoblastoma susceptibility gene 
product (pRB) (Figure 3), and perhaps more interestingly, TAg mutants that are incapable of 
binding pRb also failed to transform cells (DeCaprio et al., 1988).  TAgs from a variety of PyVs 
have been confirmed to bind Rb, indicating that this function is conserved (Dyson et al., 1990).  
Studies of Rb in TAg transformed cells also helped develop the “multiple hit” hypothesis of 
carcinogenesis, as well as enlightening our understanding of normal cell cycling (reviewed in 
(DeCaprio, 2009).  By binding and inactivating Rb family members in a J domain dependent 
manner, TAg derepresses E2F and activates E2F mediated transcription (Ahuja et al., 2005; 
Srinivasan et al., 1997; Sullivan et al., 2004; Sullivan et al., 2000).  This misregulation of E2F 
leads to initiation of S phase, which promotes viral replication by upregulating the host factors 
required for DNA replication (Chong et al., 2009; Rathi et al., 2007; Saenz-Robles et al., 2007).   
1.3.3 DNA binding domain 
The DNA binding domain, or ori binding domain (OBD) of TAg (Figure 3), is essential for 
recognizing and melting the viral origin of replication. Structures of this domain have been 
solved, and the essential activity maps to aa 131-250 (Bochkareva et al., 2006; Luo et al., 1996; 
Meinke et al., 2006).  The DNA binding activity of TAg has been well described (reviewed in 
(Bullock, 1997; Fanning and Zhao, 2009).  Using a series of ori mutants and by measuring 
effects on DNA replication, the Tegtmeyer lab defined the core ori and TAg binding site as the 
60 nucleotide sequence between 5211 and 31 (Deb et al., 1986).  Sedimentation of this complex 
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implied that the DNA binding activity of TAg required oligomers (Bradley et al., 1982; Gidoni et 
al., 1982).  Detailed mutational analysis of the binding site indicated that TAg makes specific 
contacts within the GAGGC pentanucleotide palindrome sequence of the ori (Deb et al., 1987), 
which suggested that multiple TAgs may orient to and bind at this site if each TAg recognizes 
two of the four pentanucleotide palindrome sites.  Moreover, based on the known structures of 
TAg at the ori, it is known that TAg monomers bind first, then recruit an asymmetric TAg 
tetramer, and finally a dodecamer capable of bidirectionally unwinding DNA assembles 
(Bochkareva et al., 2006; Mastrangelo et al., 1989).  It is clear from these structures that some 
conformational rearrangements are required to adapt the bound structure to the unwinding 
activity, and the nature of this change remains an active area of investigation. Using competition 
experiments, the Simmons lab was able to demonstrate that TAg can bind to non-specific DNA 
sequences (although with less affinity than to the ori), and that this non-specific binding requires 
cooperativity in trans between the ATPase domains (described below; (Lin et al., 1992; Wun-
Kim and Simmons, 1990). A variety of host transcription factors interact also via this domain 
(Table 3, TFIIB, Sp1, RNA-pol II, TBP and TEF-I), indicating that this domain is not only 
essential for viral DNA replication but also transactivation.   
1.3.4 AAA+ ATPase and associated activities 
The AAA+ ATPase domain of TAg is conserved and essential for viral replication.  This 
domain is involved in many activities during viral replication, including binding p53 (refer to 
section 1.3.5 and Figure 3) and other host proteins (Table 3, Topo I and II, TACC2).  The most 
central of these activities is the helicase activity, even though it was initially unclear whether 
TAg could unwind DNA (Giacherio and Hager, 1980; Myers et al., 1981).  Although TAg bound 
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to chromatin (Stahl and Knippers, 1983) and TAg-specific monoclonal antibodies prevented viral 
DNA replication (Mercer et al., 1983; Stahl et al., 1985), the biological function of the TAg 
ATPase activity was mysterious until helicase activity was demonstrated in vitro (Stahl et al., 
1986). Subsequent sequence analysis indicated homology between TAg and the MCMs, which 
are the eukaryotic replicative helicases (Koonin, 1993).  As a result, this homologous region of 
TAg has been described as a AAA+ ATPase domain, which acts as a hexamer with the ATPase 
active site at the interface of two monomers (Neuwald et al., 1999).  In this active site, the 
Walker A motif from one monomer binds ATP and coordinates a Mg ion, while the Walker B 
motif of the same monomer provides the catalytic glutamate that hydrolyzes the ATP held by the 
Walker A motif.  The conserved arginine finger (some times called box IV) also interacts with 
the nucleotide and iscontributed by a second monomer (Figure 2).  The hydrolysis of ATP 
induces a conformational change that provides the mechanical action necessary for helicase 
activity (Snider et al., 2008). 
The solved structure of the AAA+ ATPase domain revealed a central channel, which is 
hypothesized to channel DNA during unwinding (Li et al., 2003).  The solved structure of aa 
251-627 also contains the Zn binding domain, which was shown to be important for 
hexamerization, although it is not clear if the Zn ion itself plays any role beyond supporting the 
folding of this domain. Finally, helicase activity, which was previously mapped to aa 131-627, 
can also be demonstrated with a shorter fragment (aa 251-627), suggesting that the DNA binding 
activity of TAg is not essential for helicase activity (Li et al., 2003).  This helicase activity has 
since been used as a model for the study of other helicases, including the MCMs, papillomavirus 
E1 and adeno-associated virus Rep68 (Bochman and Schwacha, 2010; Mansilla-Soto et al., 
2009).  
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1.3.5 Binding and misregulation of p53 
p53 was identified as a host protein that was upregulated in TAg expressing cells, was 
recognized by sera from rodents with SV40-induced tumors and bound directly to TAg (DeLeo 
et al., 1979; Kress et al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979).  It was 
hypothesized that this 54kDa protein may be an important oncogene, but the connection was not 
proven until efforts by several labs showed that transfection with p53 cDNA in addition to Ras 
could transform rat embryo fibroblast cells (Eliyahu et al., 1984; Jenkins et al., 1984; Parada et 
al., 1984).  Surprisingly, later work cloned the p53 cDNA from these transformed fibroblasts and 
determined that the cells expressed a mutant form of p53, and that this mutant form lost the 
tumor suppressing function of the wild-type gene (Finlay et al., 1989; Hinds et al., 1989; Pennica 
et al., 1984).  We now know that wild-type p53 is a transcription factor that mediates cell cycle 
arrest or apoptosis in response to cellular stress as a result of DNA damage; this can prevent 
progression to S phase as a result of the TAg-mediated DNA damage response (Talos and Moll, 
2010; Wu and Levine, 1994).  TAg binds to and inactivates p53 function during an infection 
(Bargonetti et al., 1992; Harris et al., 1998; Lilyestrom et al., 2006).  The p53 binding site was 
originally mapped to two distinct regions in the ATPase domain of TAg (Table 3; (Kierstead and 
Tevethia, 1993).  The cocrystal structure of the TAg ATPase domain bound to p53 has been 
solved, which indicated that TAg inhibits p53 by binding a region overlapping the p53 DNA 
binding site, and requiring a single region on TAg (Figure 3; (Lilyestrom et al., 2006)).   
The consequences of TAg dependent inactivation of p53 during viral infection are more 
complex than simply preventing a DNA damage response, although this is one important result 
of this interaction.  Given the diversity of downstream targets that are modified by p53 (Zhao et 
al., 2000), it is becoming clear that TAg binding to p53 may fine tune a response, the outcomes 
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of which are incompletely understood.  Microarray data have suggested that some targets of p53 
are up regulated, while the DNA damage response itself is prevented (Rathi et al., 2009).  A 
careful characterization of the transformation effeciencies and growth properties of TAg in the 
presence of p53 and p53 mutants suggests that TAg may induce a p53 gain of function 
(Hermannstadter et al., 2009).  Data from the Dornreiter lab have shown that one consequence of 
TAg binding p53 is stabilization of cyclin A-Cdk kinase activity, suggesting that TAg expressing 
cells are trapped in S phase (Rohaly et al., 2010).  While initially it seemed surprising that the 
TAg oncogene would manipulate the activity of another tumor supressor, it has since become 
clear that targeting oncogenic pathways is the modus operandi during the replication of PyVs. 
1.3.6 Host range domain 
Although the C terminal host range domain is poorly conserved and largely mysterious, there is 
an eponymous phenotype associated with this region.  Specifically, truncations of TAg that 
contain only the first 627 amino acids retain the ability to transform cells lines, but lose the 
ability to replicate in some types of African green monkey cells (mutants grow on BSC, but not 
CV1 cells; (Pipas, 1985; Tornow and Cole, 1983a, b).  This region is also essential for the 
“adenovirus helper function,” which is the enhancement of adenovirus type 2 (Ad2) infection in 
an SV40 dependent manner (Cole et al., 1979; Cole and Stacy, 1987).  The host range region is 
post-translationaly modified with multiple phosphorylation and acetylation marks by several 
targets, which would suggest complex regulation, but the biological functions of these 
modifications are not yet understood (Kress et al., 1982; Poulin et al., 2004; Scheidtmann et al., 
1991; Scheidtmann et al., 1982; van Roy et al., 1983).  While there is evidence that host range 
mutants fail to assemble mature virions, the molecular basis for this effect also remains unknown 
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(Spence and Pipas, 1994).  In fact, discovering the function of this domain has proved 
challenging.  There is little evidence that the C terminus of SV40 TAg is structured.  It has been 
suggested that the diverse activities associated with the host range domain may require host cell 
interactors, but the identities of these proteins remain elusive.  In one case, Fbw7 was shown to 
bind to this region, but the predicted role for this interaction is stabilization of cyclin E kinase 
(Welcker and Clurman, 2005), which cannot explain the diverse activities associated with this 
region.  Perhaps more confounding is the lack of conservation of this domain: a host range is 
only predicted in SV40, BKV and JCV (Pipas, 1992).  If this domain truly supports virion 
assembly, how do the TAgs that lack this domain assemble virions? 
1.3.7  Differences between TAgs 
Although there are many important structural and functional similarities between TAgs from 
different viruses, the distinctions between them may help to highlight the differences in life 
history and other activities.  While most PyV share the ability to transform cells, few are efficient 
at transformation or as quick to replicate as SV40, which is why SV40 has been favored as the 
model for this virus family. One key difference between the other PyVs and their TAgs is 
tropism.  Tropism is partially determined by receptor recognition, but infection efficiency can be 
affected by changes to the sequences of the viral promoter-enhancer regions and in the early 
coding regions of PyVs (Bollag et al., 1989; de Villiers et al., 1982; Fujimura et al., 1981; 
Katinka et al., 1980).  Given that manipulation of native host protein function is the dominant 
theme of PyV infection, it seems likely that changes in either promoter or protein sequences may 
affect their recognition by host factors.  For example, there is evidence that not all TAgs bind 
host partners like Rb and p53 with similar affinity (Bollag et al., 1989; Dyson et al., 1990; Harris 
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et al., 1996).  Because this conclusion is based on co-immunoprecipitations, it is possible these 
data may instead reflect relative antibody affinities.  Notably, binding affinities for these partners 
have not been determined for all TAgs (especially from the seven PyVs discovered after 1996), 
but differences in binding affinities for these host factors would be predicted to alter infection 
efficiency.   
In contrast to SV40 TAg, most of the TAgs in this family are not yet well characterized, 
but there are some predictions that can be made based on sequence analysis.  While all TAgs 
share the major domains described above (see sections 1.3.1, 1.3.3, 1.3.4), as well as sequences 
that bind Rb, the intervening sequences are less conserved.  Specifically, the length of the linker 
region between the J domain and OBD is quite divergent and only the TAgs of SV40, BKV and 
JCV are predicted to express a host range.  It is expected that these features may alter 
interactions with host proteins, and in fact MCPyV TAg binds the host protein VAM6P via the 
long linker region between the J domain and OBD (Liu et al., 2011a).  Even among the large 
number of cellular partners for TAg (Table 3), VAM6P has not been shown to interact with 
SV40 TAg. These differences might explain some of the disparate efficiencies in transformation 
and infection. 
1.4 POLYOMAVIRUSES AND HUMAN DISEASE 
Since the initial characterization of SV40 induced neoplasms in mice (Stewart et al., 1958), there 
have been questions about the role of PyVs in disease.  Although these viruses are widely 
distributed, there is generally little disease burden from PyV infection.  The polyomavirus-
related diseases that have been described predominantly affect the immunosuppressed, and as 
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such the majority of these diseases are not studied in great detail.  Given the long history and 
detailed understanding that we have of PyV biology, it seems ironic that these orphan diseases 
are inadequately treated.   
1.4.1 Disease in immunocompetent patients 
1.4.1.1 SV40 
Although known as a DNA tumor virus, there is little convincing evidence to link SV40 
infection to human cancers or cancer in the natural host, which is the Rhesus Macaque (Eddy et 
al., 1961; Sweet and Hilleman, 1960).  Much of the evidence for SV40-induced transformation 
(section 1.2.1) derives from studies in non-permissive cell lines, specifically in rodent lines.  
Nevertheless, researchers have looked for a link between SV40 and cancer.  The official stance 
of the US government is that the data are insufficient to determine if there is a causal relationship 
between SV40 and cancer (Stratton et al., 2003).  However, this is in large part due to the 
difficulty of determining which individuals were exposed to SV40 and at what dose (Stratton et 
al., 2003).  It is generally accepted among most researchers that there is not a credible direct link 
between SV40 infection and increased cancer risk (Levine, 2009). 
Current evidence does not discount the possibility that SV40 may be a synergistic risk 
factor for mesothelioma when combined with asbestos exposure. SV40 sequences can be 
identified in some but not all mesothelioma samples (Klein et al., 2002; Shivapurkar et al., 2000; 
Shivapurkar et al., 1999; Testa and Giordano, 2001).  The Carbone lab showed that neither 
exposure to asbestos nor SV40 infection could transform cells, but when combined cells were 
transformed (Bocchetta et al., 2000).  In these experiments, asbestos exposure activated p53, 
preventing cell lysis and maintaining TAg expression from the episomal viral vector (Bocchetta 
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et al., 2000).  The episome may explain the failure of some groups to detect SV40 sequences in 
mesotheliomas, while others have suggested that SV40 sequences are detected as a result of lab 
contamination (Klein et al., 2002).  Together, one view is that SV40 may be one risk factor for 
the complex disease of mesothelioma, which may also arise from a number other factors besides 
asbestos exposure (Klein et al., 2002; Pershouse et al., 2006). 
1.4.1.2 Other PyVs  
Current evidence based on seropositivity and PCR detection suggests that the majority of 
the human PyVs are acquired early in childhood and remain persistent (Bolen and Consigli, 
1980; Kantola et al., 2010; Kunitake et al., 1995; Zheng et al., 2004).  Based on detection in fecal 
matter or urine, it is thought PyVs are acquired through a fecal-oral or possibly respiratory route 
(Bofill-Mas et al., 2001; Monaco et al., 1998).  The initial infection is presumably benign in 
healthy patients.  Although sometimes identified in acutely ill patients, there has not yet been any 
specific set of symptoms linked to initial PyV infection (Dalianis et al., 2009; Neske et al., 2009; 
Wattier et al., 2008).  Interestingly, even in healthy patients, periodic levels of increased viral 
shedding throughout life are thought to maintain seropositivity, although it is not clear what 
prompts this apparent increased viral replication (Kean et al., 2009; Schowalter et al., 2010).  
However, the persistence of infection leaves these viruses free to replicate should the host 
become immunocompromised.   
1.4.2 Known disease in immunosuppressed patients 
Both BKV and JCV were discovered in 1971, and represent the first native human PyVs 
(Gardner et al., 1971; Padgett et al., 1971).  As both were discovered in acutely sick patients, 
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efforts focused on characterizing the role of these viruses in disease.  It has been reported that 
between 20-80% of the population has antibodies against most PyVs, depending on geography, 
and that there is little if any seroprotective effect (Kean et al., 2009; Pastrana et al., 2009). Given 
the wide distribution of PyVs and their lifetime prevalence, immunosuppressed patients have an 
increased susceptibility to developing PyV related diseases. 
It is important to note that immunosuppressed populations are growing worldwide. 
Advances in transplant technology have improved outcomes for many patients who suffer organ 
failure, and those patients are surviving longer after transplant (OPTN, 2009).  Further, the 
World Health Organization estimated that 33 million people globally are living with AIDS, and 
that number continues to grow as anti-retroviral drugs prolong AIDS survival rates (WHO, 
2008). As these populations continue to grow, so will the apparent impact of PyVs.  
1.4.2.1 BKV 
A role for BKV is well established in BKV Associated Nephropathy (BKVAN) after 
kidney transplant (Binet et al., 1999; Nickeleit et al., 1999).  BKVAN is marked by increased 
viral shedding in urine and blood, and more than doubles the probability of organ rejection 
(Dharnidharka et al., 2009).  This condition is also sometimes called Polyomavirus Associated 
Nephropathy (PVAN), in part, because it was previously difficult to distinguish between the 
different PyVs by histological methods, and it is not yet clear if other PyVs can cause similar 
symptoms.  Estimates are that BKVAN occurs in between 3-30% of kidney transplant patients 
(Basse et al., 2007; Giraldi et al., 2007; Hirsch et al., 2002).   Previously, diagnosis required an 
invasive biopsy, but fortunately rapid detection is now possible with qPCR techniques, which 
has lead to better standards for monitoring disease progression (Bechert et al., 2010; Elfaitouri et 
al., 2006; Vats et al., 2006).   
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BKV also causes hemorrhagic cystitis after hematopoietic stem cell transplant in an 
estimated 10% of patients (Bedi et al., 1995; Kondo et al., 1998; Peinemann et al., 2000; Seber et 
al., 1999).  Hemorrhagic cystitis is a painful inflammation and causes bleeding in the bladder and 
urethra that puts the patient at risk for further complications (Sencer et al., 1993).  Interestingly, 
only half of patients shedding BKV after transplant will develop hemorrhagic cystitis (Bedi et 
al., 1995; Hirsch and Steiger, 2003), and preliminary evidence suggests that rearrangements in 
the noncoding regulatory region of BKV correlate to the development of clinical symptoms 
(Broekema et al., 2010; Chen et al., 2001; Stoner et al., 2002).  With improved monitoring and 
treatment options, the total risk of disease has decreased, but there are risks associated with 
treatment (discussed in section 1.4.2.5).  In both cases, these diseases suggest tropisms for the 
kidney or urinary tract. 
1.4.2.2 JCV 
JCV was first detected in the brain of a patient who died of progressive multifocal 
leukoencephalopathy (PML) (Padgett et al., 1971).  In contrast to BKV and SV40, JCV has a 
tropism for glial cells, and under immunosuppression can cause rapid demyelination, leading to 
neurodegeneration and eventually death (Padgett et al., 1977; Tan and Koralnik, 2010). As the 
majority of patients with this disease have AIDS, highly active antiretroviral therapy (HAART) 
has decreased some of this burden, perhaps by strengthening the immune system.  However, 
while HAART allows relatively long-term survival with PML, the neurological effects persist 
(Gasnault et al., 1999; Gray et al., 2003).  The progression of this fatal disease in an 
immunosuppressed person may take less than one year without intervention, although with 
HAART therapy median survival is lengthened to 1.8 years (Engsig et al., 2009; Khanna et al., 
2009).  Unfortunately, HAART therapy is unavailable for some 90% of AIDS patients (Gray et 
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al., 2003).  Additionally, patients undergoing some types of antibody treatment for multiple 
sclerosis (including the monoclonal antibody natalizumab) or some types of chemotherapy are at 
risk for PML (Tan and Koralnik, 2010).  The best treatment option to prevent progression of 
PML is to remove immunosuppression or improve immune function (Marzocchetti et al., 2009), 
but this is clearly not an option for the entire affected population.  
1.4.2.3 MCPyV 
The populations most affected by Merkel Cell Carcinoma (MCC), a rare but aggressive 
skin cancer, are the elderly and immunosuppressed (Engels et al., 2002).  This observation 
suggested that there may be an infectious agent involved in the development of this cancer.  The 
Moore and Chang lab first showed that an estimated 80% of these carcinomas include sequences 
incorporated from a novel polyomavirus, which they named Merkel Cell Polyomavirus 
(MCPyV) (Feng et al., 2008; Gjoerup and Chang, 2010; Shuda et al., 2008).  Expression of the 
MCPyV TAg is required for proliferation in the MCC cell lines (Houben et al., 2010).  This 
discovery was the first clear and direct connection between a polyomavirus and human cancer, 
and it was quickly confirmed that MCPyV TAg had many shared characteristics with SV40 TAg, 
including a requirement for Rb binding (Houben et al., 2011), and nuclear localization (Liu et al., 
2011b).  Most interestingly, the integrated MCPyV encodes a truncated TAg, lacking an ATPase 
domain and p53 binding site (Shuda et al., 2008).  These data suggest that transformation by 
MCPyV takes advantage of some novel features of this virus.  The majority of Merkel Cell 
Carcinomas are reported to require these monoclonally integrated TAg sequences, this 
strengthens the case for an etiological role of MCPyV in disease (Becker et al., 2009; Garneski et 
al., 2009).  However, the broad distribution of MCPyV in the general population makes this 
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relationship difficult to define and may suggest there are other contributing factors for 
development of MCC. 
1.4.2.4 TSV 
Although a rare condition, trichodysplasia spinulosa had been described as an affliction 
in select transplant patients, characterized by alopecia, follicular spines, and erythematous 
papules predominantly on the face (Haycox et al., 1999; Wyatt et al., 2005).  The earliest reports 
of this condition suggested that there were viral structures within the papules, and that these 
might be papovaviridae (Haycox et al., 1999).  However, the limited number of patients reported 
with this condition (Wyatt and colleagues reported the 3rd and 4th known case (Wyatt et al., 
2005)) made it difficult to confirm this hypothesis.  In 2010, rolling circle PCR was used to 
amplify and sequence the viral particles, confirming the identity of a novel polyomavirus termed 
Trichodysplasia Spinulosa Virus (TSV) (van der Meijden et al., 2010).  The authors went on to 
show that while both the patient and his mother carried this virus, the young transplant patient 
carried much higher titers of the virus.  After topical treatment with a 1% cidofovir, cytosine 
analog and general antiviral sometimes used to treat PyV infection (see section 1.4.2.5), the 
patient’s viral titers decreased, as did the symptoms (van der Meijden et al., 2010).  While these 
data suggest an etiological role for TSV, a direct test of the hypothesis will prove challenging 
given the rarity of condition.  
1.4.2.5 Current treatment options for PyV-related diseases 
Given that most patients who have a PyV-associated disease are already 
immunosuppressed, the consequences of not treating the disease symptoms are too severe to 
deprive patients of the available therapeutics, regardless of their inadequacy. A summary of the 
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current treatments for the common PyV-related diseases is summarized in Table 4.  These 
treatments are commonly used in conjunction with reduction of immunosuppressive therapies, 
which has made the available data on these treatment options even more difficult to interpret.   
Table 4.  Commonly used therapeutics and the dosages for PyV-related diseases. 
 
 
Drug Disease Dosage 
cidofovir BKVAN 40 mg/day (Wu and Harris, 2008) 
leflunomide BKVAN  20–40 mg/day (Wu and Harris, 2008) 
ciprofloxacin Hemorrhagic cystitis  oral (500 mg twice daily) or intravenous 
(200 mg twice daily) (Leung et al., 2005) 
cidofovir Trichodysplasia Spinulosa Topical cidofovir 1% (van der Meijden et 
al., 2010) 
none PML  
 
 
 
Transplant patients receive a high standard of care.  This is in contrast to the 90% of 
AIDS patients who do not receive standard care for their primary disease (WHO, 2008).  As a 
result, the efficacy of specific therapeutics is best described for the BKV related diseases.  For 
example, the commonly used drug cidofovir (brand name Vistide™) is a cytosine analog that 
targets cytomegalovirus and DNA polymerases in general, which has made it useful as an anti-
viral (De Clercq, 2002; De Clercq et al., 1987).  Unfortunately, cidofovir is nephrotoxic, and 
while this may be the mechanism of action for this compound (Bernhoff et al., 2008), cidofovir 
may be a poor choice to treat many kidney transplant patients (Izzedine et al., 2005).  Similarly, 
characterization of cidofovir and leflunomide (brand name Arava™) in a culture system suggests 
that while leflunomide may be two fold more effective at inhibiting BKV replication, it is also 
more toxic than cidofovir, as indicated by the selectivity index (the ratio of the effective dose to 
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the toxic dose; (Bernhoff et al., 2010; Farasati et al., 2005).  Clinical use of leflunomide has been 
associated with viral clearing and improved patient outcomes, although this has ranged from 
100% of patients showing a decrease in viral load to 66% of patients with improved kidney 
function (Faguer et al., 2007; Josephson et al., 2006a; Wu and Harris, 2008).  Ciprofloxacin 
(brand name Cipro™) is another compound that was shown to inhibit viral infection and viral 
DNA replication in vitro, but has yet to be fully tested clinically (Ali et al., 2007).   
Ciprofloxacin seems to be favored for hemorrhagic cystitis patients, in whom it has been shown 
to reduce the viral load (Johnston et al., 2010; Leung et al., 2005).  Some physicians caution that 
ciprofloxacin may not be selective enough for treatment of transplant patients (Randhawa, 2005). 
Of these three commonly used treatments, cidofovir, leflunomide and ciprofloxacin, none have 
been tested in a large-scale clinical trial (Hilton and Tong, 2008; Wu and Harris, 2008), and 
retrospective studies have suggested the effect is indistinguishable from reduction of 
immunosuppression (Johnston et al., 2010).   
There is not currently any specific treatment for PML (Tan and Koralnik, 2010).  It 
should be noted that while an ideal therapeutic would need to cross the blood-brain barrier to be 
effective, administering drugs intrathecally is relatively common in the following treatments.  
Cidofovir has been used to treat PML based in part on in vitro data suggesting that other 
nucleoside analogs inhibit viral replication in a cell culture system (Hou and Major, 1998).  
While there may be an increase in survival rates, researchers suggest that this treatment simply 
prolongs life with moderate to severe disability (De Luca et al., 2008).  Rarely, non-AIDS 
patients, including those with leukemia or lymphoma, develop PML; evidence from the 
treatment of non-AIDS PML patients suggested cytarabine, a chemotherapeutic and cytosine 
arabinoside, prevents PML (Aksamit, 2001), but trials of cytarabine in AIDS patients showed no 
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survival benefit (De Luca et al., 1999; Hall et al., 1998).  This raises the possibility that there 
may be fundamental differences in the disease progression of PML in non-AIDS versus AIDS 
patients, which should be considered during treatment (Boren et al., 2008; Tan and Koralnik, 
2010).  After a demonstration that JCV may use the serotonin receptor 5HT2a as the viral docking 
site (Elphick et al., 2004), efforts to treat PML with the serotonin receptor blocker mirtazapine 
(brand name Remeron™) are currently under investigation.  While preliminary results 
suggesting improved clinical outcomes appear promising (Cettomai and McArthur, 2009), a 
small trial comparing patient survival did not demonstrate significant improvement over patients 
receiving no treatment (Marzocchetti et al., 2009).   
1.4.3 Linking recently discovered PyVs to disease 
The recent discovery of new members to the PyV family such as WUV (Gaynor et al., 2007), 
KIV (Allander et al., 2007), MCPyV (Feng et al., 2008; Shuda et al., 2008), HPyV6 and 7 
(Schowalter et al., 2010), TSV (van der Meijden et al., 2010) and HPyV9 (Scuda et al., 2011) 
opens the possibility that these viruses may be associated with diseases.  As molecular 
epidemiologists race to characterize the distributions of these poorly characterized viruses, the 
evidence required to support or disprove disease etiology will become readily available (Hill, 
1965).  It is now possible to quantitate the levels of virus associated with diseased tissues using 
molecular techniques such as ELISAs, qPCR and rolling circle PCR (Kean et al., 2009; Murata 
et al., 2009; Schowalter et al., 2010). However, suitable molecular methods may not be sufficient 
to describe causation of pathology.  None of the PyVs discovered in the last decade replicate 
outside the host, in culture or otherwise; clearly development of replication systems for these 
viruses will greatly facilitate their characterization.  Both JCV and MCPyV can be studied in 
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unique cell lines that express viral components, specifically, the JCV produces viral particles, but 
the MCPyV only expresses the truncated TAg that correlates with MCC.  These cell culture 
systems represent adaptation from both the host cell and the integrated virus that may not reflect 
the natural biology of JCV or MCPyV (Elphick et al., 2004; Feng et al., 2008; Liu et al., 2011b).  
Even the replication systems used for BKV and JCV are slow and deliver low viral yield, it is not 
clear if this reflects the native biology of the virus, or is a limitation of the system.  Another 
complicating factor in tying PyVs to disease is that PyVs establish a life-long infection and 
appear to be widely distributed, which may obscure the role of benign and malignant replication.  
More practically, the bulk of the world populations of immunosuppressed patients are not within 
reach of modern medicine, reemphasizing that finding novel ways to prevent or treat PyV-related 
diseases should remain a priority for the field. 
1.5 PERSPECTIVES 
Although studies of SV40 and other PyVs have driven important discoveries in many fields of 
biology, important and relevant questions remain.  It is of interest whether PyVs have roles in 
disease, and how the molecular differences in TAg or other viral features affect the pathogenicity 
of viral replication.  However there are less familiar although equally interesting questions 
remain unanswered. While the roles of most PyV in disease have yet to be established, it remains 
to be seen why healthy patients occasionally shed high levels of PyVs.  What determines the 
periodic activation of PyV replication in humans, and how do PyVs continue to evade clearance 
by the immune system despite these bursts of activity?  The trafficking of PyVs from the cell 
surface to the nucleus is a conspicuously slow process, and the mechanisms by which this 
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happens are not well described.  How does a PyV transit from a caveosome to the ER, and how 
does the virus direct this trafficking?   
More recent virus discovery efforts have increased the number of known human PyVs to 
nine.  While molecular epidemiologists work to determine if there are further links between 
PyVs and disease, it is clear that treatment options are insufficient for the PyV-related diseases 
already identified, namely BKVAN, PML and MCC.  The work described in this dissertation 
represents one effort to address this paucity.   
1.6 DISSERTATION OVERVIEW 
As described above, the family of PyVs is a growing public health concern, both as the members 
of this family increase and as the population of immunosuppressed patients increases.  Since all 
PyVs express a large TAg, which carries a conserved and essential viral replication activity, I 
believe that TAg is a viable drug target to universally treat PyV-associated diseases. The goal of 
my project was to identify small molecular inhibitors of the ATPase activity of TAg and 
characterize these compounds in viral replication assays. 
The first phase of this work was initiated by a collaboration with the Gestwicki lab at the 
University of Michigan.  A library of small molecules was screened using quinaldine red (QR) to 
identify inhibitors of SV40 TAg endogenous ATPase activity.  From a library of a 2500 
compounds, two small molecules were identified which are more potent than any previously 
described SV40 inhibitor.  A structure activity relationship (SAR) was described, and methods 
were established to test these compounds for the efficacy on BKV replication.  This effort is 
detailed in Chapter 2. 
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Given the promising results of the QR screen, a search for SV40 TAg ATPase inhibitors 
was expanded.  In a parallel effort, 330,000 compounds from the NIH Molecular Libraries Probe 
Centers Network (MLPCN) compound library were screened in collaboration with the Noah lab 
at the Southern Research Institute and the Golden lab at the University of Kansas.  The screen 
was adapted to use a commercially available reagent, ADP Hunter, which facilitated assay 
miniaturization.   Hits from this screen were chemically refined and more potent derivatives were 
obtained.  Although the toxicity of the identified compounds makes them difficult to use in 
culture systems, the activity of these “tool” compounds is described in Chapter 3.   
The parallel nature of my dissertation work presents an opportunity to comment on the 
prospect of finding PyV inhibitors using these and other approaches.  Chapter 4 is a discussion of 
the impact and relevance of my work. 
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2.0  HIGH THROUGHPUT SCREENING IDENTIFIES BISPHENOL INHIBITORS 
OF POLYOMAVIRUS REPLICATION. 
2.1 INTRODUCTION 
Polyomaviruses are a family of double stranded DNA viruses that replicate in non-dividing cells, 
and in humans these viruses persist as a life-long infection (Imperiale and Major, 2007).  The 
majority of the population appears to be infected with at least one if not more of the human 
polyomaviruses (Kean et al., 2009).  In healthy patients, polyomavirus infection does not result 
in disease symptoms, but in immunosuppressed patients replication of these viruses can proceed 
unabatedly and results in several catastrophic diseases (Jiang et al., 2009a).  For example, 
reactivation of BK virus in clinically immunosuppressed patients can lead to BK Virus 
Associated Nephropathy (BKVAN), or hemorrhagic cystitis (Hirsch and Randhawa, 2009).  JC 
virus can cause progressive multifocal leukoencephalopathy in AIDS patients and in patients 
receiving specific treatments for Multiple Sclerosis (Safak and Khalili, 2003).   
In the past few years, six new polyomaviruses have been identified, each with varying 
links to human disease (section 1.4): The KI and WU viruses were identified from patients with 
respiratory infections (Allander et al., 2007; Gaynor et al., 2007); Merkel Cell Polyomavirus was 
recognized as sequences incorporated into Merkel Cell Carcinomas (Feng et al., 2008; Shuda et 
al., 2008); Human Polyomaviruses 6 and 7 were identified as high copy sequences on the skin of 
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healthy individuals (Schowalter et al., 2010); Trichodysplasia spinulosa virus was found in high 
copy in dysplastic hair follicle cells (van der Meijden et al., 2010); and most recently a human 
virus that is highly similar to the monkey lymphotropic virus was sequenced from 
immunosuppressed patients and named Human Polyomavirus 9 (Scuda et al., 2011).  Early 
evidence suggests that these viruses may be reactivated in immunosuppressed individuals (Sharp 
et al., 2009).  Given the recent and rapid increase in the number of known polyomaviruses, it is 
likely that additional members of this virus family with connections to other diseases will 
emerge, particularly as the immunocompromised population expands (Kunisaki and Janoff, 
2009) and because polyomaviruses are adept at replicating at low levels in non-dividing host 
cells (Fanning et al., 2009). Unfortunately, the current treatments for polyomavirus related 
diseases are not specific, inadequate and/or have undesirable side effects (Josephson et al., 
2006b). 
In addition to the message encoding capsid proteins, polyomaviruses express only one 
other essential transcript, which encodes the highly conserved, multidomain transforming factor, 
the large tumor antigen (TAg) (Cantalupo et al., 2005; Pipas, 1992).  TAg activates the cellular 
DNA damage response while blocking the apoptic response, triggers cell cycle progression via 
binding to Rb and p53 family members, as well as a variety of other factors that regulate host 
cells (Pipas, 2009).  To initiate viral DNA synthesis, TAg binds to the viral origin of replication 
and serves as the replicative helicase via its AAA+ ATPase domain (Li and Kelly, 1984).  In 
addition, TAg harbors an essential “J domain” that stimulates the ATPase activity of the hsp 
family of molecular chaperones (Campbell et al., 1997; Fewell et al., 2002; Kelley and 
Georgopoulos, 1997; Srinivasan et al., 1997). The TAg-hsc70 complex is hypothesized to help 
release the transcription factor E2F from Rb (Sullivan et al., 2000), which is required for cell 
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cycle activation. These properties are essential for viral replication and are conserved amongst 
most of the TAgs (Cantalupo et al., 2005).   
Of the eight known human polyomaviruses, in vitro replication systems only exist for BK 
and JC virus.  In contrast to the very slow replication of these viruses in culture, the related 
Simian Virus 40 (SV40) replicates well in monkey kidney cell lines and expresses a highly 
conserved version of TAg.  In fact, most of our current understanding of TAg function emerged 
from studies on SV40 (Pipas, 2009).   
Because the TAgs are highly conserved, and because human cells lack a TAg homologue, 
I suggest that this protein may provide a therapeutic target to prevent polyomavirus replication 
and treat associated diseases.  I further hypothesized that compounds that inhibit the ATPase 
activity of TAg, which is specifically required for viral replication, might be identified.  As a 
first proof-of-principle for this concept, our lab recently determined that one compound, MAL2-
11B, which modestly slows both the ATPase activity of TAg and the ability of the TAg J domain 
to stimulate hsp70 ATPase activity, can inhibit the replication of SV40 and BKV (Wright et al., 
2009). However, MAL2-11B is not suitable as a therapeutic agent due to its low solubility, poor 
membrane permeability, and relatively low antiviral potency.  Moreover, MAL2-11B was not 
identified in a systematic screen using TAg as a probe, but was a structural analogue of 
compounds already known to alter the ability of J domain-containing proteins to activate the 
ATPase activity of hsp70 (Fewell et al., 2004; Wright et al., 2008).  Thus, the agent was neither 
identified nor optimized as a TAg-specific target. 
To identify more potent and selective polyomavirus inhibitors, in collaboration with the 
Gestwicki lab at the University of Michigan, we developed a novel high throughput screen with 
purified SV40 TAg.  The screen took advantage of a new platform to assess modulators of ATP-
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hydrolyzing enzymes, and the library included MAL2-11B-like compounds, as well as 
compounds that have been developed and approved for other uses.  As hoped, this approach led 
to the isolation of inhibitors of the TAg ATPase activity that were significantly more potent than 
MAL2-11B.  A preliminary structure-activity relationship (SAR) was then performed to identify 
the key chemical features of the molecules that give rise to their effects.  The two lead 
compounds from these subsequent efforts also inhibited the replication of both SV40 and BKV 
in cultured cells with an ED50 that was 10-fold higher than the dose at which modest toxicity was 
apparent, thus providing a satisfactory therapeutic index (TI).  Because the lead compounds were 
approved by the FDA for other applications, our collaborative efforts set the stage for the 
continued development and testing of a new class of anti-polyomavirus agents. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
The MicroSource MS2000 library contains ~2200 bioactive compounds with a minimum of 95% 
purity. The collection includes drug components (50%), natural products (30%) and other 
bioactive compounds (20%) (Miyata et al., 2010).  
Bithionol (CAS 97-18-7) and hexachlorophene (CAS 70-30-4) were purchased from 
Sigma-Aldrich, and the compounds ST024951 (1), ST029256 (2), ST033374 (3) ST033385 (4), 
ST057728 (5) and ST5308743 (6) were purchased from Timtec (Newark DE).  The compound 
5250892 (7) was obtained from ChemBridge (San Diego, CA), and resorcinol sulfoxide (8) and 
R128546 (9) were purchased from Sigma-Aldrich.  The purities of these bisphenol-like 
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compounds were confirmed by HPLC/UV, and by mass spectrometry when ionization was 
possible.  Cidofovir was kindly provided by Dr. Abhay Vats (University of Pittsburgh). Eight 
known dihydropyrimidines were synthesized as described (Wisen et al., 2008), and their 
structures were confirmed using high resolution mass spectrometry and 1H NMR. 
SV40 TAg was purified essentially as reported (Wright et al., 2009).  In brief, Sf9 cells 
were infected with a baculovirus engineered for the expression of wild type TAg for 45 h.  The 
cells were harvested and lysed, and the lysate was clarified by high-speed centrifugation.  The 
resulting supernatant was loaded on to an immunoaffinity column containing the monoclonal 
TAg antibody pAB419 (Harlow et al., 1981) covalently linked to Protein G Sepharose Fast-Flow 
beads.  The column was washed, and fractions highly enriched for TAg were eluted at pH 11. 
After the pH was adjusted to neutrality, the protein was dialyzed against 10mM Tris-Cl, pH 8.0, 
1mM EDTA, 100mM NaCl, 10% glycerol, and 1mM DTT.  TAg-containing fractions and the 
purity of the final preparation were verified by Coomassie Brilliant Blue staining of SDS-
polyacrylamide gels and by western blot analysis.  TAg was stored at -80°C until use. 
2.2.2 A high throughput screen to identify inhibitors of TAg ATPase activity 
A collection of ~150 dihydropyrimidines was screened in 96-well plates by our collaborators in 
the Gestwicki lab at the University of Michigan. Briefly, a stock solution of TAg was prepared in 
assay buffer (100 mM Tris-Cl, pH 7.4, 20 mM KCl, and 6 mM MgCl2, 0.01% Triton X-100) to 
yield a final concentration of 2.5 nM (0.018 μg/μL). An aliquot of this solution (14 μL) was 
added to each well of a clear 96-well plate and 1 μL of either the assay compound (final 
concentration 200 µM) or DMSO was added. The reaction was initiated with the addition of 10 
μL of 2.5 mM ATP.  The plates were then incubated for 3 h at 37 °C.  After incubation, each 
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well received 80 μL of the quinaldine red reagent (Miyata et al., 2010), which was quenched by 
the addition of 10 μL of a 32% sodium citrate solution. However, screening of the larger 
MS2000 collection necessitated development of a higher density format platform. Toward this 
goal, a high throughput screen to identify inhibitors of the ATPase activity of TAg was 
performed as described (Miyata et al., 2010), but with several modifications.  First, 5uL of the a 
stock solution of TAg (final concentration 2.5 nM) was added to each well of opaque, white, 
low-volume, nonsterile, polystyrene 384-well plates (Thermo Fisher Scientific, Inc).  It was 
critical to use these plates because assay sensitivity was strictly dependent on fluorescence 
quenching between the polystyrene plates and the quinaldine red agent (data not shown).  To 
each well, 0.2 μL of either the compound (at ~5 mM in DMSO) or DMSO was added.  The 
Gestwicki lab found that assay performance decreased above 5% DMSO.  The reaction was then 
initiated with the addition of 2 μL of 3.2 mM ATP, and the plates were incubated for 3 h at 37 
°C.  After incubation, each well received 15 μL of the quinaldine red reagent, which was 
quenched by the addition of 2 μL of a 32% sodium citrate solution. The plates were incubated for 
an additional 15 min before fluorescence intensity (excitation 430 nm, emission 530 nm) was 
measured on a PHERAstar plate reader. The Z factor (Zhang et al., 1999) was calculated to be 
0.70, which is indicative of a large and consistent difference between the signals of the positive 
and negative controls. The coefficient of variation ranged from 6 to 10% and the signal:noise 
was approximately 50. 
2.2.3 Biochemical and kinetic assays to assess TAg activity 
A steady state ATPase assay with purified SV40 TAg was performed as reported previously (Cyr 
et al., 1992; Wright et al., 2009).  In short, TAg was preincubated with the indicated compound 
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for 15 min on ice, and upon addition of α32P-ATP the reaction was moved to 30ºC.  At the 
indicated times, aliquots were removed, the reaction was quenched, and the ATP and generated 
ADP species were resolved by thin layer chromatography.  The resulting data were analyzed on a 
Fujifilm BAS-2500 phosphoimager and quantified using ImageGuage software (Fuji Film 
Science Lab).  The data obtained represent the results from at least 3 independent replicates.  
IC50 values were determined by titrating compounds into this assay such that the volume of 
DMSO was constant, and data were standardized relative to a DMSO control.  A sigmoid, 3-
parameter line regression of the resulting data was performed using SigmaPlot (Systat Software, 
San Jose, CA).   
A variation of this assay was used to obtain the desired kinetic constants via a 
Lineweaver-Burk plot.  In these assays, ATP was titrated from a final concentration of 7.14 µM 
to 50 µM and in the presence or absence of the indicated compound, and the rates of the 
reactions were determined as described above.  Each assay was performed at least three times.  
These data were plotted as a double reciprocal, and the Km and Vmax values were determined 
from a line fit.  The differences in the obtained data sets were determined by ANCOVA, 
performed by SAS (SAS Institute, Cary, NC).  Pairwise comparisons were performed for both 
the slope (used to determine the Km) and intercept  (used to determine the Vmax) of the line 
determined by SAS, and the p values for these comparisons are reported. 
Similarly, the steady state ATPase assay was performed with two other purified proteins, 
hsp70 and p97.  The human hsp70 was supplied by Raj Chovatiya and is described elsewhere 
(Chiang et al., 2009); although purified hsp70 is not a potent ATPase alone, this protein is active 
in this assay due to a proteolytically cleaved and active ATPase domain fraction that co purifies 
with full length hsp70. Each reaction used 3 μg of protein. The bovine p97 was a generous gift 
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from the DeMartino Lab (University of Texas Southwestern) and 5 μg were used in each ATPase 
reaction.  All other conditions for this assay are the same as described for TAg. 
TAg dependent DNA replication was assayed in vitro using a revised Li and Kelly 
method (P. Cantalupo, personal communication; (Li and Kelly, 1984; Wright et al., 2009).  
Reactions were prepared in a buffer solution that includes a mix of nucleotides, creatine-
phosphate, creatine kinase and a plasmid containing the SV40 ori, pUC.HSO (Wold et al., 1987).  
In the assay shown in Figure 11, 3 μg TAg and 90 ng HeLa cell lysate prepared by freeze-thaw 
were incubated with the compound for 15 min on ice prior to addition of the radiolabeled dCTP 
and DNA.  Samples were collected after 30, 60 and 90 min at 37 °C and ethanol precipitated.  
The resulting samples were separated on a 1% agarose gel and visualized using a 
phosphoimager. 
Expression of TAg was detected by Western blot as previously described (Wright et al., 
2009).  Briefly, cells were infected with SV40 at MOI=1.  At 48 hpi, lysates were harvested 
using Branton’s lysis buffer, and the concentration of lysates was normalized by Bradford assay.  
For each sample, 30 μg of lysate was loaded and separated by SDS-PAGE.  The proteins were 
transferred to a nitrocellulose membrane, and decorated with pAB419 (to detect TAg) or anti-
hsp70 or anti-actin antibody (Cell Signaling) as indicated.  The primary antibody was decorated 
with an HRP conjugated anti-mouse (TAg) or anti-rabbit (hsp70 and actin) antibody, and 
visualized with Pierce Supersignal ECL reagents on a Kodak image station IS440.   
Limited proteolysis was based on a previously described protocol with some modification 
(Weisshart et al., 2004). TAg was purified as above (section 2.2.1). Reactions were assembled 
with 3 μg TAg, 30 μM compound in DMSO and 4mM nucleotide (either ATP or AMP-PNP), 
then incubated for 20 min on ice prior to addition of protease.  As denatured TAg control sample 
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included 3.5 μL of TCA sample buffer (80 mM Tris HCl pH 8, 8 mM EDTA, 120 mM DTT, 
3.5% SDS, 0.29% glycerol, 0.08% Tris base and 0.01% bromophenol blue) in place of DMSO or 
nucleotide, then heated at 75 °C for 15 min and cooled before addition of protease.  Reaction 
were incubated at 37 °C for 5 min with 1.8 ng of Proteinase K (Sigma) diluted in 10 mM Tris 
pH8.0, 1.0 mM EDTA, 100 mM NaCl and 10% glycerol; the final volume of 25 μL, and this.  
The reaction was stopped with 5 μL of 100% trichloroacetic acid (Fischer Scientific) and 
incubated for 10 min on ice.  Reactions were centrifuged at 13,000xg at 4 °C for 10 min and the 
supernatants were removed.  The pellets were resuspended in TCA sample buffer, and then 
separated by 12.5% SDS-PAGE.  The proteins were visualized with Coomassie Brilliant Blue.  
As a control, the same procedure was performed using 3 μg Bovine Serum Albumin (Fermentas) 
in lieu of TAg, and these samples were separated by 10% SDS-PAGE and visualized by 
Coomassie Brilliant Blue. 
2.2.4 Viral replication and cell culture assays 
CV1 cells were grown in MEM with 10% FBS and pen/strep and Vero cells (kindly provided by 
Dr. Bruce McClane, University of Pittsburgh) were grown in DMEM containing 10% FBS and 
pen/strep at 37 ºC in a 5% CO2 incubator.   
BKV stocks were provided by Dr. Michael Imperiale, University of Michigan.  Crude 
BKV stocks were prepared based on a protocol from the Imperiale lab.  Vero cells were 
expanded to 50-60% confluence on 12 T150 flasks in DMEM containing 10% FBS, and 
pen/step.  Vero cells were infected at MOI 0.1 IU/cell with crude stock of BKV (made on RPTE 
cells (Low et al., 2004)) in DMEM containing 2% FBS, pen/step and 0.5 μg/mL Amphotericin B 
(Invitrogen) at 37° C for 1 h in a total volume of 6mL. After infection, the media was replaced 
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with 20mL fresh DMEM containing 2% FBS, pen/strep and 0.5 μg/mL Amphotericin B.  Some 
flasks were supplemented with 2 mL media 2dpi, and this seemed to improve the viral yield 
(Table 7).  The infection continued for 3-4 weeks, until all cells appeared nonadherent.  Cells 
were lysed by 3 freeze-thaw cycles, and the cell debris was further harvested from cultures by 
scraping up all cells into the media.  The crude stock was stored at -20 °C.   Given the cell debris, 
before further infection, the viral stock was agitated with a vortex mixer for 10-20 sec to release 
virus bound to cell membranes and then spun briefly to separate the membranes from virus 
containing supernatant immediately before infection. 
Immunofluorescence microscopy was performed based on a protocol from the Weisz lab 
(University of Pittsburgh (Guerriero et al., 2006)).  Vero cells were grown on poly-Lys treated 
glass coverslips and infected with BKV.  At 48 hpi, cells were washed with PBS, then fixed with 
4% paraformaldehyde for 20 min at room temp.  Fixation was stopped with two washes of PBS 
with 1 mM glycine.  The cells were permeabilized with 0.5% Triton X-100, after which they 
were washed twice again with PBS with 1mM glycine.  In preparation for addition of antibody, 
the cells were “blocked” with PBS with 1mM glycine and 0.25% Bovine Serum Albumin for 5 
min.  Cells were incubated for 20 min with 50 μL of a 1:20 dilution of pAB416 hybridoma 
supernatant (unpurified).  Preparation of this supernatant is discussed in section 3.2.2.  Cells 
were washed twice briefly in PBS with 1mM Glycine. Next, cells were incubated with a 1:100 
dilution of the secondary antibody, Alexa Fluor488 goat anti-mouse (Invitrogen), for 20 min in 
the dark.  Coverslips were mounted on slides with AntiFade Gold with DAPI (Invitrogen) and 
were visualized on an Olympus BX60 epifluorescence microscope with 100x oil immersion 
objectives, unless specified. A Hamamatsu Argus-20 CCD camera was used to capture images.  
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Focus fluorescence units were calculated by determining the ratio of infected (TAg-expressing) 
cells to uninfected cells from multiple random fields from several slides. 
To quantitate the effect of compound on viral replication, plaque assays were performed.  
SV40 stocks were prepared by plating CV1 cells into 24-well dishes and infecting the cells with 
SV40 at a MOI of 2 for 2 h.  Next, the media was removed and replaced with media containing 
the desired compound or an equivalent volume of DMSO.  Two biological replicates 
corresponding to each treatment were performed.  The media was refreshed at 24 hpi, and again 
supplemented with either DMSO or the indicated compound.  At 48 hpi, the cells were frozen 
and thawed 3 times to provide a viral stock.  This stock was titered by plaque assay using at least 
3 technical replicates, based on a previously reported protocol (Murata et al., 2008).  In brief, 
CV1 cells were grown on 6 cm dishes to near confluence and dilutions of the viral stock were 
plated onto the monolayer for 2 h, and then replaced by a 4mL overlay of media in 0.9% Noble 
agar.  On 3 and 6 dpi, an additional agar overlay was made.  At 9 dpi, the agar was removed and 
the monolayer was stained with crystal violet.  Plaques were counted by eye, and viral mediated 
cell clearing was confirmed by light microscope. 
A quantitative DNA replication assay for SV40 was performed as previously described 
(Huryn et al., 2011; Murata et al., 2009; Randhawa et al., 2005b).  CV1 cells were infected with 
SV40 at an MOI of 6, and after a 2 h infection the media was removed and replaced with media 
containing the desired compound or an appropriate volume of DMSO.  The media containing the 
compound was refreshed at 24 hpi and at 48 hpi before the media was aspirated and DNA was 
harvested by a modified Qiagen mini-prep.  Specifically, cells were washed in PBS and then 250 
µL of buffer P1 was added to each well. Next, 250 µL of P2 was immediately added to lyse the 
cells.  When cells were visibly lysed by examination by light microscope, the lysate was 
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removed and incubated with 500 µg Proteinase K at 55 ºC for 1 h.  The lysate was neutralized 
with N3 Buffer, and mixed gently.  Samples were centrifuged for 10 min at 15,000g at 4 ºC, and 
the resulting supernatant was loaded onto the supplied mini-column and centrifuged for 1 min at 
15,000g at room temp.  The column was washed in 700 µL PE, and briefly centrifuged to 
remove residual ethanol.  Finally, 50 µL of TE pre-warmed to 50 ºC was added to the column 
and equilibrated for 5 min before a final 1 min elution at room temperature was performed.  The 
resulting DNA stock was then quantified by quantitative PCR (qPCR; see below). 
To quantify the replication of BKV, Vero cells were infected with BKV for 1 h at an 
estimated MOI of 0.01.  The infectious media was removed and replaced with 1 mL media 
containing the indicated compound or DMSO.  Media containing the compound or the DMSO 
control was refreshed daily for 5 d.  The cultures were lysed 5 dpi by three freeze-thaw cycles at 
-20 ºC.  This viral stock was further homogenized by pipetting before quantification by qPCR. 
qPCR was performed to quantify the amount of SV40 or BKV DNA and to assess the 
extent of viral replication. These DNA stocks, obtained above, were serially diluted for qPCR 
assays as described (Huryn et al., 2011).  Absolute quantification was performed using pSVB3 
(Pipas et al., 1983) as a reference for SV40 and using pBKV (Dalrymple and Beemon, 1990) as a 
reference for BKV.  Each of these plasmids contain the entire viral genome cloned in to a 
BamH1 site.  A mix of primers and Taqman probe  (IDT DNA) (for SV40 5’ 
(FAM)/ATCAGGAACCCAGCACTCCACT/(IOWA BLACK) 3’, primer 1- 5’ 
GATGAACACTGACCACAAGG 3’, primer 2- 5’ GCACATTTTCCCCACCT 3’) were used to 
detect SV40.  The primers for BKV detection are reported elsewhere (Huryn et al., 2011).   
To assess compound toxicity, an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay was performed (Cory et al., 
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1991; Minguez et al., 2003).  CV1 cells were plated in 96 well dishes and grown to 90% 
confluency.  The desired concentration of compounds was added to warm MEM and plated onto 
cells in at least three technical replicates.  At 24 h, the media was aspirated and the indicated 
compound dissolved in media was added fresh.  At 48 h, the media was again aspirated but was 
replaced with diluted MTS reagent (Promega) in MEM lacking phenol red.  The plate was 
returned to the 37 °C incubator for 3 h.  Data were collected on a BioRad iMark Microplate 
Reader (Hercules, CA) at 490 nm.  The data were compared to both a DMSO (negative) and 1 
µM staurosporine (positive) control.  The LD50 was determined by sigmoid 3-parameter line 
regression of the data using SigmaPlot (Systat Software, San Jose, CA).  
2.2.5 In silico chemical similarity searches     
Similarity searches were conducted by our collaborators in the Gestwicki lab in an in-house 
database MScreen (http://mscreen.lsi.umich.edu/) using each scaffold against the external library 
set consisting of structures from Asinex, ChemBridge, ChemDiv, MayBridge, NCI, PubChem, 
Sigma, and TimTec. All structures within 70% similarity were retrieved for each chemical 
scaffold. The combined results were imported into the software program DVS and fingerprints 
using the 166 public MACCS keys were computed for the structures. Fingerprints were not 
successfully computed for all of the structures. Tanimoto distances were computed for each 
chemical scaffold against all of the retrieved structures. The results were then imported into 
Benchware DataMiner along with the structures and the original scaffolds. To aid in sorting, 
each original scaffold was given a Tanimoto distance of “-1” to itself. 
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2.3 RESULTS 
2.3.1 Identification of bisphenols that inhibit TAg ATP hydrolysis 
I hypothesized that inhibitors of the conserved and essential SV40 TAg ATPase activity would 
be general inhibitors of polyomaviruses, since each virus encodes a highly conserved TAg. 
Toward this goal, the Gestwicki lab adapted a procedure originally developed to identify 
inhibitors of the ATPase activity of hsp70 (Chang et al., 2008; Miyata et al., 2010). Briefly, this 
method involves measuring the enzymatic release of inorganic phosphate from ATP using the 
quinaldine red (QR) reagent. First, a library of approximately 150 dihydropyrimidines was 
screened to identify close structural derivatives of MAL2-11B that may be better TAg inhibitors 
(Wisen and Gestwicki, 2008; Wright et al., 2009). The compounds in this collection were 
screened at 200 µM in 96-well plates, as described in section 2.2.2. From this process, thirteen 
compounds were identified that inhibited > 35% of the ATPase activity of TAg. The activities of 
these compounds were then confirmed by re-screening them against TAg in duplicate. To 
complement these inhibitors and to identify alternative chemical scaffolds, the Gestwicki lab 
next screened the commercially available Spectrum Collection (MicroSource Discovery Inc., 
Groton, Conn), which contains 2,240 known bioactives and drugs approved by the FDA for a 
range of indications. However, because of the larger size of this library, a higher throughput (e.g. 
384-well plates) version of the QR assay was required. Therefore, pilot experiments were 
conducted with TAg to understand whether a miniaturized version would still give robust 
screening performance. Briefly, it was found that the signal was linear for at least 3 h when the 
concentration of TAg was at least 2.5 nM (0.018 µg/µL), the levels of ATP were 1 mM, and the 
reaction was performed at 37 °C (see Figure 4). Moreover, the assay exhibited good screening 
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parameters under these conditions, with an average Z factor between 0.6 and 0.7. Encouraged by 
these findings, the MS2000 collection in low volume, 384-well microtiter plates was screened to 
identify potential inhibitors. These compounds were screened at approximately 100 µM and, 
from this process, 33 (1.4% of the collection) compounds were identified as potential inhibitors 
because they reduced ATPase activity by > 20% (Figure 4). Of these compounds, the twenty 
compounds with the best inhibitory activity were confirmed in duplicate. Together, these 
combined screening efforts resulted in the identification of 13 dihydropyrimidines and 20 other 
compounds that appeared to directly inhibit TAg ATPase activity.  
  68 
 
  69 
Figure 4. Development of a high throughput screen for TAg ATPase inhibitors. 
(A) The phosphate signal is linear for at least 3 h at 0.25 μg/well (2.5 nM) of TAg, 1 mM ATP and 37 
°C. Phosphate levels were measured using quinaldine red (QR) and converted to pmoles using a set of sodium 
phosphate standards. (B) Relationship between TAg concentration and raw phosphate signal (OD620). To 
conserve protein, 0.25 μg per well (2.5 nM) was chosen for screening. Results are the average of triplicate 
wells and the error bars represent the standard deviation. (C) The results from screening the MS2000 
collection. TAg was screened in 384-well plates, as described in section 2.2.2. The red line is 3 standard 
deviations of the negative control. The purple line is the Z factor, calculated by plate.  The controls (positive 
(red): no enzyme; negative (blue): DMSO) were present on each plate. (D) Chemical structures of the active 
compounds from the MS2000 collection that were confirmed in duplicate and then screened in the steady-
state, radioactive ATPase assay (Figure 5A). 
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Next, to remove false positives, I wanted to test these compounds in an independent, 
steady state ATPase assay. This assay relies on 32P radioactivity instead of the colorimetric QR 
reagent. From the list of active compounds, 8 of the most potent dihydroyrimidines were re-
synthesized and 12 of the commercially available compounds from the MS2000 list were 
purchased. These compounds included a number of flavones, polyphenols and bisphenols, such 
as quercitin, baicalein, and chloranil (Figure 4). Using the radioactivity-based ATPase assay, 
Alex Ireland, an undergraduate with whom I worked, established that only three of these 
compounds, bithionol, chloranil and hexachlorophene, were significantly more potent inhibitors 
than MAL2-11B when used at a final concentration of 100 µM (Figure 5).  The remainder of the 
compounds were either false positives or their activities were not significantly better than 
MAL2-11B.  One possible application for these compounds is discussed in section 4.2.  Because 
chloranil caused TAg to aggregate under the utilized assay conditions (Figure 6), I focused my 
efforts on bithionol and hexachlorophene (Figure 5B).  Titrations of bithionol and 
hexachlorophene into the steady state ATPase assay revealed apparent IC50 values of 2 and 4 
µM, respectively (Figure 5C).  Thus, the potencies of bithionol and hexachlorophene were 
greater than those of any other reported TAg inhibitor, including MAL2-11B, ellagic acid, and 
spiperone (Goodwin et al., 2009; Wright et al., 2009).    
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Figure 5. A high throughput screen identifies inhibitors of TAg ATPase activity. 
A.  The indicated compounds were tested in triplicate at a final concentration of 100 µM in a steady 
state ATPase assay.  B. The structures of bithionol, right, and hexachlorophene, left, are shown. C. Results 
from triplicate ATPase assays are shown, +/- SD, for bithionol, grey bars, and hexachlorophene, black bars, 
at the indicated concentrations.  In parts A and C, results were standardized to a DMSO control. 
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Figure 6. Chloranil cause TAg aggregation in vitro   
Mock steady state ATPase assays were assembled in the presence of a final concentration of 100 μM 
of either MAL2-11B (2-11B), bithionol (Bith) hexachlorophene (Hexa), chloranil (Chl), or an equal volume of 
DMSO.  2% TCA was added a pellet control.  After a 15 min pre-incubation on ice with the indicated 
compound, 50 μM ATP was added and the reaction was incubated for another h at 30°C. Reactions were 
centrifuged for 5 min at 15,000g. Next, the supernatant (S) and pellet (P) fractions were resolved by 10% 
SDS-PAGE, and proteins were visualized by Coomassie Brilliant Blue stain. TAg remained soluble in the 
presence of DMSO, MAL-211B, bithionol or hexachlorophene, but the majority of the detected protein in the 
presence of chloranil appear as a high molecular weight aggregate in the well (top arrow) and was absent at 
the predicted position for TAg (bottom arrow).  
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2.3.2 A structure-activity relationship for bisphenol-like TAg ATPase inhibitors 
Because both bithionol and hexachlorophene are bisphenols, I hypothesized that the directed 
screening of related compounds would help to establish a structure-activity relationship (SAR) 
for the inhibition of TAg ATPase activity.  To this end, an in silico search was performed and 60 
compounds were identified that were either structurally similar to these compounds or could be 
employed to test specific hypotheses regarding the chemical groups that mediate the inhibitory 
activity on TAg.  I selected a subset of these compounds based on commercial availability, using 
structures that would address specific hypothesises about this structure, such as substituents at 
different positions and flexibility between rings (Figure 7A), and these were screened in the 
steady state ATPase assay at a final concentration of 30 µM (Figure 7B).  This concentration was 
chosen based on the fact that bithionol and hexachlorophene inhibited the ATPase activity of 
TAg by ~80% at this concentration (Figure 5C). Alex Ireland found that only two of the tested 
compounds inhibited the ATPase activity of TAg, and these agents, (compounds 7 and 9, 6,6'-
thiobis(2-bromo-4-chlorophenol) and 6,6'-methylenebis(2-bromo-4-chlorophenol)), are most 
structurally similar to bithionol.  Based on the data in Figure 7B, I also conclude that some 
essential features for TAg inhibition include a bisphenol moiety, flexibility at the biraryl linker 
group, and the presence of substituents at positions 2 and 4 on the phenols; however, bulky 
groups at these positions appeared to disrupt inhibitory activity.  
  75 
 
 
 
 
 
 
  76 
Figure 7. A structure activity relationship for the action of select bisphenols and bisphenol-like 
compounds for inhibition of TAg ATPase activity. 
A.  An in silico search for bisphenol-related structures based on Tanimoto distances was performed 
(see section 2.2.5), and from these results nine compounds were selected for further analysis (see section 
2.2.1).  B.  The indicated compounds were tested in a steady-state ATPase assay at a final concentration of 30 
µM.  The results are shown relative to a DMSO control (-), in triplicate, +/- SD.  
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2.3.3 Bithionol and hexachlorophene have off target effects on hsp70 and p97 
Convinced of the in vitro efficacy of both compounds on TAg, I wanted to determine whether 
these compounds would act as general ATPase inhibitors.  Two other ATPases, a mammalian 
hsp70 and bovine p97, were tested.  Previously, work in the lab demonstrated that the control 
compound MAL2-11B was an inhibitor of the TAg-stimulated hsp70 activity, but did not inhibit 
the stimulation of all J domain containing proteins (Wright et al., 2008; Wright et al., 2009).  
Before attempting such assays with the bisphenols, I wanted to test whether the bisphenols might 
directly inhibit the activity of hsp70.  While hsp70 normally has very little ATPase activity 
without a co-chaperone, at this time, there was a preparation of hsp70 in the lab that contained a 
mix of full-hsp70 and the ATPase domain of hsp70 (R. Chovatija, data not shown).  This 
preparation had a high level of endogenous activity, which is thought to be the activity of the 
uncoupled ATPase domain.  I showed this activity could be inhibited by the bisphenols (Figure 
8).  For this reason, I determined it would be difficult to distinguish whether the bisphenols 
might have a bipartite inhibition of both the J domain and ATPase domain of TAg.  Although 
this is not conclusive evidence that bithionol and hexachlorophene are hsp70 inhibitors, I chose 
not to pursue this activity further. 
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Figure 8. Bithionol and hexachlorophene are more potent inhibitors of hsp70 activity than MAL2-
11B. 
The effect of each compound at 100 μM was tested on hsp70 in a steady state ATPase assay.  Percent 
activity was calculated relative to the activity of the hsp70 with DMSO control over the duration of the 
reaction.  Each condition was performed in triplicate, and reported +/- SD. 
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I also wanted to test the effects of these compounds on p97, which is both a 
multifunctional essential chaperone-like protein and a mammalian AAA+ ATPase (Ju and Weihl, 
2010; Kakizuka, 2008).  I was surprised to find robust, but differential effects on p97 ATPase 
activity with these compounds at 30 μM.  Alex Ireland further characterized this difference by 
performing steady state ATPase assays with additional time points (Figure 9).  As shown in 
Figure 9, bithionol stimulates p97 activity, while hexachlorophene inhibits p97.   The 
hexachlorophene inhibits p97 slightly less than TAg at the same concentration.  Given that the 
activities of p97 are essential for a variety of protein folding and homeostasis functions in the 
cell (Ju and Weihl, 2010; Ye et al., 2005), I was concerned that this might lead to cytotoxic and 
off target effects.  Fortunately, when cytotoxicity was assessed by MTS assay (Table 5) it 
appeared not to be a concern. 
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Figure 9. Bithionol stimulates p97 ATPase activity while hexachlorophene inhibits p97. 
This ATPase assay was performed under the same conditions as demonstrated for TAg ATPase 
assays.  This experiment is displayed as a time course to highlight the rapid stimulation of p97 activity by 
bithionol.  Red squares indicate p97 with DMSO, blue diamonds indicate no p97, green triangles represent 
p97 with 30 μM Bithionol, purple Xs indicate p97 with 30 μM hexachlorophene.  Both reactions including 
bisphenols are demonstrated n=3, and error bars indicate +/- SD. 
 
 
 
2.3.4 Bithionol and hexachlorophene inhibit SV40 replication 
Bithionol and hexachlorophene were derived from the Spectrum 2000 library as FDA-approved 
compounds for their bacteriostatic and antiparasitic properties.  In fact, both compounds were 
widely used as topical antiseptics before more potent and less toxic alternatives became 
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available.  In addition, bithionol has successfully been used to treat outbreaks of the parasite 
Paragonimus westermani in humans, and can be taken orally at a concentration of 40 mg/kg 
every other day (Kim, 1970; Price et al., 1993).  To our knowledge, neither compound has been 
examined for its ability to treat a viral infection. 
To examine whether the bisphenolic TAg inhibitors inhibit polyomavirus replication, the 
activities of bithionol and hexachlorophene were first tested in an SV40 plaque assay.  CV1 
monkey kidney cells were infected with SV40 and treated with bithionol and hexachlorophene at 
a final concentration of 30 µM.  As a control, we also retested MAL2-11B at a final 
concentration of 100 µM.  Next, a crude viral stock was obtained and titered by plaque assay.  
We first observed that MAL2-11B reduced the number of plaques by nearly 60% (Figure 10A), 
which is consistent with previously published results (Wright et al., 2009).  We also discovered 
that bithionol and hexachlorophene inhibited viral replication nearly 100-fold relative to the 
DMSO control, indicating that both compounds are significantly more potent inhibitors of SV40 
propagation than MAL2-11B.   
To confirm these results and to provide a quantitative method to rapidly test TAg 
inhibitors, a qPCR assay was developed to measure SV40 DNA replication in our cell culture 
system.  This assay is based on previous work to detect the human polyomavirus BKV in patient 
samples (Randhawa et al., 2005a).  The assay takes advantage of the small size of the 
polyomavirus genome (~5 kb), which can be purified like plasmids.  In short, cells were infected 
as described for the plaque assay and were then washed and lysed using commercial mini-prep 
buffers.  The viral DNA was collected and titered by absolute quantification in a qPCR assay 
(see section 2.2.4).  Finally, the data were compared to an untreated, infected control. 
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Figure 10.  Bithionol and hexachlorophene inhibit SV40 replication. 
A. SV40 replication in CV-1 monkey kidney cells was assessed in the presence of MAL2-11B, 
bithionol or hexachlorophene for 2 d, after which the replication-competent virus was titered by plaque 
assay.  The data represent 3 separate infections, each measured in at least two technical replicates, +/- SD.  B.   
Replication of viral DNA in a parallel experiment was quantified by qPCR under identical conditions to those 
used in part A.  The data represent the means of 12 independent experiments, +/- SE. 
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As anticipated, I again found that MAL2-11B at a final concentration of 100 µM 
inhibited DNA replication in culture by ~60% (Figure 10B).  Further, both bithionol and 
hexachlorophene inhibited DNA replication ~100-fold at 30 µM (Figure 10B).  This result is 
completely consistent with the results of the plaque assay, thus validating this protocol. Although 
not all viral DNA replicated during infection leads to infectious viral particles (Rigby and Berg, 
1978), I observed a clear correlation between the outcome of the plaque assay and the qPCR 
assay.  More generally, the data support my hypothesis that a directed isolation of TAg ATPase 
inhibitors can be used to identify compounds that inhibit polyomavirus replication. 
In an effort to refine the mechanism of these drugs, an in vitro DNA replication assay 
was performed.  This assay was based on a classical assay, which takes advantage of the ability 
of TAg to recruit host cell machinery from HeLa cell lysate to replicate DNA (Li and Kelly, 
1984).  The readout for this assay is incorporation of a radiolabeled nucleotide into growing, 
replicated DNA.  Although my experiments indicated that both bithionol and hexachlorophene 
inhibit viral DNA replication in the cell culture system, neither compound inhibits DNA 
replication in this assay (Figure 11).  Many conditions were explored for this assay, including 
preincubation of TAg with the small molecules, modification of time and temperature, but under 
no conditions did bithionol and hexachlorophene inhibit DNA replication.  Although this result 
was unexpected, noted differences between the in vitro and in culture systems may partially 
explain this outcome, which will be discussed in greater detail in sections 2.4 and 4.3. 
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Figure 11.  Bithionol and hexachlorophene do not inhibit DNA replication in vitro. 
In this figure, 3 μg TAg and HeLa lysate at a final concentration of 9 ng/μL were incubated with the 
compound for 15 min on ice prior to addition of the radiolabel and DNA.  In each reaction, DMSO alone (+) 
or the indicated compound (MAL2-11B denoted 211B) was added at multiple concentrations, denoted below 
the compound (values are μM).  These   samples were collected at t=30, 60 and 90 min (increasing time is 
indicated by black triangles), and ethanol precipitated.  The products were separated on a 1% agarose gel, 
which was visualized by phosphoimager.  Note: higher concentrations of the bisphenols were not examined 
since beyond 100 μM effects would most likely be non-specific. 
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One possible mechanism to explain the inhibition of viral replication is that the 
compounds compromise host cell viability.  To exclude this scenario, a cell viability assay—the 
MTS assay (see section 2.2.4)—was performed with each compound in CV1 cells.  The data 
were also compared to a DMSO negative control and to a positive control, the toxic agent 
staurosporine (Tanaka et al., 1995).  Importantly, the compounds were added and the cells were 
treated under conditions that were identical to those used when the effects of the compounds on 
SV40 replication were assessed.  In this assay, the MI50 (metabolic index-50) is defined as the 
concentration of compound that yields one-half the MTS signal compared to the negative 
(DMSO) control.  The MI50 values obtained for bithionol and hexachlorophene were 50 µM 
(Table 5).  We therefore conclude that the antiviral effects of these agents are independent of 
their modest toxicities. 
 
 
 
Table 5.  MI50 and Therapeutic index for bithionol and hexachlorophene. 
Both the MI50 and Therapeutic Index were determined by an MTS assay in CV1 monkey kidney 
cells.  MI50 is defined as the concentration of compound that yields one half the MTS signal of the control 
cells.  Therapeutic Index is calculated as the MI50/IC50, and indicates compound specificity. 
 
 
Compound MI50 Therapeutic Index 
Bithionol 50 µM 12.5 
Hexachlorophene 50 µM 25 
 
  86 
One clue about the difference in the in vitro and cell culture replication assays came from 
looking at TAg expression during an infection.  TAg expression was examined 48 hpi with or 
without drug treatment (Figure 12).  Given the unstructured linkers that connect the folded 
domains of TAg, it is common to see aggregation of TAg in the well and at the interface of the 
stacker and separating gel (M. Saenz, personal communication; see also Figure 17).  However, 
even with aggressive use of reductants, in cells treated with bithionol or hexachlorophene TAg 
appeared to be an insoluble aggregate when infected lysates were examined by Western blot.  
Expression levels of the chaperone hsp70, which would normally be upregulated by a global 
stress response, did not appear to respond to drug treatment (Figure 12)(Mayer and Bukau, 
2005), suggesting the effect on TAg solubility is not due to global denaturing of cellular proteins. 
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Figure 12. Expression of soluble TAg is decreased during treatment with bithionol and 
hexachlorophene. 
CV1 cells were infected with SV40 (or a Mock infection, as indicated), and then incubated with 
media with the indicated concentration of compound or an equivalent volume of DMSO for 48 h.  MAL2-11B 
was used at 100 μM.  Cells were lysed and equal amounts of lysate were separated by SDS-PAGE and 
transferred to nitrocellulose. Western blot analysis of 30 μg of cell lysates was performed using antibodies 
specific for TAg, hsp70 and actin. 
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It may be possible that bithionol and hexachlorophene cause TAg-specific unfolding, or 
gross conformational changes.  One way to detect such changes would be by limited proteolysis 
with a protease.  The tryptic fragments of TAg have already been characterized (Weisshart et al., 
2004).  Based on this evidence, I tested whether these fragments would be changed by the 
presence of bithionol or hexachlorophene.  As demonstrated in Figure 13A, neither bithionol nor 
hexachlorophene changed the conformation of TAg as detected by limited proteolysis with 
Proteinase K.  Since this was consistent between experiments, I tested whether these compounds 
might affect the proteolysis of a control protein, in this case BSA.  Figure 13B shows that while 
these compounds do not denature BSA, in contrast to the SDS control, there are some fragments 
that are not resolved in the presence of bithionol or hexachlorophene.  This may suggest a 
modest change in BSA conformation, in contrast to the patterns shown in Figure 13A.  
Combined with the evidence in Figure 12, these data suggest that neither bithionol nor 
hexachlorophene cause global denaturing of proteins in general or TAg specifically.  These data 
imply that the mechanism of action of these compounds stems from a particular interaction with 
TAg. 
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Figure 13. Limited proteolysis indicates bithionol and hexachlorophene do not cause TAg unfolding. 
A. Reactions were assembled with 4mM of the indicated nucleotide, 3 μg TAg with DMSO (D), 30 
μM bithionol (B) or 30 μM hexachlorophene (H) and incubated for 20 min on ice.  As a control, a sample of 
TAg that was heated to 75 °C in the presence of SDS (S) before addition of Proteinase K.  To start the digest, 
1.8 ng of Proteinase K were added to each reaction for 5 min at 37 °C, before the reaction was quenched with 
trichloroacetic acid, and the protein fragments were precipitated.  The resulting protein fragments were 
separated by SDS-PAGE and visualized with Coomassie Brilliant Blue stain. A sample of undigested TAg (U) 
was included for comparison.  Arrow indicates full length TAg, triangles indicate fragments that result from 
proteolysis.  B.  BSA was Proteinase K digested under similar conditions, including addition of DMSO (D), 30 
μM bithionol (B) or 30 μM hexachlorophene (H).  No nucleotide was present in these reactions.  The reactions 
were stopped with trichloroacetic acid, and the resulting protein fragments were separated by SDS-PAGE 
and visualized with Coomassie Brilliant Blue stain. A sample of undigested BSA (U) was included for 
comparison.  Arrow indicates full length BSA, and the triangles indicate fragments that result from 
proteolysis.  The * indicates fragments that are only present in the absence of bithionol or hexachlorophene. 
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In order to test this hypothesis and to characterize how bithionol and hexachlorophene 
inhibit the ATPase activity of TAg, ATP was titrated into the steady state ATPase assay while 
the concentration of inhibitor was held constant.  These data were analyzed by double reciprocal 
(i.e., Lineweaver-Burk) plots.  To verify that meaningful kinetic information could be obtained, I 
also assessed the ability of ADP to function as a bona fide competitive inhibitor for TAg’s 
ATPase activity.  Figure 14 presents an example of this analysis, and as expected ADP increases 
the Km for ATP whereas the Vmax stays relatively constant, which is typical of competitive 
inhibition (Segel, 1976).  When bithionol and hexachlorophene were examined at a final 
concentration of 3 µM, which inhibits TAg ATPase activity by ~50%, there were statistically 
significant increases in the Km values for ATP.  Effects on the Vmax values were also apparent but 
these were not significantly different from the DMSO control (Table 6).  The simplest 
interpretation of these data is that bithionol and hexachlorophene act as competitive inhibitors for 
ATP.  However, because of the significant differences in the structures of ATP and these two 
bisphenols, it is also possible that the compounds bind another site, which alters the 
conformation of TAg (see section 2.4). 
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Figure 14. Example of Lineweaver Burk analysis of TAg with ATP and ADP. 
A Lineweaver-Burk analysis of TAg was performed over a range of ATP concentrations and was 
used to determine the Km and Vmax.  Data represent values obtained in the presence of either DMSO 
(triangles) or 150µM ADP (circles).  Assays were performed at least in triplicate, and are shown as means of 
the data, +/- SD. 
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Table 6. Bithionol and hexachlorophene change the Km of TAg ATP hydrolysis. 
Kinetic parameters (Km and Vmax) were determined by Lineweaver-Burk analysis of TAg in the 
presence of 150 µM ADP or 3 µM bithionol or hexachlorophene over a range of ATP concentrations, as 
shown in FIGURE 4.  ANCOVA was used to determine the p values for each pair-wise comparison. 
 
 
 
 
 
 
 
 
 
* p<0.01, TAg + DMSO versus TAg + ADP or bithionol; 
** p<0.05, TAg + DMSO versus TAg + hexachlorophene; 
TAg + DMSO versus TAg + ADP, bithionol or hexachlorophene, p>0.5 
 Km   
(µM) 
Vmax 
(pmol/min) 
TAg + DMSO 110  3.5  
TAg + ADP  200 * 2.9  
TAg + Bithionol 590 * 10  
TAg + Hexachlorophene 290 ** 6.6  
  94 
2.3.5 Bithionol and hexachlorophene inhibit BKV replication 
I next wanted to examine whether bithionol and hexachlorophene could inhibit the replication of 
a clinically relevant polyomavirus, BKV.  Although I was able to establish conditions for 
examining BKV infection by immunofluorescence (IF, Figure 15), this method did not detect 
BKV infection with sufficient resolution to examine the effects of inhibitors.  This is a 
predictable limitation of this slow growing virus.  However, this assay did validate the BKV 
stock and infection conditions used in later assays.  Based on a protocol from the Imperiale lab, 
Vero cells grown on cover slips were infected for 3 d with BKV, and then co-stained with DAPI 
and pAB416 (1:20), an antibody that recognizes both SV40 and BKV TAg (Harlow et al., 1981) 
(Figure 15).  The Imperiale lab demonstrated that expression of BKV TAg begins within 12 h of 
infection (Jiang et al., 2009b); quantitation of focus fluorescence units (ffu) can be a faster way 
to assay the titer of viral stocks compared to quantitation of the plaque forming units (pfu), 
which requires multiple complete rounds of infection.  However, not all PyV infections proceed 
from initiation to replication; Todaro and colleagues suggested that 1 in 100 viral particles of 
SV40 lead to a successful infection (Todaro and Green, 1966)  As a result, this method can over-
estimate the actual titer of virus.  
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Figure 15. BKV TAg can be detected by immunofluorescence. 
Vero cells were infected with BKV for 3 d before IF staining for DNA and TAg.  Blue indicates the 
DAPI stained nuclear DNA, and green indicates pAB416 and Alexa Fluor 488 goat anti-mouse IgG (TAg).  A. 
A mock infection probed with undiluted pAB416 demonstrates one type of background issue sometimes seen 
in this assay.  B. BKV infected Vero cells stained with undiluted pAB416.  In this case the cytoplasmic 
staining is not thought to indicate TAg expression, but high background levels.  C. Infected Veros stained 
with pAB416 diluted 1:20.  This dilution of antibody reduced background such that some, but not all, cells 
appeared to express nuclear TAg.  The nucleus does not significantly change size at this stage in infection. 
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As shown in Figure 15C, very little cytopathic effect was visible from the BKV infection, 
in contrast to SV40, which causes nuclear swelling during infection (data not shown).  BKV TAg 
was consistently detected in Vero cells, and the stocks were titered at 8x103 ffu/mL.  This low 
stock titer is an indication of the how much less efficient BKV is compared to SV40 (for 
reference, my SV40 stocks are consistently 1x107 pfu/mL or greater, where pfu is a more 
stringent readout for viral particles than ffu).  Given this low titer and infection efficiency, the 
expected 100-fold decrease in viral replication upon addition of inhibitor would have shown less 
than 1 infected cell per slide, invalidating this method of detection for the proposed experiments. 
However, future experiments could get around this limitation by using higher titer stocks, which 
may be possible to obtain if the virus is purified from the crude stock.  Based on the data from 
these titrations, I suspect that the low efficiency of infection is due to tropism.  The crude stock 
prepared from the Imperiale lab was prepared in human renal proximal tubule cells, which are 
the native host for BKV (Low et al., 2004).  For each infection, the titer decreased about 25-fold, 
as demonstrated in Table 7.   Since the viral stocks were passaged through Vero cells twice (one 
time to make the stock, and a second time in the titration), the apparent MOI is decreased by 
several hundred or a thousand-fold.  Although Vero cells are competent for BKV replication, it 
has been suggested that HEK293 cells may be a better cell line for making crude stocks from (M. 
Jiang, personal communication). 
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Table 7.  Titers of BKV stocks as determined by immunofluorescence. 
Two different approaches were used in preparing stocks: ‘fed’ cells were supplemented with media 2 
dpi, and ‘unfed’ were not.  Both infections continued 14dpi until the crude stocks were harvested.  Based on 
the known titer of the Imperiale lab stock, infections with each of these crude stocks were performed with 
identical volumes at an estimated MOI of 1.  The infected and uninfected cells were counted to determine the 
relative infection.   
 
 
Stock Relative infection 
(MOI=1) 
Imperiale 1:25 cells infected 
‘fed’ stock 1:480 cells infected 
‘unfed’ stock 1:1220 cells infected 
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Instead, to quantitatively address the activity of the compounds during infection, a more 
sensitive and quantitative qPCR detection method was used to assess the activity of bithionol and 
hexachlorophene on BKV replication.  In this assay, a low titer infection was performed in Vero 
cells, and the DNA was quantified by qPCR, as performed for SV40 (Figure 16).  Data were 
compared to a DMSO control, MAL2-11B and to cidofovir, which has been shown to inhibit 
BKV replication in vitro and has been used clinically (Farasati et al., 2005; Johnston et al., 
2010).  The results of this experiment showed that bithionol and hexachlorophene inhibit BKV 
replication by ~70% at a 30 µM, and this effect is comparable to the impact of MAL2-11B or 
cidofovir on BKV when used at much higher final concentrations (100 and 350 µM, 
respectively; Figure 16). Interestingly, hexachlorophene maintained its potent inhibition at 
10 µM, but bithionol was significantly less effective at this lower concentration (Figure 16).  A 
model to describe this phenomenon is provided in section 2.4.  Together, these data indicate that 
the directed screening for TAg ATPase inhibitors can be used to identify inhibitors of 
polyomavirus infection.  Among these inhibitors, two compounds were identified that are more 
potent than clinically evaluated anti-virals.  Our data also indicate that second-round screening 
for inhibition SV40 replication via qPCR assay is a valid route to isolate inhibitors of BKV 
replication, which is significantly more laborious to propagate and analyze. 
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Figure 16. BKV DNA replication is inhibited by bithionol and hexachlorophene. 
Both bithionol and hexachlorophene inhibit BKV DNA replication in Vero monkey kidney cells.  The 
replication of BKV DNA was assessed after 5 d of infection with MAL2-11B, cidofovir, bithionol or 
hexachlorophene at the indicated concentrations, and the levels of viral DNA were quantified by qPCR as 
described in the section 2.2.4.  The data were standardized to the DMSO control, +/- SE.  Data represent the 
means of 12 experiments from four independent infections. 
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2.4 DISCUSSION 
Previous screening strategies to identify polyomavirus inhibitors took advantage of indirect read-
outs for viral infection, which led to the identification of ellagic acid and spiperone as inhibitors 
of TAg expression in SV40, BKV, and JCV infected cells (Goodwin et al., 2009).  A preliminary 
analysis of these compounds indicated that they may block viral entry.  While these efforts have 
identified inhibitors of viral propagation, target and off-target effects could not be ascertained.  
In contrast, I took advantage of my knowledge of polyomavirus biology to identify components 
of the viral life cycle that could be disrupted by small molecules.  We then created an assay to 
target the TAg dependent activity. The assay takes advantage of the fact that TAg’s ATPase 
activity is essential for viral replication (Castellino et al., 1997; Fanning et al., 2009), and that 
human cells lack a TAg homologue.  The data presented in this Chapter indicate the success of 
this targeted, mechanism-based approach.  Based on the excellent Z factor and signal-to-noise 
for the targeted screen (0.7 and 50, respectively), the specificity and structural similarities of the 
lead compounds, and the fact that the estimated therapeutic index for these compounds is >10 
(Table 5), I am confident that more potent and efficacious inhibitors can be obtained via 
subsequent efforts with more diverse libraries.  
My work was initiated to address the paucity of available therapeutics for polyomavirus 
infection.  Previous work to identify compounds that inhibit polyomavirus led to the discovery of 
cidofovir, leflunomide (Farasati et al., 2005), and the quinolones (Ali et al., 2007).  These agents 
have been used with some success in the clinic.  Cidofovir inhibits BKV in vitro and is 
commonly used as a treatment for BKVAN (Farasati et al., 2005), but high creatine levels, which 
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are typical in nephropathy, contraindicate its use.  In addition, there has been no controlled 
clinical study to suggest that the lower dosage levels used in BKVAN actually compromise viral 
replication beyond the impact of reducing immunosuppression (Hirsch and Randhawa, 2009).  
Similarly, the immunosuppressant used to treat rheumatoid arthritis, leflunomide, has been 
shown to decrease BKV replication in vitro but has not been rigorously examined in clinical 
trials (Faguer et al., 2007; Josephson et al., 2006a).  A third class of compounds used for the 
treatment of BKVAN are the quinolones, including ciprofloxacin and ofloxacin.  While these 
antibiotics have shown promise both in vitro and in the clinic (Leung et al., 2005; Randhawa, 
2005), some patients cannot tolerate them, and they exhibit relatively low potency (Ali et al., 
2007). In addition, our lab previously uncovered MAL2-11B as an inhibitor of SV40 and BKV 
replication, but this agent was neither obtained via directed screening efforts nor optimized as an 
anti-viral (Wright et al., 2009).  The low solubility and efficacy of this compound requires 
further refinement if this scaffold is to be pursued as an anti-viral agent. 
As described above, bithionol and hexachlorophene were included in the library used for 
our screen by virtue of the fact that they are FDA approved for other applications.  Both 
compounds have been used as topical anti-microbials, but it is known that overexposure can be 
toxic (Kimbrough, 1973; Powell and Lampert, 1973).  Under conditions in which the potential 
neurotoxic effects of these agents are not as problematic, bithionol and hexachlorophene also 
have veterinary applications as anti-parasitic and anti-fluke agents.  In fact, these compounds 
may be of use for the veterinary treatment of Avian Polyomavirus, which can cause acute death 
in a wide range of psittacine birds (Katoh et al., 2010).  Further, in geographical regions where 
fluke outbreaks in humans are more problematic, bithionol has been used to successfully clear 
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infections in humans after oral administration (Bacq et al., 1991; Kim, 1970; Lee and Kim, 2006; 
Price et al., 1993; Seo et al., 1982). 
The correlation between SV40 inhibition and BKV inhibition confirms my hypothesis 
that the isolation of SV40 TAg ATPase and SV40 replication inhibitors can lead to the 
identification of inhibitors of other polyomaviruses.  However, it was curious that bithionol and 
hexachlorophene inhibit BKV to a different extent when used at a final concentration of 10 µM, 
although their effects on the ATPase activity of TAg and on SV40 replication were essentially 
identical.  This phenomenon may reflect bithionol’s differential interactions between the SV40 
and BKV TAgs, which—while highly conserved (74% identity)—are certainly not identical (see 
section 1.3).  Alternatively, this difference may be a result of the different time courses needed to 
assess viral infection.  Given that SV40 replication is assayed after two days, and BKV 
replication is assessed after five days, compensatory and/or off-target effects of one agent (but 
not the other) may accumulate over the duration of the infection.  It is also worthwhile to note 
that while bithionol and hexachlorophene are structurally similar they may not interact 
identically with TAg.  Indeed, their effects on the Km for ATP in TAg are unique (Table 6).  A 
recent report indicated that these agents inhibit glutamate dehydrogenase, but interestingly they 
bound somewhat differently to this hexameric enzyme when analyzed structurally (Li et al., 
2009).  Hexachlorophene binds the center core of the hexamer, while bithionol binds at the two-
fold axis between pairs of subunits.  Thus, it is possible that bithionol and hexachlorophene also 
interact differently with TAg, perhaps even at a site that is distinct from the ATP binding pocket.  
Indeed, even though the effects of bithionol and hexachlorophene on the Vmax of TAg were not 
statistically significant (Table 6), it is possible that the compounds have pleiotropic effects on 
TAg: a primary binding site might be at or near the nucleotide pocket, as has been observed by 
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competitive inhibition of the NADPH binding enzyme 3-oxoacyl-ACP reductase 
(Wickramasinghe et al., 2006), whereas secondary binding may occur between monomers at the 
hexameric interfaces in TAg.  This question can best be resolved via a structural analysis of 
bisphenol binding to TAg, an effort that is underway.  Regardless, it is important to emphasize 
that whatever off-target effects these agents may possess, the magnitude of these interactions is 
insufficient to alter cell viability anywhere near the effective concentration needed to inhibit 
SV40 or BKV replication.  
It should be noted that determining the molecular mechanism of these small molecules on 
TAg was pursued aggressively without success.  Purified TAg was not amenable to native gel 
electrophoresis (data not shown), which may have allowed me to examine the oligomeric state of 
TAg in the presence of the inhibitory compounds.  This may have been related to the fact that 
more recent preparations of pure TAg appeared to be insoluble in a simple pelleting assay, 
despite displaying robust ATPase activity (data not shown).  Although minor changes to the 
purification protocol may be responsible for these changes, these also greatly improved protein 
yield, and did not hinder the proteins activity in a variety of other in vitro assays (see section 
3.3.1).  Limited proteolysis of TAg by proteinase K did suggest that bithionol and 
hexachlorophene did not induce major conformational changes in the protein (Figure 13).  Based 
on our screening method, I believe that the anti-viral activity displayed by bithionol and 
hexachlorophene directly targets TAg, although it remains unclear how these compounds inhibit 
TAg either in vitro or during an infection.   
Unfortunately, without a better understanding of the molecular mechanism, any 
explanation of the distinct results on DNA replication in vitro and in culture is speculation.  
However, given the known discrepancies in these assays, I will suggest some hypotheses for this 
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activity.  It is known that the J domain of TAg is required for viral replication, but it appears to 
be dispensable in the in vitro system (Weisshart et al., 1996), so this is not the first time such a 
distinction has occurred.  Although the ATPase activity of TAg is essential for replication of 
viral DNA, it is not clear that this is the rate-limiting step in either assay.  In fact, there has not 
been a direct correlation between the concentrations of small molecules that inhibit TAg ATPase 
and that inhibit DNA replication in vitro (Huryn et al., 2011; Wright et al., 2009).  Since it is 
known that DNA stimulates the ATPase activity of TAg (Giacherio and Hager, 1979), it is 
possible that the presence of DNA in the replication assay or during an infection overcomes the 
effect of the inhibitors.  This may explain the lack of a correlation of the effects of the 
compounds between the in vitro DNA replication assay and the ATPase assay. 
Overall, the experiments reported in this chapter document three important findings.  
First, we were able to design a high throughput screen to identify inhibitors of the SV40 TAg.  
This method was suitable for screening in 384-well plates and it may be co-opted in the future to 
screen larger and more diverse libraries.  Second, we identified two FDA-approved compounds 
that inhibit both TAg ATPase activity and the replication of two polyomaviruses, SV40 and 
BKV.  Third, we developed and verified the efficacy of qPCR assays that can be employed to 
perform secondary and tertiary screens to more rapidly verify the efficacies of polyomavirus 
inhibitors in future efforts.  The recent explosion in the number of new polyomaviruses and the 
fact that the population of immunocompromised individuals is rising indicate that there is a dire 
need for new antiviral therapies.  My work has not only provided a novel strategy to identify 
potent and specific polyomavirus inhibitors, but the two most promising candidates from this 
effort may now be re-formulated and tested for their effects in the clinic.  In parallel, high 
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throughput screening efforts to identify even more potent inhibitors with improved therapeutic 
potential have been undertaken, and are discussed in Chapter 3. 
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3.0  HIGH THROUGHPUT SCREENING IDENTIFIES A BISPHENOL INHIBITOR 
OF SV40 LARGE T-ANTIGEN ATPASE ACTIVITY. 
3.1 INTRODUCTION   
Polyomaviruses (PyVs) are a family of non-enveloped viruses with double-stranded DNA 
genomes that are able to transform cells and promote tumor formation.  There are ten PyVs that 
are known to infect humans; one of these, the Simian Virus 40 (SV40), was unknowingly 
introduced into the population as a contaminant of the original polio vaccine. The oncogenic 
SV40 is a well-characterized model used to examine the underlying mechanisms of growth 
control and cancer, and induces tumors in rodents, although it is not tumorigenic in humans 
(Pipas, 2009; Poulin and DeCaprio, 2006).  Approximately 50-80% of humans are seropositive 
for one of these viruses, suggesting life-long infection (Kean et al., 2009). 
Two other PyVs, JC Virus (JCV) and BK Virus (BKV), result in morbidity and mortality 
in immunocompromised patients (see section 1.4.2). JCV is a neurotropic polyomavirus and the 
causative agent of progressive multifocal leukoencephalopathy (PML), a demyelination disease 
of the central nervous system associated with a high mortality rate. BKV infects kidney epithelial 
cells, and lytic infection in immune-compromised patients can cause BKV or polyomavirus 
associated nephropathy, which is associated with high graft loss if not recognized early 
(Weinberg and Mian, 2010).   Integration of Merkel Cell Virus (MCPyV) sequences into Merkel 
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cells (in skin) seems to be the cause of Merkel cell carcinomas (Shuda et al., 2009), and 
Trichodysplasia Spinulosa Virus (TSV) appears to be the cause of post-transplant trichodysplasia 
spinulosa (van der Meijden et al., 2010).  Further studies are needed to confirm if the other 6 
PyVs have a role in disease.  Unfortunately, there is no specific treatment for polyomavirus 
related diseases (Johnston et al., 2010; Josephson et al., 2006b). 
SV40 is an excellent model for studying the PyVs because the conditions for the 
replication of this virus in cell culture are well-characterized and because all PyVs encode a viral 
protein, the large T-antigen (TAg), which is essential for viral replication.  TAg is a multidomain 
protein that is transcribed early after infection.  Among other features, TAg contains an N-
terminal J domain, the central Origin Binding Domain, and the C-terminal helicase domain.  
TAg forms a double hexamer that utilizes host cellular protein factors to coordinate bidirectional 
DNA replication (Bullock, 1997), in addition to binding to and inactivating p53 and the Rb 
tumor suppressor family of proteins. In 1997, it was reported that TAg encodes a functional J 
domain chaperone (reviewed in (Brodsky and Pipas, 1998).  The N-terminal J domain, which 
stimulates the ATPase activity of the cellular hsp70 chaperone, is essential for both virion 
assembly and disruption of Rb-E2F-binding, and mutations that compromise this chaperone 
function block viral replication and cellular transformation.  Lastly, the oncogenic potential of 
SV40, JCV, and BKV can be recapitulated by TAg alone (Bollag et al., 1989). TAg is conserved 
among polyomaviruses, (Simmons, 2000) and there is the possibility that inhibitors of SV40 
TAg may be effective across the PyV family (Wright et al., 2009). 
TAg is also an ATP-dependent helicase, which is an essential activity that facilitates the 
unwinding of DNA during viral replication (Stahl et al., 1986).  ATP binding to the TAg ATPase 
domain stimulates TAg hexamerization and dodecamer assembly; the active dodecamer partially 
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melts the viral DNA and associates with proteins required for replication (reviewed in (Bullock, 
1997). Therefore, chemical modulators of SV40 TAg ATPase activity might represent a new 
avenue to combat PyV-associated diseases.  Mutations that reduce TAg’s endogenous ATPase 
activity also block viral replication (Castellino et al., 1997).  Previous efforts to identify PyV 
inhibitors employed in vitro assays that measured inhibition of TAg-mediated p53 interactions 
(Carbone et al., 2003) and TAg-mediated ATP hydrolysis, (Wright et al., 2009) and led to the 
identification of new TAg inhibitors.  However, the existing inhibitors exhibit low potency 
and/or low specificity, and are not necessarily amenable to future chemical optimization 
strategies.  Therefore, the isolation of novel TAg inhibitors with unique chemical scaffolds is 
vital, particularly as the incidence of PyV-associated diseases is rising (see section 1.4). 
To this end, in collaboration with the Noah Lab at the Southern Research Institute we 
performed a high throughput screen (HTS) suitable for the discovery of novel PyV inhibitors.  A 
biochemical, fluorescence-intensity assay using the ADP Hunter kit in a 1536-well microplate 
format was developed to measure TAg ATPase activity in the presence of potentially inhibitory 
small molecule compounds from the NIH/Molecular Libraries Probe Centers Network (MLPCN) 
compound collection.  Hits from the primary screen were counter-screened for assay interference 
in the ADP Hunter Screen and for cytotoxicity.  Secondary assays, which utilized quantitative, 
established techniques for target validation, allowed for the prioritization of ‘hits’ from the 
primary screen based on potency, cytotoxicity, and target specificity.  Three small molecule 
modulators that inhibited the ATPase activity of TAg were identified using the HTS.  
Subsequent chemical refinement by the Golden Lab at Kansas University produced one 
compound (a bisphenol derivative) that was confirmed to interfere with the replication of SV40 
in infected cells.  Further chemical optimization derived a fourth effective biochemical inhibitor 
  109 
of TAg ATPase activity (bisphenol A), but the use of this inhibitor for in vitro or in vivo 
investigations is complicated by its cytotoxicity. 
3.2  MATERIALS AND METHODS 
3.2.1 Recombinant TAg expression and purification   
For this effort, the consistency and yield of TAg purification were improved.  Starting with the 
previously described protocol (Cantalupo et al., 1999), the purification protocol was slightly 
modified.   A total of 4x108 Sf9 insect cells grown in Grace’s Complete Media containing 10% 
FBS and Pen/Strep were infected with wild type-TAg expressing baculovirus and plated in 15 
10-cm dishes (Gibco) for 45 h.   The cells were harvested by scraping and washed in PBS-EDTA 
with protease inhibitors.  The cocktail of protease inhibitors (Leupeptin at 2 μg/mL, Aprotinin at 
2 μg/mL (Roche), soybean Trypsin inhibitor at 1 μg/mL (Roche), Pepstatin at 1 μg/mL, E64 at 1 
μg/mL (Roche), TPCK at 1 μg/mL (Sigma), and PMSF at 1 mM) were added freshly to all 
buffers until the dialysis step.  Modest improvements were made by decreasing the lysis volume 
to 15 mL, which was achieved by adding 1 mL Kelly’s lysis buffer per 10 cm dish infected 0.2M 
LiCl, 20 mM Tris pH8.0, 1 mM EDTA, 0.5% NP40, and 1 mM DTT.  The lysate was clarified 
using a 2 μm filter and then centrifuged for 30 min at 15,000 rpm, in an SS-34 rotor at 4°C.  The 
lysate was loaded onto a PAb419-Protein G Sepharose Fast Flow column (GE Healthcare) at 10 
mL/h using a peristaltic pump.   The column was washed with 15 mLs of each of the three wash 
buffers.  The first wash buffer contains 20 mM Tris pH 8.0, 0.5 M NaCl, 1 mM EDTA, 1% 
NP40, 10% glycerol, and 1mM DTT.  DTT and protease inhibitors were freshly added.  The 
  110 
second wash buffer was the same as the first but lacks NP40, while the third wash buffer was 
identical to the second but adjusted to pH 9.0.  TAg was eluted from the column with 20 mM 
CAPS pH 11.0, 0.5 M NaCl, 1 mM EDTA, 10% glycerol and 1 mM DTT directly into 0.5 M 
Tris pH 7.0, 1 mM EDTA, and 10% glycerol.  Peak fractions were dialyzed into 10 mM Tris 
pH8.0, 1.0 mM EDTA, 100 mM NaCl, 10% glycerol, 1 mM DTT overnight at 4°C.  These 
fractions were flash frozen in liquid nitrogen, and purity was confirmed by subjecting fractions 
to SDS-PAGE followed by Coomassie Brilliant blue stain and western blot with a TAg specific-
antibody (described below).  The activity of TAg was confirmed by steady state ATPase assay. 
3.2.2 Expression and purification of PAb419 from hybridoma cells 
PAb419 hybridoma cells express a TAg specific antibody that is ideal for purification of SV40 
TAg (Cantalupo et al., 1999; Harlow et al., 1981). The culture was kept between 5 x 104 and 5 x 
105 cells/mL in DMEM with 10% FBS, and since these cells are non-adherent, they were gently 
mixed prior to counting on a hemocytometer.  Cells were diluted 1:10 or 1:20, and sub-cultured 
between 2-4 d.  There was no need to remove the old medium, as this contained antibody. The 
hybridomas were expanded to at least ten T150 dishes (Falcon). 
Once fully expanded, the culture was allowed to grow until the cells died (~14 d), 
because when the cells leave log phase, they over-express antibody and release it into the 
medium.  Death can be induced by reducing serum levels, but this was not necessary.  The media 
was collected from an expired culture, and spun at 100xg in a clinical centrifuge for 10 min at 
RT.  The antibody-containing supernatant was harvested.  If debris remained, an additional 10 
min spin was used to clear the antibody solution prior to column purification.  The typical yield 
was 20-50μg antibody/mL of cellular supernatant.  This supernatant was either used directly for 
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detection of TAg by immunofluorescence or Western blot, or purified with Poros Protein A 
column (Invitrogen) if antibody was used for the column purification TAg.   
To purify the antibody, 50-100 mL supernatant was loaded onto a 1-2 mL Poros Protein 
A column, and the column was run at 1 mL/min, or by gravity.  The column was washed with 25 
column volumes of PBS-Tween 20 (0.05%), and the antibody eluted in 0.1 M glycine-HCl, pH 
2.5.  The eluate can be dialyzed into another buffer or stored at this pH with 0.02% NaN3 at 4°C 
to preserve for future use. 
3.2.3 Screening Assay Validation Conditions   
The early high throughput screen validation assays were conducted in 384-well black, clear-
bottom microplates (#3712 Corning Inc., Corning, NY).  Assay buffer consisted of 100 mM Tris-
HCl, 20 mM KCl, 6 mM MgCl2, and 0.1 mg/mL BSA, pH 7.4.  Initially, 5 µL of test compound 
(single dose, 20 µM final concentration, as described below) in assay buffer with 5% DMSO was 
added to the respective plate wells.  Purified TAg was diluted to a concentration of 14.4 ng/µL in 
assay buffer.  A total of 15 µL of TAg (14.4 ng/µL, 216 ng total) in assay buffer was added to 
each well and allowed to incubate for 30 min at ambient temperature.  Following incubation, 5 
µL of 5mM ATP (A7699, Sigma-Aldrich, St. Louis, MO) in assay buffer was added to the 
respective wells, and incubated for 120 min at ambient temperature.  Total reaction volume 
(without endpoint reagent) was 25 µL.  Commercially available kits (e.g., Malachite Green 
Phosphate Assay Kit, POMG-25H, from BioAssay Systems, Hayward, CA and the ADP Hunter-
Plus Kit [DiscoverX, Freemont, CA]) were used according to the manufacturer’s instructions to 
measure ATP hydrolysis.  Enzyme and buffer volumes were dispensed using a WellMate 
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(Matrix, Hudson, NH).  Compounds were dispensed manually.  The final DMSO concentration 
was 1.0%.   
3.2.4 Pilot and Primary Assay Conditions   
The assay was conducted in 1536-well black, clear-bottom microplates (#3891 Corning Inc., 
Corning, NY), and was used for both the full library single-dose screen and the confirmatory 
dose-response evaluation of hits.  Assay buffer is listed above.  Initially, 250 nL of test 
compound (single dose, 20 µM final concentration, as described below) in assay buffer 
supplemented with 5% DMSO was added to the respective plate wells.  Purified TAg was diluted 
as above.  A total of 750 nL of TAg (14.4 ng/µL, 10.8 ng total) in assay buffer was added to each 
well and allowed to incubate for 30 min at ambient temperature.  Following incubation, 250 nL 
of 5 mM ATP in assay buffer was added to the respective wells, and incubated for 120 min at 
ambient temperature.  Total reaction volume (without endpoint reagent) was 1.25 µL.  Enzyme 
and buffer volumes were dispensed using a BioRAPTR FRD (Beckman Coulter, Fullerton, CA).  
Compounds were dispensed using an Echo 500 Series Liquid Handler (Labcyte, Sunnyvale, CA).  
The final DMSO concentration was 1.0%.   
Endpoint readings:  The endpoint method was by fluorescence detection, using the ADP 
Hunter Kit (Charter, 2006) and the manufacturer’s instructions.  The plates were bottom-read for 
fluorescence intensity using an Envision plate reader (Perkin Elmer, Waltham, MA) at an 
excitation/emission of 530/590 nm, respectively. 
Controls and Compound Addition: The positive control (MAL2-11B; (Wright et al., 
2009) was diluted in 4% DMSO/assay media and added to the control wells of each plate (250 
nL at 5x concentration, for a final reaction concentration of 100 µM) before the addition of TAg.  
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The final concentration of MAL2-11B was 100 µM.  Additional controls included full reaction 
wells (containing TAg, DMSO blank, and ATP), and background wells (containing assay buffer, 
DMSO blank, and TAg) on each plate. The final DMSO concentration was 1% for all plate 
wells. 
3.2.5 Counter-Screens for cytotoxicity and assay interference   
In each assay, compounds were added in dose-response format. The cytotoxicity assay was cell-
based in 384-well plate format and used Madin-Darby Canine Kidney cells (MDCK, ATCC, 
Manassas, VA, CCL-34, passage 55).  The cytotoxicity assay was conducted for 72 h, after 
which cell viability was determined using Cell-Titer Glo (Promega, Madison, WI) (Noah et al., 
2007).  To measure assay interference, the counter-screen was performed using the primary 
assay method (above), but without TAg (buffer only).  A final concentration of 10 µM ADP was 
used instead of ATP, and the assay was read 10 min following the addition of the endpoint 
reagents. 
3.2.6 DNA replication assays  
DNA replication assays, using a reporter plasmid that contained the SV40 origin of replication, 
were performed as previously described (Wright et al., 2009) as well as in section 2.1.3.   
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3.2.7 Cell Culture 
Madin-Darby Canine Kidney (MDCK) cells were obtained from American Type Culture 
Collection.  African Green Monkey kidney cell line BSC-1 (ATCC, Manassas, VA, CCL-26) 
were used for the cytoprotection and viral load reduction assays.  Cells were cultured in DMEM 
with 2 mM L-glutamine, 1X pen/strep, and 10% FBS.  CV1 cells were cultured in MEM with 
10% FBS and pen/strep.  The cells were maintained at 37°C, 5.0% CO2 to 90% confluence. The 
cells were trypsinized, and recovered. The trypsin was neutralized with culture media. 
3.2.8 Preparation of SV40 
SV40 stocks were prepared from the plasmid pSVB3.  This plasmid contains the entire SV40 
genome incorporated into the pBR322 backbone at a BamH1 site (Peden et al., 1980).  pSVB3 
was digested by BamH1, and then phenol:chloroform extracted.  The clean DNA fragments were 
diluted to 3 μg/mL and ligated with T4 DNA ligase overnight at 15 °C.  The low concentration 
of DNA in the ligation reaction favors circularization over concatamerization.  The ligation 
reaction was heat killed and then transfected into CV1 with Lipofectamine (Invitrogen), 
according to manufacturers instructions.  The media was changed the next day, and the 
transfection proceeded 6 d before the cells were freeze-thawed three times to lyse.  This created a 
low titer viral stock, which was used to infect CV1 cells in 10 cm dishes.  The CV1s were 
supplemented with 2mL of fresh media 2 dpi, and the infection continued a total 8 dpi, or until 
there was significant CPE.  This viral stock was titered by plaque assay, as described in section 
2.2.4.  Typical yield was between 8x107 and 1x108 pfu/mL. 
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3.2.9 Cytoprotection assays  
This assay was used to test the ability of compounds to protect from viral cytopathic effects 
(CPE).  BSC-1 cells in DMEM with 10% FBS and 4mM L-glutamine (Assay Media) were plated 
in 96-well microplates at 15,000 cells/well.  After 18 h, test compounds were diluted to a final 
concentration in the range of 200 - 1.6 µM as indicated, added to the cells, and incubated for 30 
min.  Afterward, 100 TCLD50s (50% tissue culture lethal dose, the virus stock dilution that 
induces CPE in 50% of the cells at endpoint) of SV40 virus (prepared as described in section 
3.2.9) were added to each well.  Cell viability was determined after 120 h using Cell-Titer Glo 
(Promega, Madison, WI) (Noah et al., 2007).  
3.2.10 Compound handling for the HTS effort 
The NIH Molecular Libraries Probe Centers Network (MLPCN) compound library was used for 
the primary HTS screening. Compounds (stored in 100% DMSO) were diluted into Assay Media 
(see section 3.2.8) by automation and added to the plates in 5 µl volumes using a Biomek FX 
liquid handler (Beckman Coulter, Fullerton, CA). The final compound concentration used in 
primary, single-dose screening was 20 µM, with a final DMSO concentration of 1%.     
3.2.11 Data acquisition and analysis 
96 full reaction wells, 96 background wells, and 64 control drug wells per plate were used to 
calculate the Z' value (Zhang et al., 1999) for each plate and to normalize the data on a per plate 
basis. Results for each concentration of compound were expressed as percent inhibition (% 
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Inhibition), which was calculated as: 100*((Median Enzyme Control-High Dose Control Drug) - 
(Test well-High Dose Control Drug))/(Median Enzyme Control-High Dose Control Drug). The 
dose response data were analyzed using a four parameter logistic fit to the data (XLFit equation 
205) with the maximum and minimum locked at 100 and 0. From these curves IC50 values were 
calculated for TAg and CC50 values were calculated for MDCK cell cytotoxicity. A Selectivity 
Index for compounds showing TAg inhibition was calculated as SI = CC50/EC50.   Raw data were 
imported to Activity Base Data Management software (IDBS, Alameda, CA) for determination 
of Z, Z’, S/B, S/N, and percent inhibition for assayed compounds.  Compounds showing greater 
than 30% inhibition of TAg ATPase activity were considered “hits”. Statistical calculations were 
made as follows:  Z = 1 – ((3σR + 3σB)/|µR - µB|), where µR is the mean reaction signal, σR is 
the standard deviation of the reaction signal, µB is the mean background control signal, and σB 
is the standard deviation of the background control signal. Z’ = 1 – ((3σd + 3σB)/|µd - µB|), 
where µd is the mean MAL2-11B control signal, σd is the standard deviation of the MAL2-11B 
control signal. Signal to background (S/B, fold increase) = µR/µv.  Signal to noise (S/N) = (µR - 
µB)/((σR)2 + (σB)2)1/2 (Zhang et al., 1999).  Each assay validation step was performed in 
triplicate with the exception of the pilot validation screens with 6,930 compounds, which was 
performed in duplicate. 
3.2.12 Compound acquisition and/or synthesis 
Many of the compounds were obtained from commercial sources. All compounds, regardless of 
source, were purified by silica gel chromatography and analyzed by LCMS and NMR.  
Bisphenol A (CAS# 80-05-7, 2,2-Bis(4-hydroxyphenyl)propane, SID 92277586) was acquired 
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commercially from TCI America. Silica gel chromatography was then performed with 1:1 
hexanes/ethyl acetate as eluent, analyzed by LCMS at 214 nm and the structure was confirmed 
by proton and carbon NMR.  1H NMR (400 MHz, DMSO-d6) d 1.55 ( (s, 6H, CH3); 6.68 (d, J = 
8.7 Hz, 4H); 7.01 (d, J = 8.7 Hz, 4H); 9.17 (s, 2H, ArOH); 13C NMR (100 MHz, DMSO-d6) δ 
154.9; 141.1; 127.3; 114.6; 40.9; 30.9; TLC Rf: 0.51 (1:1, hexanes:ethyl acetate).  HPLC 
(Acquity BEH Shield C-18, 5-95% CH3CN in H2O): Retention time = 2.713 min; bisphenol A 
did not ionize.  
3.3 RESULTS 
3.3.1 Improving TAg purification protocol 
To undertake a very high throughput screen (HTS) for TAg inhibitors, active TAg needed to be 
efficiently purified.  Previously published purification protocols produced TAg relatively quickly 
(pure, dialyzed TAg was prepared 3 dpi) with yields of less than 1mg of protein (Cantalupo et 
al., 1999).  In this method, TAg is expressed in Sf9 cells from a baculovirus stock, and purified 
over a monoclonal antibody column.  Because TAg is very labile and requires specific 
phosphorylation events for robust activity (Chen et al., 1991; Hubner et al., 1997; McVey et al., 
1989), I preferred to modify the previous protocol rather than redesign the purification scheme 
(Hoss et al., 1990). Factors that were considered to improve the yield were to improve 
expression, maximize binding to the antibody column, and minimize protein loss during washes.   
As summarized in Table 8, I modified several variables in the purification.  I determined 
that the recommended infection time of 45 h was ideal for TAg expression, and that the 
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particular viral stock used did not seem to greatly affect yield.  Baculovirus stocks are not 
generally titered for this type of use because of the quick turnover (one expansion of the “stock” 
in ten 10-cm dishes results in enough baculovirus for two TAg preparations), but seem to have a 
similar viral yield when the appropriate protocol for expansion is followed (Cantalupo et al., 
1999).   However, I did choose to modify the lysis conditions. The column had a tendency to 
clog during the very slow load of the lysate, which is why the volume of Kelly’s lysis buffer 
used was more than 1 mL/10 cm dish.  However, anecdotal evidence suggested that resuspending 
the column to repair the clog seemed to negatively impact the yield and protein activity. I 
hypothesized that during the 2.5 hours the column was loading, proteins were aggregating on the 
column preventing efficient flow.  By decreasing the volume of lysis buffer, the time required to 
load the lysate was decreased, as was the risk of clogging.   
Next, I determined that the majority of the wash volume (recommended at 25 times the 
column volume) was not necessary, and the major protein washing off the column was TAg.  
Therefore, the wash volume was decreased to 10 mL without significantly impacting the purity 
of the final protein.  While the time spent in dialysis did not seem to negatively affect the activity 
of the protein, I did determine that protein purified at a higher concentration was relatively more 
active than protein purified at a lower concentration.  One factor that consistently impacted the 
outcome of the final protein concentration was the column, which lost affinity for TAg after 
about 7-10 purifications.    Although the column can be stored for years, multiple uses resulted a 
decline in purification efficiency, which can be determined by detecting TAg in the third column 
wash buffer (Figure 17). 
Overall, these changes to the protocol made modest changes to the expected yield of 
purification, but greatly increased the predictability of the protocol and decreased the overall 
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time needed to purify TAg.  This facilitated the purification of the ~ 12 mgs that were required 
for the HTS performed by the Noah Lab. 
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Figure 17. Modifications to TAg purification protocol improve yield. 
Abbreviations are as follows: L- lysate, FT- column flow through, W1- Wash 1, W2- Wash 2, W3- 
Wash 3, TAg- purified TAg after dialysis. Arrow indicates full length TAg.  Dashed arrow represents a 
contaminant that may be cleaved TAg or free antibody; the presence of this band is indicative of low activity 
in the final purified protein.  A. Samples from the protocol initially used for TAg purification. Left panel is a 
Western blot with pAB419, and the right panel is a Coomassie Brilliant blue stained gel. It is clear that TAg is 
in W3 in both cases, and it is evident from the right panel that TAg is the major component of W3.  B. After 
protocol modification and a new column, less TAg was lost in W3. 
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Table 8.  Notes from TAg purification during optimization. 
The following data highlight the changes made to the TAg purification protocol and the effect on outcomes.  Among the variables tracked, the 
date of the baculovirus stock and the hours of this infection seemed not to make a significant difference.  Reducing the volume of Kelly’s Lysis Buffer 
(KLB) that was used to lyse the Sf9 cells seemed to affect column clogging during loading.  The duration of dialysis did not seem to impact yield or 
activity, but the volume of the wash buffer used was minimized to a volume where minimal levels of any protein (and specifically TAg) were washed off.  
This had the greatest impact on TAg total yield and concentration.  NR indicates not recorded. 
 
 
Date of 
Prep 
Viral 
stock 
Hours 
infected KLB Volume 
Column 
clogged? Dialysis (h) 
Volume of 
washes (mL) Yield (mgs) 
[Tag] 
μg/μL 
11/12/08  45 25  16 22 1 0.55  
12/9/08 12/2/08 46 20 N 6  22 0.48 0.26 
12/11/08 12/2/08 45 20 N 6  22 0.528 0.3 
12/15/08 11/15/08 45 25 Y 4  10 0.96 0.4 
12/18/08 12/2/08 45 15 N 16 11 1.21 0.55 
1/21/09 11/15/08 45 15 N 17 11 1.38 0.46 
1/24/09  45 15 N 5 11 1.54 0.7 
1/26/09 11/27/08 45 10 N 15 10 NR 0.39 
1/29/09  45 10 N 6 10 1.1 0.55 
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3.3.2 Primary Assay Development and Validation 
In collaboration with the Noah lab, a biochemical assay to screen diverse compound libraries 
for efficacy against the ATPase activity of SV40 TAg was developed and validated.  During 
assay development, the Noah lab defined the optimum endpoint detection method 
(fluorescence) and time, DMSO tolerance, optimum enzyme concentration, and confirmed 
equivalency to other established ATPase assays (e.g., in comparison to malachite green).  They 
also confirmed the efficacy of a positive control, MAL2-11B (Wright et al., 2009), an inhibitor 
of the ATPase activity of TAg in this assay.  They began with the adaptation and validation of 
the 96-well microplate assay format for TAg-mediated ATPase activity to a 384-well microplate 
format. This included quantification of HTS assay parameters such as coefficient of variation 
(CV), signal-to-background (S/B), signal-to-noise (S/N), Z-value, and establishment of the 
positive and negative control conditions, values, and compounds.  The assay was linearly 
miniaturized into 1536-well microplates.  HTS validation included a survey of any edge and 
liquid handling effects and reagent and read stability, and was completed by duplicate pilot 
screening of a 6,390 compound library. Each development step was performed in triplicate, and 
validation steps were performed in duplicate unless otherwise noted. 
 Malachite green can be used to determine the amount of free phosphate liberated as a 
product of TAg-mediated ATP hydrolysis.  This assay method is based on the complex formed 
between malachite green molybdate and free orthophosphate under acidic conditions.  Although 
this assay endpoint method provided sufficient reliability and S/B ratios for detection of TAg 
ATPase activity in 96-well microplate format, the limiting reagent in screening a large library of 
compounds (>300,000) was the amount of purified TAg available for screening.  Because the 
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expression and purification of recombinant TAg was both economically and temporally costly, 
it was necessary to miniaturize the assay as much as possible while maximizing robustness and 
S/B.   
A comparison of the malachite green assay and a commercially available product, the 
ADP Hunter kit (Charter et al., 2006) was also performed to measure inhibition of TAg-
mediated ATPase activity, with the caveat that compounds that inhibit the reagent enzyme 
cascade or are themselves inherently fluorescent will result in a false signal. The fluorescent 
signal is red-shifted, minimizing potential interference from fluorescent compounds.  Both 
assay methods were evaluated for S/B, Z, control drug interference, read stability, sensitivity, 
and DMSO tolerance.  To do this, the Noah lab first compared the limits of detection 
(sensitivity) of both the malachite green and ADP Hunter assays.  The limit of substrate 
detection for the ADP Hunter assay is two-fold lower than that seen using the malachite green 
assay (Figure 18). The ratio of signal-to-background (S/B) values at 1 µM substrate is 2.04 for 
ADP Hunter, and 1.06 for malachite green.  The maximal S/B values are 19.33 (ADP Hunter) 
and 7.75 (malachite green).  This indicated that ADP Hunter could be miniaturized further 
without losing signal, and prompted us to choose the ADP Hunter endpoint methods for all 
subsequent validation experiments. 
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Figure 18. Comparison of assay sensitivity using the malachite green and ADP Hunter endpoint 
methods. 
The graph shows the increase in assay signal with a titration of substrate (phosphate or ADP, 
respectively). The X-axis shows substrate concentration in μM, and the Y-axis shows the percentage of the 
maximum signal at each substrate concentration. Each point represents the mean from three assays. To 
simplify the figure, error bars are not shown; standard deviation for each point was < 2%. 
 
 
 
We then determined assay sensitivity to DMSO.  For large-scale screening, compound 
libraries are generally stored in DMSO, which at higher concentrations (>1%) may dramatically 
affect cellular membrane permeability and viability (Irvine et al., 1999).  The assay tolerated 
DMSO concentrations up to 5% without an effect on the detection parameters.  To promote 
increased compound solubility in the assay media, we standardized the assay to run in 1% 
DMSO for all subsequent primary screening. Additional experiments using the control 
compound MAL2-11B (at a final concentration of 100 μM) determined that DMSO did not 
interfere with the assay sensitivity (data not shown) (Wright et al., 2009).  Lastly, the assay 
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background signal was highest in the absence of ATP but with TAg present, indicating that non-
enzymatic ATP hydrolysis is only a minor contributor to background signal (data not shown).  
Instead, the higher background signal in the presence of TAg suggests that residual ADP was 
present in the purified TAg that contributed to a higher background signal.  Because of this 
observation, ATP was omitted in the negative control wells (- reaction), but TAg was retained 
in order to reflect an accurate assay signal window.  For the screening conditions a final reaction 
TAg concentration of 8.6 ng/µL was chosen, and a reaction time of 120 min, as longer 
incubations of the reaction did not result in an appreciable signal return (data not shown).     
3.3.3 Pilot and Primary Screening  
To complete assay validation, the Noah lab linearly reduced the well volume of the 
reaction for direct transference into a 1536-well microplate format and conducted a duplicate 
pilot screen of 6,390 compounds.  Table 9 lists the pilot screen data.  It shows that 68% of the 
hits that decreased fluorescence in each pilot screen more than 19% (which was the S/N 
threshold) correlated, indicating that the assay reliably identified potential ATPase inhibitors.                 
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Table 9.  Summary of the TAg ATPase HTS assay pilot validation and primary screen. 
 
 
Pilot Screen Parameters Screen 1 Screen 2 
n compounds 6,390 6,390 
mean Z a,b 0.69 + 0.05 0.55 + 0.06 
mean S/B a,b 2.7 2.4 
S/N a,b 24 27 
pilot screen > 19% inhibition 
hit ratea,c 
0.58% (n = 37) 0.59% (n = 38) 
> 19% inhibition hit rate 
correlation coeff.c 
68% 
Significance p =  < 0.005 
Primary Screen Parameters   
mean Z a,b 0.68+/- 0.04  
mean inhibition 2.04% +/- 5.36%  
mean S/B a,b 3.9  
> 44% inhibition hit ratea,c 0.81%  (n = 2500)  
Dose response confirmation of  > 
44% inhibition hit rate 
48%  
  
aValues for Z, S/B, S/N, and pilot screen hit rates are averaged from duplicate screens. 
Standard deviations are given as +/- values. 
bCalculations for Z, S/B, and S/N are detailed in section 3.2.11. 
cHit rate is based on the number of compounds that inhibited fluorescent signal by > 44% in 
duplicate pilot and primary screens. 
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The Noah lab followed the pilot validation with a full screen of the NIH Molecular 
Libraries Probe Centers Network compound collection (306,015 compounds), which was 
screened in single dose at a concentration of 20 µM.  Primary screening data are also shown in 
Table 9. A total of 2153 hits that inhibited ATPase activity >44% were available for 
confirmation.  These were screened in dose-response over a 625-fold concentration range (from 
100 µM to 0.16 µM) for assay interference, cytotoxicity, and inhibition of ATPase activity.  
Assay interference counter-screening (using 10 µM ADP) was performed simultaneously with 
the confirmatory assay to exclude compounds that inhibit the coupling enzymes in the assay kit.  
Compounds that were positive in the counter-screen (inhibitory by assay interference) were 
considered inactive.  Compounds that inhibited in the primary screen but had no effect in the 
counter-screen were considered active.  Finally, a cytotoxicity screen of the hits in MDCK cells 
was performed.  Of the 2153 compounds, 104 reduced TAg-mediated fluorescence without 
interfering with the assay itself or exhibiting extreme toxicity.  The primary assay IC50 values 
for these compounds ranged from <0.16 µM to 53 µM. 
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3.3.4 Assay Hit Characterization by Secondary Assays 
The 104 confirmed hits were further restricted by their degree of “drug-likeness,” that is to what 
extent each compound looked non-toxic, cell permeable and amenable to chemical refinement.  
Compound promiscuity (the number of times hits were identified in other PubChem primary 
screens) was also surveyed, and compounds isolated as hits in >20% of assays were excluded 
from further consideration, as were chemical scaffolds that were not amenable to medicinal 
chemistry.  Three compounds (Figure 19) were selected for further evaluation using targeted, 
mechanistic secondary assays (see Figures 19, 20 and 21).  These compounds (PubChem SIDs 
85281215, 85281217, and 85281218) were purchased from commercial sources, purified, and 
retested in the primary assay for confirmation of activity.  The IC50 values for the three ranged 
from 7 µM to 27 µM, while the control compound MAL2-11B had an IC50 of 19.4 µM (Figure 
19).  To determine target specificity, I tested SIDs 85281215, 85281217, and 85281218 in a 
secondary biochemical assay for TAg-dependent DNA replication (Figure 20).  In this assay, 
TAg recruits cellular machinery from the supplied HeLa cell lysate to polymerize trace 
radioisotope-labeled nucleotides into replicating DNA over time.  Each compound was tested at 
100, 300, and 800 µM.  While all three compounds inhibited TAg dependent DNA replication at 
800 µM (Figure 21), SID 85281215 is the most potent biochemical inhibitor of DNA 
polymerization, and DNA replication was absent at 300 µM.  
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Figure 19. Compounds confirmed as active against SV40 TAg ATPase activity in a biochemical 
assay. 
Structures of the three primary assay hits and control compound MAL2-11B are depicted. The 
corresponding biochemical assay inhibitory concentrations (IC50), the cell-based effective concentrations 
(EC50), and the cytotoxic concentrations (TC50) are tabulated for each compound. ND indicates that the 
values were not determined due to high compound cytotoxicity. 
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Figure 20. Specificity for TAg is demonstrated by TAg dependent in vitro DNA replication assays. 
The figure compares the effects of increasing concentrations of MAL2-11B (2-11B), and SIDs 
85281215 and 92277586 on TAg-dependent DNA replication. Products were analyzed by agarose gel 
electrophoresis. The increasing polymerization of high-molecular weight DNA (HMW DNA) is observed in 
uninhibited lanes, but is decreased where compound-mediated enzymatic inhibition occurs. The 
concentration of compound in μM is indicated at the top of the figure. Increasing reaction time (t=30, 60 or 
90 min) is indicated by a black wedge. 
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Figure 21. All three scaffolds inhibit TAg dependent in vitro DNA replication at high concentration, 
but to varying effects. 
In vitro TAg dependent DNA replication was performed in the presence of the indicated compounds.  
TAg, DNA, HeLa cell lysate and a radiolabeled dCTP were mixed in the presence of an ATP regenerating 
system at 37°C for t=30, 60 or 90 min, as indicated by the black wedge.  From each time point, the DNA was 
ethanol precipitated and resolved on an agarose gel.  Incorporation of the radiolabel indicates DNA 
replication.  This activity is TAg dependent, and has been shown to be dependent on the concentration of 
HeLa lysate and time (data not shown). (* indicates DNA lost during precipitation) 
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To examine the selectivity and in vitro efficacy of these chemotypes, the Noah lab tested 
the ability of the three compounds, SIDs 85281215, 85281217, and 85281218, to protect against 
SV40 virus-induced cell death in a BSC-1 cell culture cytoprotection assay. Of the three, only 
SID 85281215 sustained cell viability (16%) in the cytoprotection assay, but the effect was 
limited due to observed cytotoxicity near the effective concentration (EC50) (Figure 22).  
Cytoprotection assays also showed that the TC50 (toxic concentration) values for the test 
compounds ranged from 34 µM to greater than 200 µM (Figure 22).   
3.3.5 Analog design and syntheses  
Chemical optimization was initiated on compound SID 85281215 (5-[dichloro-(1-
phenyltetrazol-5-yl)methyl]-1-phenyltetrazole).  Systematic alteration of the dichloro-bis-
tetrazole scaffold resulted in a steep structure-activity relationship (SAR) profile for an initial 
set of compounds.  The series also required the use of challenging and unreliable chemistry to 
obtain analogs (J. Golden, personal communication); therefore, similarly tethered bis-aryl 
scaffolds were investigated.  This effort was aimed at identifying structurally-related leads that 
could be derived from more accessible synthetic methods.  In principle, this could provide a 
more tractable SAR and yield improved activity profiles.  One of the several scaffolds that was 
surveyed belonged to the bisphenolic series of compounds.  Bisphenol A (SID 92277586, or 4-
[2-(4-hydroxyphenyl)propan-2-yl]phenol) was purchased as part of this exploratory SAR effort.  
The compound had an EC50 = 6.2 μM in the CPE assay and a TC50 = 7.9 μM (Figure 22), thus 
possessing a narrow therapeutic margin. To improve this profile, a standard SAR approach was 
undertaken to reveal the importance of various structural features of this scaffold.  Bisphenol A 
is a symmetrical compound containing a geminal dimethyl linkage that tethers two identical 4-
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substituted phenols.  The impact of changing the substituted positions of the hydroxyl groups, 
replacing the phenolic hydroxyl groups, molecular desymmetrization by altering aryl 
substitution on one side, or modifying the linker was investigated (Table 10).  Interestingly, 
these results confirm the separate SAR that was determined for the bisphenols identified in 
Chapter 2 (see section 2.2.2).  After optimization efforts and by using the biochemical and in 
vitro assays described above, we identified SID 92277586 as the most effective TAg inhibitor. 
In the primary biochemical assay, this compound exhibited a comparably high IC50 of 41.4 µM 
(Table 10) but it showed somewhat better efficacy than either SID 85281215 or MAL2-11B in 
the DNA replication assay (some inhibitory at 100 µM, and complete inhibition at 300 µM, 
Figure 20), and in the cytoprotection assay (EC50 = 6.2, Figure 22).  However, SID 92277586 
still retained high cytotoxicity, with an SI (specificity index) of 1.3.   
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Figure 22. Cytoprotection and cytotoxicity of TAg inhibitors. 
The indicated compounds were tested (200-1.26 µM) in cytoprotection assays using BSC-1 cells, and 
% cell viability was measured six d post-drug or post-viral infection.  The dashed line represents cells in the 
presence of compound only (cytotoxicity), and the solid line represents infected cells with compound 
(cytoprotection).  Compound structures are indicated for the two compounds identified in by this screen.  
The corresponding numerical EC50 and TC50 values are given in Figure 19. 
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Table 10. A structure activity relationship for bisphenol A and analogues. 
Green highlights the modified portion of each structure.  Compounds with a primary assay EC50 > 
100 µM were not tested in secondary assays.  ND indicates that no data was obtained during the experiment, 
either because the compounds had a primary assay EC50 > 100 µM or because the compound CC50 in the 
cytoprotection (CPE) assay was lower than the EC50.  
 
 
Entry Pubchem SID Structure 
Primary 
assay 
EC50 µM 
Secondary 
CPE assay 
EC50 µM 
Cellular 
toxicity 
TC50 µM 
Therapeutic 
index 
EC50/CC50 
1 SID 92277586 
 
41.4 6.2 7.9 1.2 
2 SID 96022078 
 
>100 ND ND ND 
3 SID 99206586 
 
>100 ND ND ND 
4 SID 99206566 
 
100.0 ND 71.2 ND 
5 SID 93575587 
 
>100 ND ND ND 
6 SID 99206560 
 
>100 ND ND ND 
7 SID 99206561 
 
26.7 11.9 24.0 2.0 
8 SID 96022079 
 
18.0 ND 196.0 ND 
9 SID 99234230 
 
70.1 ND >200 ND 
10 SID 99234234 
 
37.7 ND 9.9 ND 
11 SID 99234233 
 
35.7 ND 21.2 ND 
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3.4 DISCUSSION 
We employed a high throughput, biochemical assay as the primary screen to identify 
compounds that inhibit SV40 viral replication by targeting the SV40 large T antigen ATPase 
activity.  During assay development we defined assay parameters and validated the screen. We 
performed a primary screen and several counter-screens, which resulted in the identification of 
scaffolds that inhibited TAg ATPase activity.  Lastly, we performed secondary assays for 
specificity and in vitro efficacy. 
We designed the biochemical HTS to address the lack of specific treatments for PyV-
related diseases. I hypothesized that inhibitors of SV40 TAg might also be effective against 
more clinically-relevant PyVs based on the conserved and essential nature of this activity.  
Other small molecules that inhibit the chaperone and ATPase activities of TAg have been 
identified recently (Wright et al., 2009).  One recently identified compound, MAL2-11B, also 
inhibits the replication of SV40 in infected cells; however due to its low potency, solubility and 
cell permeability, it is not suitable as a therapeutic.  Nevertheless, this compound was used as 
the positive control for our primary screen (Wright et al., 2009). 
Ultimately a desirable lead compound would be one that reduces the replication rate of 
the SV40 virus by specifically inhibiting the ATPase and DNA replication activity of TAg (with 
an EC50 more potent than MAL2-11B, i.e. < 10 µM), is non-toxic (SI > 10), and has a broad 
applicability for other PyVs, including those that afflict humans (i.e., JC and BK viruses).  One 
of the three primary screen hits (85281215) showed minimal in vitro efficacy by inhibiting 
SV40-induced cell death in a BSC-1 cell model, but this compound was cytotoxic at a 
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concentration only slightly above the effective concentration.  Further optimization of the bis-
tetrazole scaffold (SID 85281215) resulted in an additional compound (SID 92277586) with 
high biochemical efficacy, moderate in vitro efficacy, and again, low selectivity.  While these 
compounds are effective probes in a biochemical system, their inherent toxicity currently limits 
their use in cell-based systems. However, the chemical scaffolds are starting points for a 
continuing chemistry effort to synthesize related compounds with lower effective and higher 
toxic concentrations.       
The four compounds identified as TAg inhibitors (SIDs 85281215, 85281217, 
85281218, and 92277586) are part of the MLPCN library, and each has been screened in several 
hundred different assays and formats.  This is a goal of the Molecular Libraries Program, which 
seeks to develop a database for characterization of compounds within the MLPCN chemical 
library (Wheeler et al., 2007).  Table 11 summarizes the number of times these compounds were 
identified as hits versus the total number of assays in which they were screened.  The table also 
shows target-specific assays in which all three compounds were identified.  As determined via 
Pubchem (http://pubchem.ncbi.nlm.nih.gov/), these compounds have been shown to inhibit 
hydroxyprostaglandin dehydrogenase 15-(NAD) isoform 1; (AID:894) prostaglandin E receptor 
2; (AID:160544) phosphopantetheinyl transferase; (AID:1819) Microtubule-associated protein 
tau  aggregation; (AID:1475) Mint1; (AID:2093) and nuclear receptor ROR-gamma 
(AID:2139). These targets are similar in that they all possess DNA-binding or ligand-binding 
domains, although there is limited information available to link these characteristics.  The 
observation that the three compounds identified in the primary screen as TAg ATPase inhibitors 
also have overlapping activity in six other targeted screens suggests that the compounds 
specifically inhibit the targets and do not operate in a non-specific manner.  
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Table 11.  Summary of hit coincidence of TAg ATPase inhibitors. 
 
 
Compound 
hits/screens 
SID 85281215 - 37/353 a 
assays 
SID 85281217 - 17/438 a 
assays 
SID 85281218 - 29/339 a 
assays 
Target hydroxyprostaglandin 
dehydrogenase 15-(NAD) 
isoform 1 
hydroxyprostaglandin 
dehydrogenase 15-(NAD) 
isoform 1 
 
prostaglandin E receptor 2  prostaglandin E receptor 2 
phosphopantetheinyl 
transferase 
phosphopantetheinyl 
transferase 
phosphopantetheinyl 
transferase 
aldehyde dehydrogenase 1 aldehyde dehydrogenase 1  
Microtubule-associated 
protein tau 
Microtubule-associated 
protein tau 
Microtubule-associated 
protein tau 
Mint1 Mint1 Mint1 
nuclear receptor ROR-
gamma 
 nuclear receptor ROR-
gamma 
aNumber of times compound was identified as an inhibitor/total number of assays in which the 
compound was screened. 
 
 
 
Chemical optimization of SID 85281215 ultimately resulted in identification of SID 
92277586, also known as bisphenol A (BPA), which has been shown to be estrogenic and 
cytotoxic at low concentrations (Erler and Novak, 2010). Bisphenol compounds have previously 
been identified as putative ATPase inhibitors, and antagonize Ca2+ influx via a mitochondrial 
ATPase (Ardon et al., 2009). Compounds of this type have also been shown to inhibit cell 
growth by acting as catalytic inhibitors of topoisomerase IIα (Liang et al., 2008). The 
convergence of these two activities may account for the biochemical and cytotoxicity assay 
results shown here for compounds 85281215 and 92277586.  More recently, BPA was found to 
induce activation of ERK1/2 and transcriptionally regulate c-fos in human breast cancer cell 
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lines, thereby implicating the compound in carcinogenesis (Dong et al., 2011). Studies have 
reported the adverse effects of µM concentrations of BPA on the nervous system and, 
potentially, on neonatal brain development (Kim et al., 2007) as well as reproductive organ 
development (Richter et al., 2007).  The use of the bisphenol scaffold as a potential therapeutic 
is discussed in section 4.3.  Although the cytotoxicity of BPA in different cell types varies 
tremendously, the cytotoxicity of BPA in BSC-1 cells (African green monkey kidney epithelial 
cells) at ~10 µM suggests that it is particularly nephrotoxic (Table 10).   
In summary, primary and secondary screening have led to the discovery of a bisphenol, 
BPA, that specifically inhibits the ATPase activity of SV40 large T antigen. Activity data from 
the confirmatory and secondary assays were analyzed to identify key scaffolds for additional 
SAR studies and probe optimization efforts.  This BPA proved to be a more potent biochemical 
inhibitor of TAg ATPase activity than currently available molecules such as MAL2-11B, but 
had a low selectivity when tested in vitro for SV40 viral replication inhibition.   Although the in 
vitro/vivo use of compounds identified by this particular screen is limited due to the cytotoxic 
effects, this screening algorithm itself was successful and could be applied to evaluate other 
small molecule libraries for inhibitors of TAg and consequently PyV replication.    
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4.0  CONCLUSIONS AND PERSPECTIVES 
The recent discovery of new polyomavirus (PyV) family members (Allander et al., 2007; Feng 
et al., 2008; Gardner et al., 1971; Gaynor et al., 2007; Padgett et al., 1971; Schowalter et al., 
2010; Scuda et al., 2011; van der Meijden et al., 2010) and the expansion of immunosuppressed 
populations (WHO, 2008) make PyV-related diseases a growing public health concern.  All 
PyVs express a large T Antigen (TAg), which is conserved and essential for viral replication 
(section 1.3).  This suggested that TAg may be PyV specific drug target.  My dissertation work 
started with the hypothesis that inhibitors of the ATPase activity of SV40 TAg might inhibit the 
replication of other PyVs.  Based on the promising preliminary results of a quinaldine red 
screen of the MS2000 library, a larger ADP Hunter screen of the NCI library was performed in 
parallel.  Hits from both screens were characterized, and both screens identified bisphenols as 
inhibitors of TAg.  In this chapter, I will make a comparison of the screening methods used in 
this dissertation and suggest further ways to use the resulting data.  Next, I will discuss the 
applications of the compounds that were identified, and how this has lead to refinement of my 
starting hypothesis.  Finally I will suggest the implications of this work for future efforts to 
identify PyV-inhibitors and therapeutics. 
  141 
4.1 COMPARISON OF THE SCREENING METHODS USED AND OTHER 
APPLICATIONS OF THIS APPROACH 
In the preceding chapters, I discussed two screens to identify inhibitors of TAg ATPase activity.  
My efforts represented a novel approach to identify PyVs inhibitors, in part because a high 
throughput format was used, but more importantly, because the target of hits from such screens 
is well defined.  In contrast, other labs have suggested methods to identify PyVs inhibitors 
based on the detection of DNA replication, either during a normal infection or by using a 
reporter (Fradet-Turcotte et al., 2010; Murata et al., 2009).  If used as a primary screen, this 
alternative method is likely to target host proteins that may result in unwanted side effects.  For 
example, a description of the effects of Vitamin A (retinoic acid) on PyV replication suggested 
that this compound decreased both viral and cellular DNA replication (Russell and Blalock, 
1984).  Neither proposed method has yet been reported in a successful drug screen.  Therefore, I 
chose to develop a targeted approach to minimize the potential off target effects.  
TAg has other essential enzymatic activities, however the ATPase appears to be the best 
target for screening.  While the J domain of TAg is another potential target, because it is also 
conserved and essential (section 1.3.1), J domain specific inhibitors have not yet been 
identified. Most inhibitors of J domain-dependent stimulation of hsp70 exert their effect directly 
on the Hps70 (Wisen et al., 2010). In fact, the relative specificity of MAL2-11B on TAg over 
other J domain containing proteins is unique (Wright et al., 2009).  The difficulty in targeting 
distinct J domains results in part because the J domain contains only a 4 helical bundle that most 
likely adapt different conformations, and because of the high conservation of the J domain 
sequence between J domain containing proteins (Walsh et al., 2004).  Another screen identified 
inhibitors of TAg’s p53 binding using an ELISA based method, which were meant to be used to 
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treat PyV related cancers (Carbone et al., 2003).  Although this is an interesting approach that 
may enable host cell responses to detect and destroy the virus, the method has not yet been 
miniaturized to accommodate screening of large libraries.  Further, if inhibitors of TAg-p53 
binding inhibit other p53 binding interaction, these may result in cytotoxic effects, which was 
not addressed in this study.  Assays targeting these activities might make for interesting 
secondary screens. 
In contrast, the ATPase domain of TAg is an ideal target for screening for several 
reasons.  First, a variety of screening methods have been used to detect other ATPase or kinase 
inhibitors (Chang et al., 2008; Charter et al., 2006; Miyata et al., 2010), and these were adapted 
for our screen.  Second, the activity of the ATPase domain is essential for DNA replication, 
which if sufficiently inhibited should be rate limiting during viral replication.  Third, this 
domain is conserved and essential, allowing me to use SV40 TAg as a proxy TAg for other 
PyVs.  However, a possible limitation of targeting this activity is that general ATPase 
inhibitors, or inhibitors of AAA+ ATPases, may be identified and need to be distinguished.  An 
ideal inhibitor of TAg would need to be TAg specific, and not disrupt other essential AAA+ 
ATPases, such as p97 or the MCMs (Ju and Weihl, 2010; Koonin, 1993; Snider et al., 2008).  
Disrupting p97 activity was recently shown to affect an array of cellular targets, including 
impairing ERAD and autophagy while inducing caspase activity (Chou et al., 2011).  In 
principle, this screening approach could identify TAg specific inhibitors, especially if followed 
by a counter-screen for p97 inhibitors.   
Having performed two screens with the same target but different readouts raised some 
interesting questions.  Is one method more advantageous?  Do both screens identify similar 
inhibitors? The major distinction between the two screens is that ADP Hunter uses an indirect 
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enzymatic readout for ADP levels, in contrast to either malachite green or quinaldine red, which 
detect the presence of inorganic phosphate.  The apparent equivalency of these two methods 
would suggest that similar, if not identical, compounds could be found in both screens and that 
screening sensitivities should be similar.  Both methods reported similar Z-factors and hit rates, 
indicating objectively that the results of both screens should be similar in their ability to 
distinguish potent compounds.  In a direct comparison of the two methods, the ADP Hunter 
screen appeared to be more sensitive than malachite green and this is why it was selected for the 
screen (Figure 18).  However, ADP Hunter also made some compounds tested in this assay 
appear more potent, in particular MAL2-11B (which was determined to have an IC50 of 20 μM 
in contrast to the previously reported value of 50 μM; (Huryn et al., 2011).  An advantage of the 
ADP Hunter screen is that the counter-screen (screening the compounds with the ADP Hunter 
enzymes in the absence of TAg) can quickly identify compounds that may have general affects 
on enzymes.  One interesting consequence of this fact is that, although included in the library, 
the ADP Hunter screen did not identify bithionol and hexachlorophene as potent and specific 
inhibitors.  As discussed further is section 4.3, this is likely because both have appeared to have 
general effects on ATPases and other enzymes and were identified as false positives by the 
counter-screen.  Another difference was that the quinaldine red method was performed in 384 
well plates, in contrast to the ADP Hunter screen which was performed in 1536 well plates, 
meaning that a quinaldine red screen would be slower, or require further refinement.  Given the 
known advantages and disadvantages of both methods, there is not a clear reason to choose one 
method of ATPase inhibitor detection over another.  
One of the important aspects of my work was the development of high throughput 
techniques used for these screens.  It is likely that both methods will have further application in 
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identifying inhibitors of ATPases tied to other diseases, such as hsp70 in cancer. In particular, 
the quinaldine red screen represents a new approach that will prove useful for screening other 
ATP dependent processes.  This method was developed to identify hsp70 inhibitors, and has not 
yet been widely used (Miyata et al., 2010).  Although both screens have been used before on 
other ATPase targets (Charter et al., 2006; Miyata et al., 2010), to my knowledge the use of 
quinaldine red or ADP Hunter to identify anti-viral drugs represents a unique application of 
these methods. 
The screen of 330,000 compounds discussed in Chapter 3 covers a significant portion of 
known chemical space.  Therefore, I believe that there is minimal need to repeat high 
throughput screens with SV40 TAg until new libraries are developed.  Alternatively, re-
screening these libraries directly on the purified TAgs from other PyVs may circumvent some 
of the difficulties we have had in predicting which SV40 TAg inhibitors may inhibit other PyVs 
(see section 4.4).   
4.2 FURTHER UTILITY FOR THE GENERATED SCREENING DATA 
Although the described screening methods will only identify inhibitors that disrupt the ATPase 
activity of TAg, there are several ways this can happen.   For example, a competitive inhibitor 
may bind in the place of ATP; or compounds may bind at a site that prevents the necessary 
conformational change that hydrolyzes ATP or that prevents the formation of the active site by 
inhibiting hexamer formation.   Because we have identified compounds with similar scaffolds, I 
predict that all of the compounds act by a similar mechanism although my current efforts have 
not conclusively determined the mechanism of action of these compounds.  The volume and 
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diversity of compounds available in the Molecular Libraries Probe Production Centers Network 
(MLPCN) is likely to provide scaffolds capable of operating through each these activities with 
some potency.  Identifying such compounds may require less stringent cutoffs for identification 
of lead compounds, which would place a greater emphasis on chemical refinement of promising 
scaffolds. 
One advantage of the high throughput screening approach described in Chapters 2 and 3 
is that the existing data are available for re-analysis.  Since very stringent cut-offs for the 
compounds were used (IC50 less than MAL2-11B), in light of the subsequent results, it may 
prove advantageous to reconsider the hits identified using different criteria, perhaps selecting 
less potent compounds that may be more amenable for chemical refinement to improve 
bioavailability or specific bioactivity.  Notably, the screen described in Chapter 3 examined one 
of the largest chemical libraries available without identifying a compound with more therapeutic 
potential than MAL2-11B. In addition, the chemical refinement of compound 85281215 proved 
to be a major obstacle, suggesting that having multiple scaffolds to refine may help future 
efforts.   
The results of the ADP Hunter screen (Chapter 3) have been uploaded to Pubchem 
(http://pubchem.ncbi.nlm.nih.gov/), making this data available for other researchers.  For 
example, those looking for specific ATPase inhibitors may select against compounds that also 
inhibit TAg.  Alternatively, compounds could be selected for desirable secondary effects, in 
particular if I were to reanalyze the results of the ADP Hunter Screen.  For example, the 
Pubchem interface makes it possible to find compounds that have been identified in multiple 
screens, such as hsp70 inhibitors or p53 activators.  One of the reasons that MAL2-11B is 
effective is that inhibits both the ATPase activity of TAg and the hsp70 (Wright et al., 2008; 
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Wright et al., 2009), which may suggest that other compounds that can be selected with multiple 
targets may be advantageous.  While doing such comparisons is straightforward for the screen 
described in Chapter 3, the results of which have been loaded to Pubchem, investigation of 
specific chemical structures is also possible for hits from the screen described in Chapter 2.  
This may be one way to select for compounds with a bipartite effect that may make them more 
potent viral inhibitors.  
4.3 APPLICATIONS OF THE IDENTIFIED POLYOMAVIRUS INHIBITORS 
As a result of the two performed screens, I identified compounds that inhibit both TAg activity 
in vitro and PyV replication.  Bithionol and hexachlorophene are among the most potent PyV 
inhibitors identified.  It is interesting that our second screen (Chapter 3) also identified a 
bisphenol inhibitor, in this case Bisphenol A.  The structure activity relationship defined in both 
Chapter 2 and Chapter 3 suggests that some bisphenols exert a unique effect on TAg that is 
dependent on specific structural features.  Are bisphenols a class of TAg inhibitors?  Perhaps, 
but in general, bisphenols are known to interact with and modulate the activity of many 
proteins, which is further discussed below.   
Even though the data presented in Chapters 2 and 3 suggests that there is a unique 
structure activity relationship between the bisphenol compounds and their effect on TAg (Figure 
7 and Table 10), we were disappointed to identify a scaffold that lacks therapeutic value.  Both 
bithionol and hexachlorophene have been FDA approved for human use, and in some cases can 
be administered orally.  However, these effects are due to the antiseptic and promiscuous effects 
on multiple, diverse targets, including but not limited to, Glyceraldehyde 3-phosphate 
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dehydrogenase, NFκB, and caspases 3/7, and β-catenin via the E3 Siah-1 (Li et al., 2009; Miller 
et al., 2010; Min et al., 2009).  The diversity of bisphenol targets is thought to be responsible for 
the antiseptic and anthelmintic effects of these compounds (Takeuchi et al., 1985; 
Wickramasinghe et al., 2006).  Given that these small molecules interact with a wide variety of 
targets, it is not possible to make the case for TAg specificity.  In fact, the details of the 
bisphenol structure activity relationship further limit the opportunities for future chemical 
refinement towards specificity.  Because there are few R groups on this small scaffold that are 
not essential for the unique TAg interaction, there are not many remaining sites available for 
modification.  This chemical limitation suggests that this compound cannot be improved in 
terms of drug-like qualities. 
The many off target effects of bisphenols discourages their use in clinical settings, even 
of a modified compound based on the bisphenol scaffold.  Hexachlorophene had been favored 
as a preoperative topical antiseptic and in the delivery room and in other obstetric applications, 
but a rash of fatal accidents involving young children discouraged its use (Canzonetti and 
Dalley, 1952; Kimbrough, 1973).  Instead, the compound bithionol was used as a replacement 
in similar settings (Powell and Lampert, 1973).  While bithionol has been used in humans to 
treat blood flukes, especially in southern Asia, it is known to have many off target effects (see 
Figures 8 and 9) which can result in side effects (Bacq et al., 1991; Kim, 1970; Price et al., 
1993; Seo et al., 1982).  Both compounds have also been used in veterinary settings, perhaps 
because the neurological effects, which include blindness, are less noticeable in the cattle, sheep 
and rodents (Corbett and Goose, 1971; Udall, 1972). Because of the known pathogenicity of the 
avian PyVs (see section 1.1.4), either bithionol or hexachlorophene may be viable choices for 
the treatment of birds that cannot be vaccinated.  Bisphenol A is known as an environmental 
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toxin with wide ranging effects on development stemming from endocrine disruption (Ardon et 
al., 2009; Erler and Novak, 2010; Richter et al., 2007; Rubin, 2011; vom Saal et al., 2007).   In 
the face of the public pushback against this ubiquitous compound, which is commonly used to 
make polycarbonate plastics, it seems unlikely to be useful even in a veterinary setting (Sharpe, 
2010).  Though not as thoroughly investigated as endocrine disruptors, it is unclear whether 
bithionol and hexachlorophene may have similar effects on development, which would 
discourage either long-term use or administration of high dosages of any of these compounds.   
Despite these limitations, these compounds may fill a need for topical polyomavirus 
inhibitors.  As described above, both bithionol and hexachlorophene are approved for topical 
use (Canzonetti and Dalley, 1952; Powell and Lampert, 1973).  Interestingly, four of the most 
recently discovered PyVs appear to have a skin tropism: Merkel Cell Polyomavirus (MCPyV), 
Human Polyomavirus 6 and 7 (HPyV6, HPyV7) and Trichodysplasia Spinulosa Virus (TSV).  
Since both TSV and MCPyV are associated with disease, this suggests that a topical therapeutic 
may be valuable.  Unfortunately, when tested on a MCPyV cell culture system, neither bithionol 
nor hexachlorophene inhibited growth of Merkel Cell Carcinoma (MCC) cells (R. Arora and Y. 
Chang, personal communication).  I hypothesize that this is because the MCC cell lines express 
a truncated TAg, which lacks the ATPase domain.  The effects of these compounds have not yet 
been tested on TSV in part because this disease is very rare and there is not yet an in vitro 
replication system for this virus.  However, both compounds would be reasonable candidates for 
treatment of these or other PyVs that infect skin. 
Although the therapeutic potential of all the compounds identified in these screens is 
probably limited, as mentioned in Chapter 3, any of the described compounds may prove to be 
valuable tools for chemical genetics.  One such example would be to use these compounds to 
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characterize TAg specific in vitro activities, such as the role of TAg in DNA replication.  As 
described in Chapter 1, a very well characterized and minimal system for in vitro TAg-
dependent DNA replication has been developed (see section 1.2.2).  However, there are some 
known, but not well understood, differences between this system and DNA replication in cell 
culture.  One example of this distinction is the requirement for a functional J domain to replicate 
DNA in vivo, but not in vitro (Weisshart et al., 1996).  It seemed conspicuous that of the many 
compounds tested in this assay, none appeared to be active inhibitors of in vitro replication at 
concentrations below 300 μM (Figures 11, 20 and 21).  Therefore, these compounds, including 
all three bisphenols as well as SIDs 85281215, 85281217 and 85281218, may provide a tool to 
understand the differences between DNA replication in vitro and in vivo.  Although the lack of 
inhibition of in vitro DNA replication may simply reflect the lack of potency of these 
compounds, this result was surprising since these compounds were more potent in assays of 
TAg ATPase activity.   
One aspect of the disparity between ATPase inhibition and DNA replication inhibition is 
that TAg ATPase activity may not be rate-limiting during DNA replication, especially in the in 
vitro DNA replication assay.  Another consideration is that in the unsynchronized cell lysate 
used in these assays (Figures 11, 20 and 21), only a small population of the TAg in the reaction 
may be recruiting the active necessary factors required for DNA replication.  This suggests the 
effects of these compounds may be more evident in the highly purified system (Waga et al., 
1994), and the use of such inhibitors may inform our understanding of the role of the ATPase 
domain during replication.  For example, DNA is known to stimulate the ATPase activity of 
TAg (Giacherio and Hager, 1979), and it is possible that the presence of DNA (which is not 
included in our screening system) may overcome the effects of an inhibitor.  For example, the 
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recent structure of TAg bound to single stranded DNA implicated unpredicted residues in DNA 
binding, which is an indication of the structural differences between monomeric TAg, and TAg 
in complex with DNA (Meinke et al., 2011).  These structural differences may mitigate binding 
by some inhibitors or change the kinetics of the ATPase reaction. Overall, a better 
understanding the relationship between ATP hydrolysis, DNA binding and DNA unwinding is 
important to understand effects on viral replication, and the described compounds may provide 
tools for this characterization. 
A skeptical reading of these findings would suggest that TAg will not be amenable to 
small molecule inhibition; the enzymatic activity of TAg is minimal and the compounds 
identified so far have problematic off target effects.  However, I remain confident that TAg can 
be a drug target, because the ATPase activity of TAg is one of the few essential enzymatic 
activities encoded by the virus.   I am currently investigating the potential for a synergistic 
effect of the bisphenols in addition to cidofovir, a known PyV inhibitor (see section 1.4.2.5).  
While we are optimistic that using lower doses of both drugs in combination may improve their 
overall efficacies while minimizing toxicity, synergism may prove more evident when 
examined with a different combination of TAg inhibitors.  Future drug screens should take 
advantage of synergistic effects by pairing drug treatment with either bithionol or 
hexachlorophene.   
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4.4 REFINEMENT OF THE HYPOTHESIS: INHIBITORS OF SV40 TAG MAY 
INHIBIT REPLICATION OF OTHER PYVS, BUT WITH DIFFERENT POTENCIES 
The described work supported the hypothesis that inhibitors of SV40 TAg can be inhibitors of 
PyV replication, but my results also led to a refinement of this hypothesis.  I also predicted that 
due to the slow replication of BKV, compounds that have a modest effect on SV40 would have 
a greater effect on BKV or other PyVs.  The relatively low viral yield, especially when BKV is 
replicating in Vero cells, indicates that the virus is not replicating at maximal efficiency.  
Therefore, I expected modest inhibition of TAg activities would make viral replication much 
less efficient; however, this was not the case.  The compounds that were tested in both viruses 
appeared less potent on BKV than was predicted from the SV40 replication data (compare 
Figures 10 and 16).  It was also interesting that bithionol and hexachlorophene did not have the 
expected identical effects on BKV replication (see Appendix B for another example of this 
disparate effect between SV40 and BKV replication). It is not clear if this difference reflects the 
biology of these two viruses or an indication that the compounds that I have identified act via 
different mechanisms.   
A frequent reviewer comment is that because BKV is “slower” there is more time to 
overcome the effects of the compound over the course of the infection.  This explanation 
perhaps provides a longer time course for the host cell to clear the drug, but still seems to be an 
insufficient explanation.  For example, this comment does not explain the different potency of 
bithionol and hexachlorophene on BKV, which were expected to have identical potencies in the 
BKV assays based on the identical potency on SV40 replication.  The demonstrated inhibition 
of BKV is an order of magnitude less than the inhibition of SV40 replication (compare Figures 
10 and 16).  Drug clearing is unlikely to be the explanation for these results, since in this assay 
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compounds were supplemented every 48 h during the infection (Figure 16). While the 
replication rate may be the basis of this difference, it is unclear how this rate results in the 
distinct effects of compounds on SV40 and BKV.  As mentioned in section 2.4, the observed 
difference in compound potencies endorses the continued use of large library screens to identify 
relevant scaffolds that may be amenable to chemical refinement, or at least to provide multiple 
hits to test in relevant assays. I have only directly compared the effects of PyV inhibitors 
between SV40 and BKV.  It seems possible, if not likely, that there may be a similar distinction 
in potencies as compounds are tested on other PyV replication systems. 
As mentioned above, screening for TAg ATPase inhibitors remains a promising way to 
target PyV replication while minimizing off target effects.  However, as the disparate effects of 
TAg inhibitors on different PyVs highlights, a better approach may be to screen the inhibitors 
on purified TAg from the PyV of interest.  The conservation of TAgs would suggest that 
inhibitors of any TAg should inhibit the entire family.  The major limitation for studies on PyVs 
is that replication systems have not been developed for most of these viruses yet.  Expressing 
and purifying TAgs from other PyVs for chemical inhibitor screening will certainly be a rapid 
way to confirm whether SV40 TAg inhibitors have effects on the entire viral family, expanding 
the utility of this approach.  JC TAg has been purified using a similar method employed in the 
purification of SV40 TAg (Bollag et al., 1996), suggesting analogous techniques could be used 
with other PyV TAgs.  Additionally, use of an exogenous DNA replication assay in cell culture 
that does not require viral replication may provide a secondary counter screen for such efforts 
(Boichuk et al., 2010; Gjorup et al., 1994).   
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4.5 RECOMMENDATIONS FOR FURTHER IDENTIFICATION OF PYV 
INHIBITORS AND THERAPEUTICS 
One fundamental question that remains is how therapeutics for PyVs should be identified. A 
parallel issue to this is that of the 330,000 compounds screened, an ideal therapeutic was not 
identified.  At a minimum, this suggests that potent TAg specific inhibitors are not abundant in 
existing libraries.  Future efforts to identify TAg or PyV inhibitors will need to find approaches 
to address this challenge, either by using different libraries or focusing on a different target.  As 
described in Chapter 1, since the majority of activities required for viral replication are 
performed by host factors, the viral targets for such compounds are relatively limited.  Indeed, 
even the essential enzymatic activities of the major screening target, TAg, are limited.   
Limited viral targets are one reason that general antivirals, which support cellular 
recognition of Pathogen Associated Molecular Patterns (PAMPs) or inhibit such activities, may 
be advantageous (Unterholzner and Bowie, 2008).  Unfortunately, PyVs do not show several of 
the common PAMPs that would trigger an innate immune response; DNA replication is nuclear 
rather than cytoplasmic, there are no free DNA ends or dsRNA and there are very limited viral 
antigens and no viral envelope proteins, all of which are known to induce Toll-like receptors 
(Mogensen, 2009; Unterholzner and Bowie, 2008).  Yet, there are features of PyV replication 
that are shared with other viral pathogens, such as inappropriate initiation of S-phase or 
endoreduplication, which may serve as better and more broad targets.  For example, compounds 
that target an activity that is not essential to a resting cell but is essential for viral replication, 
such as Bub1 activity might be uniquely potent (Hein et al., 2009).  DNA methylation (indicated 
by CpG doublets) is another common feature of viral DNA, which can protect the genome from 
being clipped (Goorha et al., 1984).  In PyVs, the presence of these doublets is not highly 
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conserved, suggesting that compounds that inhibit DNA methylation or support host recognition 
of this pattern may not inhibit the entire family equally (Subramanian, 1982).  As another 
example, it has been shown that specific post-translational modifications regulate TAg activity, 
such as essential phosphorylation and acetylation (McVey et al., 1989; Poulin et al., 2004).  It 
may be possible to modulate the kinases or acetylases responsible for this activity with minimal 
impact on host cell function.  Others have suggested that directly stimulating TLRs, in this case 
TLR3 in SV40 transformed cells, may promote an immune response directed at the viral 
antigens (Lowe et al., 2010).  Recent work characterizing transcriptional regulation in TAg 
expressing cells indicated that TAg activates Interferon stimulated genes, including Stat1 
independent of interferon, suggesting that TAg is also modulating innate immune responses 
(Cantalupo et al., 2009; Rathi et al., 2010; Rathi et al., 2009).  Applying a general antiviral to 
PyV-related diseases is how cidofovir and leflunomide came into favor (see section 1.4.2.5). 
This returns to the issue that the compounds that are currently favored for the treatment 
of PyV are not PyV specific, nor are they yet supported by sufficient evidence to justify their 
use in clinical settings (see section 1.4.2.5).  For some compounds, this is a matter of expanding 
multi-center trials to collect sufficient data (Farasati et al., 2005; Tan and Koralnik, 2010).  
Performing the necessary clinical trials to test the use of compounds that have been shown to 
inhibit PyV replication in vitro may be the fastest way to establish a therapeutic standard for 
PyV diseases.  In addition, other antiviral drugs that are known to inhibit viral DNA replication, 
which likely share similar PAMPs, in particular for papilloma or herpes virus, should be tested 
in a PyV replication system.  It has also been suggested that a PyV vaccine for humans, using 
virus-like particles or inactivated virus, such as has been used for birds (Ritchie et al., 1998a; 
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Ritchie et al., 1998b), may be a viable prophylactic for the at risk populations (K. Peden, 
personal communication).  
One missing piece that would support my investigations is an understanding of what 
causes pathogenicity in PyVs.  PyVs are widely distributed, and can be detected at relatively 
high levels without pathogenicity.  Perhaps the best quantitated example of the distinction 
between viral levels that are pathogenic or benign is the detection of TSV (van der Meijden et 
al., 2010).  In this paper, researchers documented a viral titer of 2x105 copies per cell in the 
symptomatic patient, while after treatment, when symptoms were reduced, the viral titer was 
104 copies per cell in this same patient (van der Meijden et al., 2010).  This 20-fold reduction 
may indicate that a modest effect of an inhibitor allows the host immune system to control viral 
replication and symptoms. This evidence should encourage the investigation of compounds that 
have a modest but specific effect on viral replication.  
Another approach may be to investigate the sequence specific changes that make PyVs 
pathogenic.  Limited single nucleotide polymorphisms (SNPs) have been identified for BKV, 
which have not yet been correlated with patient outcome or pathogenicity (Luo et al., 2009).  
Additionally, monitoring of viral sequences from patients has suggested that changes in the non-
coding control region may be associated with increased pathogenicity (Broekema et al., 2010; 
Sharma et al., 2007).  It is not yet clear if this is the only site of rearrangement and if these 
genetic changes lead to pathogenicity.  More recent analysis of patient samples suggested that 
individual patients are infected with a surprising diversity of viral genotypes for a DNA virus, 
especially since DNA viruses that recruit the host polymerase are predicted to have a low 
mutation rate similar to mutation rates during eukaryotic replication (P. Randhawa, personal 
communication).  This evidence suggests either that there may be specific sequence changes 
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that result in virulence, or that viral diversity gives rise to virulence by allowing for rapid 
adaptation to the responding host environment (although the quasispecies model is more 
common in RNA viruses; (Lauring and Andino, 2010).  In the end, understanding the roles of 
diverse genotypes in pathogenic PyV infection will be important to understanding virulence, 
and may present a new target to prevent virulence.  
4.6 SUMMARY AND CONCLUSIONS 
There have been several valuable contributions of my work to the field of PyV biology.  These 
include identifying a screenable target activity (the ATPase activity of TAg), adapting high 
throughput methods to identify TAg inhibitors, identifying bisphenols as a general scaffold for 
PyV inhibitors and refining the activity of this structure, and proving that inhibitors of SV40 
replication can also inhibit BKV replication.  This work provides important tools for further 
characterization of PyV inhbitors and presents candidate compounds to use chemical genetics to 
explore PyV replication.  In sum, this work supports the continued use of SV40 as a model for 
PyV replication, since assays for replication are best established in SV40, facilitating 
characterization of the compound before assays are performed on slower replicating viruses. 
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APPENDIX A 
INHIBITION OF SIMIAN VIRUS 40 REPLICATION BY TARGETING THE 
MOLECULAR CHAPERONE FUNCTION AND ATPASE ACTIVITY OF T ANTIGEN 
This work was performed in collaboration with the Wipf Lab at the University of Pittsburgh, 
and is published (Wright et al., 2009). 
 
Previous work by a graduate student in the Brodsky lab, Dr. Christine Wright, had identified a 
small molecule scaffold that targets hsp70 activity, and resulted in decreased proliferation of 
cancer cells (Wright et al., 2008).  As part of this study, the J domain of TAg was tested with 
the hsp70 in the presence of the inhibitor.  It became clear that this compound could inhibit both 
the endogenous ATPase activity of the TAg and the ability to enhance hsp70’s ATPase activity.  
The characterization of this activity was the subject of a 2009 Virus Research manuscript 
(Wright et al., 2009). 
  158 
A.1 RESULTS 
Dr. Wright demonstrated that MAL2-11B could inhibit both endogenous TAg activity, as well 
as the ability of TAg to stimulate hsp70.  It was assumed that this was a J domain dependent 
activity, because Dr. Wright demonstrated this effect was less potent with other J domains, 
suggesting J domain specificity.  Using known TAg mutants, I demonstrated that the J domain 
was essential for this activity, and that the detected activity was not from endogenous TAg 
activity.  Specifically, I took advantage of an ATPase defective mutant known as 5061, and a 
point mutation (D44N) in the HPD motif of the J domain, which renders the J domain incapable 
of stimulating hsp70 activity (Castellino et al., 1997; Srinivasan et al., 1997).  Both purified 
mutants were provided by the Pipas lab.  These data showed that hsp70 is maximally stimulated 
by wild type TAg, and by 5061, suggesting that the ATPase activity in this assay was not from 
TAg (Figure 23).  The D44N mutant showed activity most similar to wt-hsp70 alone, further 
supporting the notion that the stimulation shown in these assays was from the J domain of TAg, 
not the endogenous TAg ATPase activity.  These data further suggested that MAL2-11B acted 
by inhibiting the activity of the J domain of TAg.  
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Figure 23.  Stimulation of hsp70 ATPase activity is dependent on the TAg J domain in a single 
turnover ATPase assay. 
Filled circles, hsp70 alone; Open squares, Tag; Inverted filled triangles, TAg mutant 5061; Filled 
diamonds, D44N TAg. Error bars represent standard deviations of the data; n=3. 
  160 
 
 
  161 
Figure 24. MAL2-11B inhibits SV40 DNA replication. 
(A) MAL2-11B reduces viral propagation in plaque assays. The number of plaques visualized in 
duplicate reactions was averaged and the results were normalized to the DMSO control. The results of three 
independent experiments were then averaged and the means of the reactions ± the standard deviations of the 
data are shown. MAL2-11B compared to the DMSO control, p < 0.0002. (B) MAL2-11B inhibits SV40 DNA 
replication 48 h after treatment. Viral DNA was isolated from SV40-infected cells 48 h after treatment with 
100 μM of the indicated compounds and digested with BamHI, and the products were visualized after 
resolution on an ethidium bromide-stained agarose gel. The fact that the product corresponded to viral DNA 
was confirmed based units size (5.2 kb after BamH1 digestion) and by the fact that internal primers specific 
to SV40 DNA yielded the expected product after PCR (data not shown). (C) Time course of the effects of 
MAL2-11B, MAL3-101, and MAL3-51 on SV40 DNA synthesis. DNA was isolated at the indicated times (in 
h) and analyzed as described in part (B). Note: More material was loaded than in part (B) in order to better 
visualize the time-dependent increase in SV40 DNA. To control for the DNA loaded in these gels, we used a 
real-time PCR analysis to detect the amount of the actin gene in the same samples used in part (B) (see 
section 2.2.4). The amount of actin DNA in the DMSO control was set to “1.0”, and based on this analysis the 
relative amounts of total DNA analyzed were: DMSO, 1.0; MAL2-11B, 3.4; MAL3-51, 4.0; MAL3-101, 4.0. 
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Dr. Wright next demonstrated that MAL2-11B inhibits replication of viral DNA in 
infected cells.  She did this by harvesting DNA from infected BSC40 cells that had been treated 
with the compounds of interest.  This DNA was linearized and visualized on an agarose gel 
(Figure 24A and B).  In response to a reviewer’s comment, I was able to confirm these results, 
first by confirming that this was viral DNA by obtaining a PCR product using SV40 specific 
primers and this harvested DNA as a template, which indicated that the visualized DNA in 
Figure 24B was of viral origin.  Second, I demonstrated that the effect of the tested compounds 
was not simply due to a delay in viral DNA replication.  I performed a time course of infection 
and harvested DNA at 0, 48 and 96 hpi.  The DNA was visualized on an agarose gel (Figure 
24C), and quantitated by quantitative PCR.  I also showed that similar amounts of each sample 
were visualized on the gel in Figure 24B by detecting trace amounts of actin DNA by qPCR.   
Another lingering question was whether the effect of the compound was on TAg or a 
more general stress response or possibly due to programmed cell death.  While Dr. Wright 
demonstrated that MAL2-11B did decrease TAg expression, I showed that this compound did 
not increase hsp70 expression, which would indicate a stress response (Figure 25A).  I further 
demonstrated by Western blot that MAL2-11B did not induce PARP cleavage, which would 
have been an indication of an apoptotic response (Figure 25B(Pieper et al., 1999)). 
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Figure 25. MAL2-11B reduces TAg expression without inducing apoptosis.   
A.  Freshly confluent BSC40 cells were infected with SV40 for 2 h and subsequently treated with 
100 μM MAL2-11B for 48 h. Control cells that were uninfected, but treated with DMSO or MAL2-11B, were 
also examined. The cells were lysed and an equal amount of total cellular protein was resolved on a 
polyacrylamide gel. After transfer to nitrocellulose the blots were decorated with the indicated antisera.  B. 
Cells were treated as described in (A), except that 1 μM staurosporine was added for 4 h, where indicated, 
and the indicated concentrations of MAL2-11B were included in the medium for 48 h. Lysates were 
resolved, transferred to nitrocellulose, and probed with anti-PARP or anti-actin antibody. 
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APPENDIX B 
CHEMICAL REFINEMENT OF THE MAL2-11B SCAFFOLD IDENTIFIES A BKV 
INHIBITOR AND RAISES QUESTIONS ABOUT COMPARISONS BETWEEN PYVS 
This work was originally published in collaboration with at the Wipf lab at the University of 
Pittsburgh (Huryn et al., 2011).  These results raise an interesting question about PyV biology. 
 
Previous work in our lab identified the MAL2-11B scaffold as an interesting inhibitor of TAg 
and polyomavirus replication (Wright et al., 2009).  Specifically, MAL2-11B was shown both 
to inhibit endogenous TAg ATPase activity, as well as the ability of TAg to stimulate hsp70 
activity. This results in inhibition of both SV40 and BKV replication in cell culture.  Although 
MAL2-11B itself has limitations, including low cell permeability and potency, this bipartite 
effect may be improved by scaffold optimization.  To explore this idea, derivatives of this 
scaffold were developed by the Wipf lab and tested by Alex Ireland, an undergraduate 
researcher, in our in vitro assays.  I then examined the effects of the compounds on viral 
replication in cell culture. 
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B.1 METHODS FOR VALIDATING THE MAL2-11B DERIVATIVES. 
Purification of T Antigen : Purification of the SV40 large T Antigen (TAg) was as 
previously reported (Cantalupo et al., 1999; Wright et al., 2009). In brief, a baculovirus 
expressing TAg was used to infect Sf9 cells, which were harvested and lysed. The lysate was 
purified over a Protein G Sepharose Fast-Flow column covalently crosslinked to the monoclonal 
antibody PAb419, which recognizes TAg (Harlow et al., 1981). After washing, the enriched 
protein was released with base and dialyzed into buffer containing 10 mM Tris pH 8.0, 1 mM 
EDTA, 100 mM NaCl, 10% glycerol and 1 mM DTT. 
Steady state ATPase assay : The ATPase activity of TAg was measured using a 
previously described method (Cyr et al., 1992; Wright et al., 2009).  Protein and compound 
were incubated for 15 min on ice before the addition of a mix of radiolabeled and non-
radiolabeled ATP to a final concentration of 50 μM. The reaction was shifted to 30 °C, and 3 μL 
aliquots were removed and the reaction was quenched every 15 min for 60 min. ADP was 
resolved from ATP by TLC in a LiAc/formic acid-containing solvent and the TLC was exposed 
to a phosphoimager plate. Data were analyzed on a Fujifilm BAS-2500 phosphoimager and 
quantified using Imageguage software v.4. 
BKV DNA replication assay : Vero cells were a generous gift from the McClane lab 
(University of Pittsburgh, School of Medicine). BKV crude stocks were a gift from the 
Imperiale lab (University of Michigan). Vero cells were grown at 37 ºC in 5% CO2 in DMEM 
containing 10% FBS. 
To determine the effect of the compounds on BKV replication, a qPCR assay based on 
methods reported previously (Murata et al., 2009; Randhawa et al., 2005b) was performed. In 
brief, a low titer of BKV was used to infect low confluence Vero cells for 1 h. The media was 
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then replaced with DMEM containing the desired compound and 0.3% DMSO. The infection 
continued until 5 dpi, when the culture was lysed by freeze-thaw and the viral content was 
assayed by qPCR. To perform the qPCR assay, a mix of primers (Wright et al., 2009) and 
Taqman probe (IDT) were assembled with PerfeCta qPCR SuperMix, ROX (Quanta 
Biosciences) in MicroAmp plates (ABI) and amplified by a 7300 Real-Time PCR System. 
Absolute quantification was performed using pBKV (Dalrymple and Beemon, 1990) as a 
reference for BKV. This plasmid contains the entire viral genome cloned into a BamH1 site, 
and serves as a control. The DNA was initially melted at 95 ºC for 1 min and cycled between 
95º for 15 sec and 60ºC for 1 min. Data were quantified by 7300 System SDS version 1.3.1 
(ABI) and are reported relative to the DMSO control. 
B.2 RESULTS 
Derivatives of MAL2-11B were prepared to test whether changes to the linker region might 
improve efficacy and solubility of this scaffold.  While several of the compounds tested did not 
have any effect, the tetrazol derivative, referred to in the manuscript as compound 32, was 
slightly more potent than MAL2-11B in the ATPase assay (Figure 26 A and B).  I next 
characterized this effect on BKV by qPCR assay (Figure 26 C).  While it is clear that both 
MAL2-11B and 32 inhibit BKV replication, we were surprised that there was not a distinct 
effect of these two compounds. 
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Figure 26. Effect of MAL2-11B and the tetrazol derivative on TAg and BKV replication. 
Steady-state ATPase assays with purified T-antigen were performed as described (B.1) in the 
presence of the indicated concentrations of (A) MAL2-11B or (B) 32. Data represent the means of at least 
three determinations ± SD. (C) The replication of the BK virus and viral DNA content were assessed in the 
presence of the indicated supplements.  MAL2-11B and 32 were used at a final concentration of 100 μM. 
Data represent the means of two independent infections, each performed in triplicate, ± SEM; p ≤ 0.007 for 
DMSO vs. the compound treated samples. 
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B.3 CONCLUSIONS AND FUTURE DIRECTIONS 
The driving hypothesis of this work has been that inhibitors of SV40 TAg will inhibit the 
replication of PyVs in general.  I had also assumed that due to its slower replication and 
decreased TAg expression, that BKV would be more sensitive to TAg inhibitors than SV40.  
Therefore I expected the tetrazol, 32, to be a significantly more potent inhibitor of BKV.  I was 
surprised by the result that both MAL2-11B and 32 were less potent on BKV than anticipated 
based on previous work with SV40 (Wright et al., 2009). This was in part because it implies that 
BKV is not more sensitive to inhibitors than SV40, and also that a two-fold improvement in 
TAg inhibition in vitro may not have a significant effect on viral replication.  There certainly are 
differences in the biology of BKV and SV40 that can explain these data.  As mentioned above, 
BKV infections are much slower than SV40, and while the reason for this is not clear, during 
this time, compounds may be metabolized by the cell or bind off-targets, leaving TAg free to 
replicate BKV.  To minimize this phenomena, the media and compounds were refreshed during 
the infection.  Perhaps another explanation is that there are some fundamental differences 
between SV40 and BKV TAgs.  Our lab has not yet developed a system to purify other TAgs, 
but in vitro testing of compounds on these other TAgs might provide more evidence about the 
differences we see when infecting with different viruses.   
While previous research on TSV made us optimistic that the effects of a compound need 
only modestly effect viral replication to dramatically improve pathology (van der Meijden et al., 
2010), my results also suggest that modest improvements in antiviral effect may be more 
difficult to obtain with TAg inhibitors.  While ATPase activity is essential for viral replication, 
it is not likely to be the rate limited step in viral replication (Rohaly et al., 2010).  This suggests 
that to dramatically reduce viral replication, TAg activity must be severely curtailed, or 
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compounds that target other viral activities may need to be used in combination with TAg 
inhibitors.   
Nevertheless, a bipartite effect may prove to be more important that initially thought.  
Further derivatives of the tetrazol, 32, are being synthesized by the Wipf lab, and I look forward 
to testing them in our assays.  These results certainly confirm that we can quickly produce the 
data necessary to characterize such compounds.  Although my evidence suggests that these 
compounds may need to be significantly improved in potency to have a future as a therapeutic, 
this line of research may serve to elucidate some of the subtle differences between BKV and 
SV40 replication.  Perhaps more importantly, the MAL2-11B scaffold is more amenable to 
chemical refinement than the other compounds identified in this dissertation (e.g. the bisphenols 
or SID 85281215, see Chapters 2 and 3 respectively). 
  170 
BIBLIOGRAPHY 
Aaronson, S.A., and Todaro, G.J. (1968). Basis for the acquisition of malignant potential by 
mouse cells cultivated in vitro. Science 162, 1024-1026. 
Abend, J.R., Low, J.A., and Imperiale, M.J. (2010). Global effects of BKV infection on gene 
expression in human primary kidney epithelial cells. Virology 397, 73-79. 
Abrahams, P.J., Mulder, C., Van De Voorde, A., Warnaar, S.O., and van der Eb, A.J. (1975). 
Transformation of primary rat kidney cells by fragments of simian virus 40 DNA. J 
Virol 16, 818-823. 
Ahuja, D., Saenz-Robles, M.T., and Pipas, J.M. (2005). SV40 large T antigen targets multiple 
cellular pathways to elicit cellular transformation. Oncogene 24, 7729-7745. 
AID:894. PubChem Bioassay Database; AID= 894 qHTS Assay for Inhibitors of HPGD (15-
Hydroxyprostaglandin Dehydrogenase) 
http://pubchemncbinlmnihgov/assay/assaycgi?aid=894. National Center for 
Biotechnology Information. Accessed on June 16, 2011 
AID:1475. Pubchem Bioassay Database; AID= 1475 Quantitative High-Throughput Screen for 
Inhibitors of Tau Fibril Formation. 
http://pubchemncbinlmnihgov/assay/assaycgi?aid=1475. National Center for 
Biotechnology Information. Accessed on June 16, 2011 
AID:1819. PubChem Bioassay Database; AID= 1819 Probe Development Summary of 
Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). 
http://pubchemncbinlmnihgov/assay/assaycgi?aid=1819. National Center for 
Biotechnology Information. Accessed on June 16, 2011 
AID:2093. Pubchem Bioassay Database; AID= 2093 Summary assay for inhibitors of Mint1. 
http://pubchemncbinlmnihgov/assay/assaycgi?aid=2093. National Center for 
Biotechnology Information. Accessed on June 16, 2011 
AID:2139. Pubchem Bioassay Database; AID= 2139 Summary of probe development efforts to 
identify novel modulators of the Retinoic acid receptor-related Orphan Receptors 
(ROR). http://pubchemncbinlmnihgov/assay/assaycgi?aid=2139. National Center for 
Biotechnology Information. Accessed on June 16, 2011 
  171 
AID:160544. PubChem Bioassay Database; AID= 160544 Functional activity in RAT-1cells, 
transiently-transfected with human Prostaglandin E receptor EP1 
http://pubchemncbinlmnihgov/assay/assaycgi?aid=160544. National Center for 
Biotechnology Information. Accessed on June 16, 2011 
Aksamit, A.J. (2001). Treatment of non-AIDS progressive multifocal leukoencephalopathy with 
cytosine arabinoside. J Neurovirol 7, 386-390. 
Ali, S.H., Chandraker, A., and DeCaprio, J.A. (2007). Inhibition of Simian virus 40 large T 
antigen helicase activity by fluoroquinolones. Antivir Ther 12, 1-6. 
Ali, S.H., Kasper, J.S., Arai, T., and DeCaprio, J.A. (2004). Cul7/p185/p193 binding to simian 
virus 40 large T antigen has a role in cellular transformation. J Virol 78, 2749-2757. 
Allander, T., Andreasson, K., Gupta, S., Bjerkner, A., Bogdanovic, G., Persson, M.A., Dalianis, 
T., Ramqvist, T., and Andersson, B. (2007). Identification of a third human 
polyomavirus. J Virol 81, 4130-4136. 
Amin, A.A., Murakami, Y., and Hurwitz, J. (1994). Initiation of DNA replication by simian 
virus 40 T antigen is inhibited by the p107 protein. J Biol Chem 269, 7735-7743. 
Anders, D.G., and Consigli, R.A. (1983). Chemical cleavage of polyomavirus major structural 
protein VP1: identification of cleavage products and evidence that the receptor moiety 
resides in the carboxy-terminal region. J Virol 48, 197-205. 
Ardon, F., Rodriguez-Miranda, E., Beltran, C., Hernandez-Cruz, A., and Darszon, A. (2009). 
Mitochondrial inhibitors activate influx of external Ca(2+) in sea urchin sperm. Biochim 
Biophys Acta 1787, 15-24. 
Ashkenazi, A., and Melnick, J.L. (1963). Tumorigencity of simian papovavirus SV40 and of 
virus-transformed cells. J Natl Cancer Inst 30, 1227-1265. 
Avantaggiati, M.L., Carbone, M., Graessmann, A., Nakatani, Y., Howard, B., and Levine, A.S. 
(1996). The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct 
isoforms of the transcriptional co-activator, p300. EMBO J 15, 2236-2248. 
Bacq, Y., Besnier, J.M., Duong, T.H., Pavie, G., Metman, E.H., and Choutet, P. (1991). 
Successful treatment of acute fascioliasis with bithionol. Hepatology 14, 1066-1069. 
Bargonetti, J., Reynisdottir, I., Friedman, P.N., and Prives, C. (1992). Site-specific binding of 
wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes 
Dev 6, 1886-1898. 
Basse, G., Mengelle, C., Kamar, N., Guitard, J., Ribes, D., Esposito, L., and Rostaing, L. 
(2007). Prospective evaluation of BK virus DNAemia in renal transplant patients and 
their transplant outcome. Transplant Proc 39, 84-87. 
  172 
Bechert, C.J., Schnadig, V.J., Payne, D.A., and Dong, J. (2010). Monitoring of BK viral load in 
renal allograft recipients by real-time PCR assays. Am J Clin Pathol 133, 242-250. 
Becker, J.C., Houben, R., Ugurel, S., Trefzer, U., Pfohler, C., and Schrama, D. (2009). MC 
polyomavirus is frequently present in Merkel cell carcinoma of European patients. J 
Invest Dermatol 129, 248-250. 
Bedi, A., Miller, C.B., Hanson, J.L., Goodman, S., Ambinder, R.F., Charache, P., Arthur, R.R., 
and Jones, R.J. (1995). Association of BK virus with failure of prophylaxis against 
hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 13, 1103-
1109. 
Bellard, M., Oudet, P., Germond, J.E., and Chambon, P. (1976). Subunit structure of simian-
virus-40 minichromosome. Eur J Biochem 70, 543-553. 
Berg, P. (2004). Paul Berg - Autobiography. In Nobel Lectures (Stockholm, The Nobel 
Foundation). 
Berger, L.C., Smith, D.B., Davidson, I., Hwang, J.J., Fanning, E., and Wildeman, A.G. (1996). 
Interaction between T antigen and TEA domain of the factor TEF-1 derepresses simian 
virus 40 late promoter in vitro: identification of T-antigen domains important for 
transcription control. J Virol 70, 1203-1212. 
Berk, A.J., and Sharp, P.A. (1978). Spliced early mRNAs of simian virus 40. Proc Natl Acad 
Sci U S A 75, 1274-1278. 
Bernhoff, E., Gutteberg, T.J., Sandvik, K., Hirsch, H.H., and Rinaldo, C.H. (2008). Cidofovir 
inhibits polyomavirus BK replication in human renal tubular cells downstream of viral 
early gene expression. Am J Transplant 8, 1413-1422. 
Bernhoff, E., Tylden, G.D., Kjerpeseth, L.J., Gutteberg, T.J., Hirsch, H.H., and Rinaldo, C.H. 
(2010). Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J 
Virol 84, 2150-2156. 
Bharucha, V.A., Peden, K.W., and Tennekoon, G.I. (1994). SV40 large T antigen with c-Jun 
down-regulates myelin P0 gene expression: a mechanism for papovaviral T antigen-
mediated demyelination. Neuron 12, 627-637. 
Bialasiewicz, S., Rockett, R., Whiley, D.W., Abed, Y., Allander, T., Binks, M., Boivin, G., 
Cheng, A.C., Chung, J.Y., Ferguson, P.E., et al. (2010). Whole-genome characterization 
and genotyping of global WU polyomavirus strains. J Virol 84, 6229-6234. 
Bialasiewicz, S., Whiley, D.M., Lambert, S.B., Wang, D., Nissen, M.D., and Sloots, T.P. 
(2007). A newly reported human polyomavirus, KI virus, is present in the respiratory 
tract of Australian children. J Clin Virol 40, 15-18. 
  173 
Binet, I., Nickeleit, V., Hirsch, H.H., Prince, O., Dalquen, P., Gudat, F., Mihatsch, M.J., and 
Thiel, G. (1999). Polyomavirus disease under new immunosuppressive drugs: a cause of 
renal graft dysfunction and graft loss. Transplantation 67, 918-922. 
Black, P.H., and Rowe, W.P. (1963). An Analysis of Sv40-Induced Transformation of Hamster 
Kidney Tissue in Vitro. I. General Characteristics. Proc Natl Acad Sci U S A 50, 606-
613. 
Black, P.H., and Rowe, W.P. (1964). Viral Studies of Sv40 Tumorigenesis in Hamsters. J Natl 
Cancer Inst 32, 253-265. 
Bocchetta, M., Di Resta, I., Powers, A., Fresco, R., Tosolini, A., Testa, J.R., Pass, H.I., Rizzo, 
P., and Carbone, M. (2000). Human mesothelial cells are unusually susceptible to simian 
virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U 
S A 97, 10214-10219. 
Bochkareva, E., Martynowski, D., Seitova, A., and Bochkarev, A. (2006). Structure of the 
origin-binding domain of simian virus 40 large T antigen bound to DNA. EMBO J 25, 
5961-5969. 
Bochman, M.L., and Schwacha, A. (2010). The Saccharomyces cerevisiae Mcm6/2 and 
Mcm5/3 ATPase active sites contribute to the function of the putative Mcm2-7 'gate'. 
Nucleic Acids Res 38, 6078-6088. 
Bofill-Mas, S., Formiga-Cruz, M., Clemente-Casares, P., Calafell, F., and Girones, R. (2001). 
Potential transmission of human polyomaviruses through the gastrointestinal tract after 
exposure to virions or viral DNA. J Virol 75, 10290-10299. 
Boichuk, S., Hu, L., Hein, J., and Gjoerup, O.V. (2010). Multiple DNA damage signaling and 
repair pathways deregulated by simian virus 40 large T antigen. J Virol 84, 8007-8020. 
Bolen, J.B., and Consigli, R.A. (1980). Separation of neutralizing and hemagglutination-
inhibiting antibody activities and specificity of antisera to sodium dodecyl sulfate-
derived polypeptides of polyoma virions. J Virol 34, 119-129. 
Bollag, B., Chuke, W.F., and Frisque, R.J. (1989). Hybrid genomes of the polyomaviruses JC 
virus, BK virus, and simian virus 40: identification of sequences important for efficient 
transformation. J Virol 63, 863-872. 
Bollag, B., Mackeen, P.C., and Frisque, R.J. (1996). Purified JC virus T antigen derived from 
insect cells preferentially interacts with binding site II of the viral core origin under 
replication conditions. Virology 218, 81-93. 
Boren, E.J., Cheema, G.S., Naguwa, S.M., Ansari, A.A., and Gershwin, M.E. (2008). The 
emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. 
J Autoimmun 30, 90-98. 
  174 
Brade, L., Muller-Lantzsch, N., and zur Hausen, H. (1981). B-lymphotropic papovavirus and 
possibility of infections in humans. J Med Virol 6, 301-308. 
Bradley, M.K., Griffin, J.D., and Livingston, D.M. (1982). Relationship of oligomerization to 
enzymatic and DNA-binding properties of the SV40 large T antigen. Cell 28, 125-134. 
Brockman, W.W. (1978). Transformation of BALB/c-3T3 cells by tsA mutants of simian virus 
40: temperature sensitivity of the transformed phenotype and retransofrmation by wild-
type virus. J Virol 25, 860-870. 
Brodsky, J.L., and Pipas, J.M. (1998). Polyomavirus T antigens: molecular chaperones for 
multiprotein complexes. J Virol 72, 5329-5334. 
Broekema, N.M., Abend, J.R., Bennett, S.M., Butel, J.S., Vanchiere, J.A., and Imperiale, M.J. 
(2010). A system for the analysis of BKV non-coding control regions: application to 
clinical isolates from an HIV/AIDS patient. Virology 407, 368-373. 
Brugge, J.S., and Butel, J.S. (1975). Role of simian virus 40 gene A function in maintenance of 
transformation. J Virol 15, 619-635. 
Bullock, P.A. (1997). The initiation of simian virus 40 DNA replication in vitro. Crit Rev 
Biochem Mol Biol 32, 503-568. 
Butel, J.S., Jarvis, D.L., and Maxwell, S.A. (1989). SV40 T-antigen as a dual oncogene: 
structure and function of the plasma membrane-associated population. Ann N Y Acad 
Sci 567, 104-121. 
Butin-Israeli, V., Drayman, N., and Oppenheim, A. (2010). Simian virus 40 infection triggers a 
balanced network that includes apoptotic, survival, and stress pathways. J Virol 84, 
3431-3442. 
Campbell, K.S., Mullane, K.P., Aksoy, I.A., Stubdal, H., Zalvide, J., Pipas, J.M., Silver, P.A., 
Roberts, T.M., Schaffhausen, B.S., and DeCaprio, J.A. (1997). DnaJ/hsp40 chaperone 
domain of SV40 large T antigen promotes efficient viral DNA replication. Genes Dev 
11, 1098-1110. 
Cantalupo, P., Doering, A., Sullivan, C.S., Pal, A., Peden, K.W., Lewis, A.M., and Pipas, J.M. 
(2005). Complete nucleotide sequence of polyomavirus SA12. J Virol 79, 13094-13104. 
Cantalupo, P., Saenz-Robles, M.T., and Pipas, J.M. (1999). Expression of SV40 large T antigen 
in baculovirus systems and purification by immunoaffinity chromatography. Methods 
Enzymol 306, 297-307. 
Cantalupo, P.G., Saenz-Robles, M.T., Rathi, A.V., Beerman, R.W., Patterson, W.H., 
Whitehead, R.H., and Pipas, J.M. (2009). Cell-type specific regulation of gene 
expression by simian virus 40 T antigens. Virology 386, 183-191. 
  175 
Canzonetti, A.J., and Dalley, M.M. (1952). Bacteriologic survey of scrub technics with special 
emphasis on Phisoderm with 3 per cent hexachlorophene. Ann Surg 135, 228-233. 
Carbone, M., Rudzinski, J., and Bocchetta, M. (2003). High throughput testing of the SV40 
Large T antigen binding to cellular p53 identifies putative drugs for the treatment of 
SV40-related cancers. Virology 315, 409-414. 
Carmichael, G., Schaffhausen, B.S., Mandel, G., Liang, T.J., and Benjamin, T.L. (1984). 
Transformation by polyoma virus is drastically reduced by substitution of phenylalanine 
for tyrosine at residue 315 of middle-sized tumor antigen. Proc Natl Acad Sci U S A 81, 
679-683. 
Castellino, A.M., Cantalupo, P., Marks, I.M., Vartikar, J.V., Peden, K.W., and Pipas, J.M. 
(1997). trans-Dominant and non-trans-dominant mutant simian virus 40 large T antigens 
show distinct responses to ATP. J Virol 71, 7549-7559. 
Cettomai, D., and McArthur, J.C. (2009). Mirtazapine use in human immunodeficiency virus-
infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 66, 
255-258. 
Chang, L., Bertelsen, E.B., Wisen, S., Larsen, E.M., Zuiderweg, E.R., and Gestwicki, J.E. 
(2008). High-throughput screen for small molecules that modulate the ATPase activity 
of the molecular chaperone DnaK. Anal Biochem 372, 167-176. 
Charter, N.W., Kauffman, L., Singh, R., and Eglen, R.M. (2006). A generic, homogenous 
method for measuring kinase and inhibitor activity via adenosine 5'-diphosphate 
accumulation. J Biomol Screen 11, 390-399. 
Charter, N.W., Kauffman, L., Singh, R., Eglen, R.M. (2006). A Generic, Homogenous Method 
for Measuring Kinase and Inhibitor Activity via Adenosine 5'-Diphosphate 
Accumulation. J Biomol Screen 11, 390-399. 
Chen, C.H., Wen, M.C., Wang, M., Lian, J.D., Wu, M.J., Cheng, C.H., Shu, K.H., and Chang, 
D. (2001). A regulatory region rearranged BK virus is associated with tubulointerstitial 
nephritis in a rejected renal allograft. J Med Virol 64, 82-88. 
Chen, X.S., Stehle, T., and Harrison, S.C. (1998). Interaction of polyomavirus internal protein 
VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral 
entry. EMBO J 17, 3233-3240. 
Chen, Y.R., Lees-Miller, S.P., Tegtmeyer, P., and Anderson, C.W. (1991). The human DNA-
activated protein kinase phosphorylates simian virus 40 T antigen at amino- and 
carboxy-terminal sites. J Virol 65, 5131-5140. 
Chiang, A.N., Valderramos, J.C., Balachandran, R., Chovatiya, R.J., Mead, B.P., Schneider, C., 
Bell, S.L., Klein, M.G., Huryn, D.M., Chen, X.S., et al. (2009). Select pyrimidinones 
inhibit the propagation of the malarial parasite, Plasmodium falciparum. Bioorg Med 
Chem 17, 1527-1533. 
  176 
Chiang, L.C., Silnutzer, J., Pipas, J.M., and Barnes, D.W. (1985). Selection of transformed cells 
in serum-free media. In Vitro Cell Dev Biol 21, 707-712. 
Chong, J.L., Wenzel, P.L., Saenz-Robles, M.T., Nair, V., Ferrey, A., Hagan, J.P., Gomez, Y.M., 
Sharma, N., Chen, H.Z., Ouseph, M., et al. (2009). E2f1-3 switch from activators in 
progenitor cells to repressors in differentiating cells. Nature 462, 930-934. 
Chou, T.F., Brown, S.J., Minond, D., Nordin, B.E., Li, K., Jones, A.C., Chase, P., Porubsky, 
P.R., Stoltz, B.M., Schoenen, F.J., et al. (2011). Reversible inhibitor of p97, DBeQ, 
impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl 
Acad Sci U S A 108, 4834-4839. 
Chromy, L.R., Oltman, A., Estes, P.A., and Garcea, R.L. (2006). Chaperone-mediated in vitro 
disassembly of polyoma- and papillomaviruses. J Virol 80, 5086-5091. 
Chromy, L.R., Pipas, J.M., and Garcea, R.L. (2003). Chaperone-mediated in vitro assembly of 
Polyomavirus capsids. Proc Natl Acad Sci U S A 100, 10477-10482. 
Clever, J., Dean, D.A., and Kasamatsu, H. (1993). Identification of a DNA binding domain in 
simian virus 40 capsid proteins Vp2 and Vp3. J Biol Chem 268, 20877-20883. 
Cole, C. (1996). Polyomavirinae: The Viruses and Their Replication. In Feilds Virology, B.N. 
Fields, D.M. Knipe, and P.M. Howley, eds. (Philadelphia, PA, Lippincott - Raven 
Publishers). 
Cole, C.N., Crawford, L.V., and Berg, P. (1979). Simian virus 40 mutants with deletions at the 
3' end of the early region are defective in adenovirus helper function. J Virol 30, 683-
691. 
Cole, C.N., and Stacy, T.P. (1987). Biological properties of simian virus 40 host range mutants 
lacking the COOH-terminus of large T antigen. Virology 161, 170-180. 
Corbett, J.R., and Goose, A.J. (1971). The biochemical mode of action of the fasciolicides 
nitroxynil, hexachlorophane and oxyclozanide. Biochem J 121, 41P. 
Cory, A.H., Owen, T.C., Barltrop, J.A., and Cory, J.G. (1991). Use of an aqueous soluble 
tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3, 207-
212. 
Cotsiki, M., Lock, R., Cheng, Y., Williams, G., Zhao, J., Perera, D., Freire, R., Entwistle, A., 
Golemis, E., Roberts, T., et al. (2004). Simian virus 40 large T antigen targets the 
spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A 101, 947-952. 
Craig, E.A., Huang, P., Aron, R., and Andrew, A. (2006). The diverse roles of J-proteins, the 
obligate Hsp70 co-chaperone. Rev Physiol Biochem Pharmacol 156, 1-21. 
  177 
Crawford, L., Dulbecco, R., Fried, M., Montagnier, L., and Stoker, M. (1964). Cell 
Transformation by Different Forms of Polyoma Virus DNA. Proc Natl Acad Sci U S A 
52, 148-152. 
Cyr, D.M., Lu, X., and Douglas, M.G. (1992). Regulation of Hsp70 function by a eukaryotic 
DnaJ homolog. J Biol Chem 267, 20927-20931. 
Dalianis, T., Ramqvist, T., Andreasson, K., Kean, J.M., and Garcea, R.L. (2009). KI, WU and 
Merkel cell polyomaviruses: a new era for human polyomavirus research. Semin Cancer 
Biol 19, 270-275. 
Dalrymple, S.A., and Beemon, K.L. (1990). BK virus T antigens induce kidney carcinomas and 
thymoproliferative disorders in transgenic mice. J Virol 64, 1182-1191. 
Damania, B., and Pipas, J. (2009). Introduction. In DNA Tumor Viruses, B. Damania, and J. 
Pipas, eds. (New York, NY, Springer Science+Business Media), pp. xvii-xxvi. 
Dang, X., Bialasiewicz, S., Nissen, M.D., Sloots, T.P., Koralnik, I.J., and Tan, C.S. (2011). 
Infrequent Detection of KI, WU and MC Polyomaviruses in Immunosuppressed 
Individuals with or without Progressive Multifocal Leukoencephalopathy. PLoS One 6, 
e16736. 
Daniels, R., Sadowicz, D., and Hebert, D.N. (2007). A very late viral protein triggers the lytic 
release of SV40. PLoS Pathog 3, e98. 
Danna, K., and Nathans, D. (1971). Specific cleavage of simian virus 40 DNA by restriction 
endonuclease of Hemophilus influenzae. Proc Natl Acad Sci U S A 68, 2913-2917. 
Danna, K.J., Sack, G.H., Jr., and Nathans, D. (1973). Studies of simian virus 40 DNA. VII. A 
cleavage map of the SV40 genome. J Mol Biol 78, 363-376. 
De Clercq, E. (2002). Cidofovir in the treatment of poxvirus infections. Antiviral Res 55, 1-13. 
De Clercq, E., Sakuma, T., Baba, M., Pauwels, R., Balzarini, J., Rosenberg, I., and Holy, A. 
(1987). Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and 
pyrimidines. Antiviral Res 8, 261-272. 
De Luca, A., Ammassari, A., Pezzotti, P., Cinque, P., Gasnault, J., Berenguer, J., Di 
Giambenedetto, S., Cingolani, A., Taoufik, Y., Miralles, P., et al. (2008). Cidofovir in 
addition to antiretroviral treatment is not effective for AIDS-associated progressive 
multifocal leukoencephalopathy: a multicohort analysis. AIDS 22, 1759-1767. 
De Luca, A., Giancola, M.L., Cingolani, A., Ammassari, A., Gillini, L., Murri, R., and Antinori, 
A. (1999). Clinical and virological monitoring during treatment with intrathecal 
cytarabine in patients with AIDS-associated progressive multifocal 
leukoencephalopathy. Clin Infect Dis 28, 624-628. 
  178 
de Villiers, J., Olson, L., Tyndall, C., and Schaffner, W. (1982). Transcriptional 'enhancers' 
from SV40 and polyoma virus show a cell type preference. Nucleic Acids Res 10, 7965-
7976. 
DeAngelis, T., Chen, J., Wu, A., Prisco, M., and Baserga, R. (2006). Transformation by the 
simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling. Oncogene 
25, 32-42. 
Deb, S., DeLucia, A.L., Baur, C.P., Koff, A., and Tegtmeyer, P. (1986). Domain structure of the 
simian virus 40 core origin of replication. Mol Cell Biol 6, 1663-1670. 
Deb, S., Tsui, S., Koff, A., DeLucia, A.L., Parsons, R., and Tegtmeyer, P. (1987). The T-
antigen-binding domain of the simian virus 40 core origin of replication. J Virol 61, 
2143-2149. 
DeCaprio, J.A. (2009). How the Rb tumor suppressor structure and function was revealed by the 
study of Adenovirus and SV40. Virology 384, 274-284. 
DeCaprio, J.A., Ludlow, J.W., Figge, J., Shew, J.Y., Huang, C.M., Lee, W.H., Marsilio, E., 
Paucha, E., and Livingston, D.M. (1988). SV40 large tumor antigen forms a specific 
complex with the product of the retinoblastoma susceptibility gene. Cell 54, 275-283. 
DeLeo, A.B., Jay, G., Appella, E., Dubois, G.C., Law, L.W., and Old, L.J. (1979). Detection of 
a transformation-related antigen in chemically induced sarcomas and other transformed 
cells of the mouse. Proc Natl Acad Sci U S A 76, 2420-2424. 
Dhar, R., Subramanian, K.N., Pan, J., and Weissman, S.M. (1977). Structure of a large segment 
of the genome of simian virus 40 that does not encode known proteins. Proc Natl Acad 
Sci U S A 74, 827-831. 
Dharnidharka, V.R., Cherikh, W.S., and Abbott, K.C. (2009). An OPTN analysis of national 
registry data on treatment of BK virus allograft nephropathy in the United States. 
Transplantation 87, 1019-1026. 
Dong, S., Terasaka, S., and Kiyama, R. (2011). Bisphenol A induces a rapid activation of 
Erk1/2 through GPR30 in human breast cancer cells. Environ Pollut 159, 212-218. 
Dulbecco, R. (1975). Renato Dulbecco - Autobiography. In Nobel Lectures, W. Odelberg, ed. 
(Stockholm, The Nobel Foundation). 
Dulbecco, R., Hartwell, L.H., and Vogt, M. (1965). Induction of Cellular DNA Synthesis by 
Polyoma Virus. Proc Natl Acad Sci U S A 53, 403-410. 
Dulbecco, R., and Vogt, M. (1963). Evidence for a Ring Structure of Polyoma Virus DNA. Proc 
Natl Acad Sci U S A 50, 236-243. 
  179 
Dyson, N., Bernards, R., Friend, S.H., Gooding, L.R., Hassell, J.A., Major, E.O., Pipas, J.M., 
Vandyke, T., and Harlow, E. (1990). Large T antigens of many polyomaviruses are able 
to form complexes with the retinoblastoma protein. J Virol 64, 1353-1356. 
Eash, S., Querbes, W., and Atwood, W.J. (2004). Infection of vero cells by BK virus is 
dependent on caveolae. J Virol 78, 11583-11590. 
Eckner, R., Ludlow, J.W., Lill, N.L., Oldread, E., Arany, Z., Modjtahedi, N., DeCaprio, J.A., 
Livingston, D.M., and Morgan, J.A. (1996). Association of p300 and CBP with simian 
virus 40 large T antigen. Mol Cell Biol 16, 3454-3464. 
Eddy, B.E., Borman, G.S., Berkeley, W.H., and Young, R.D. (1961). Tumors induced in 
hamsters by injection of rhesus monkey kidney cell extracts. Proc Soc Exp Biol Med 
107, 191-197. 
Elfaitouri, A., Hammarin, A.L., and Blomberg, J. (2006). Quantitative real-time PCR assay for 
detection of human polyomavirus infection. J Virol Methods 135, 207-213. 
Eliyahu, D., Raz, A., Gruss, P., Givol, D., and Oren, M. (1984). Participation of p53 cellular 
tumour antigen in transformation of normal embryonic cells. Nature 312, 646-649. 
Elphick, G.F., Querbes, W., Jordan, J.A., Gee, G.V., Eash, S., Manley, K., Dugan, A., Stanifer, 
M., Bhatnagar, A., Kroeze, W.K., et al. (2004). The human polyomavirus, JCV, uses 
serotonin receptors to infect cells. Science 306, 1380-1383. 
Engels, E.A., Frisch, M., Goedert, J.J., Biggar, R.J., and Miller, R.W. (2002). Merkel cell 
carcinoma and HIV infection. Lancet 359, 497-498. 
Engsig, F.N., Hansen, A.B., Omland, L.H., Kronborg, G., Gerstoft, J., Laursen, A.L., Pedersen, 
C., Mogensen, C.B., Nielsen, L., and Obel, N. (2009). Incidence, clinical presentation, 
and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients 
during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect 
Dis 199, 77-83. 
Erler, C., and Novak, J. (2010). Bisphenol a exposure: human risk and health policy. J Pediatr 
Nurs 25, 400-407. 
Faguer, S., Hirsch, H.H., Kamar, N., Guilbeau-Frugier, C., Ribes, D., Guitard, J., Esposito, L., 
Cointault, O., Modesto, A., Lavit, M., et al. (2007). Leflunomide treatment for 
polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 20, 
962-969. 
Fairman, M.P., and Stillman, B. (1988). Cellular factors required for multiple stages of SV40 
DNA replication in vitro. EMBO J 7, 1211-1218. 
Fanning, E., and Zhao, K. (2009). SV40 DNA replication: from the A gene to a nanomachine. 
Virology 384, 352-359. 
  180 
Fanning, E., Zhao, X., and Jiang, X. (2009). Polyomavirus Life Cycle. In DNA Tumor Viruses, 
B. Damania, and J.M. Pipas, eds. (New York, NY, Springer New York). 
Farasati, N.A., Shapiro, R., Vats, A., and Randhawa, P. (2005). Effect of leflunomide and 
cidofovir on replication of BK virus in an in vitro culture system. Transplantation 79, 
116-118. 
Feng, H., Shuda, M., Chang, Y., and Moore, P.S. (2008). Clonal integration of a polyomavirus 
in human Merkel cell carcinoma. Science 319, 1096-1100. 
Fewell, S.W., Pipas, J.M., and Brodsky, J.L. (2002). Mutagenesis of a functional chimeric gene 
in yeast identifies mutations in the simian virus 40 large T antigen J domain. Proc Natl 
Acad Sci U S A 99, 2002-2007. 
Fewell, S.W., Smith, C.M., Lyon, M.A., Dumitrescu, T.P., Wipf, P., Day, B.W., and Brodsky, 
J.L. (2004). Small molecule modulators of endogenous and co-chaperone-stimulated 
Hsp70 ATPase activity. J Biol Chem 279, 51131-51140. 
Fiers, W., Contreras, R., Haegemann, G., Rogiers, R., Van de Voorde, A., Van Heuverswyn, H., 
Van Herreweghe, J., Volckaert, G., and Ysebaert, M. (1978). Complete nucleotide 
sequence of SV40 DNA. Nature 273, 113-120. 
Finlay, C.A., Hinds, P.W., and Levine, A.J. (1989). The p53 proto-oncogene can act as a 
suppressor of transformation. Cell 57, 1083-1093. 
Fradet-Turcotte, A., Morin, G., Lehoux, M., Bullock, P.A., and Archambault, J. (2010). 
Development of quantitative and high-throughput assays of polyomavirus and 
papillomavirus DNA replication. Virology 399, 65-76. 
Frearson, P.M., Kit, S., and Dubbs, D.R. (1966). Induction of dihydrofolate reductase activity 
by SV40 and polyoma virus. Cancer Res 26, 1653-1660. 
Friend, S.H., Bernards, R., Rogelj, S., Weinberg, R.A., Rapaport, J.M., Albert, D.M., and Dryja, 
T.P. (1986). A human DNA segment with properties of the gene that predisposes to 
retinoblastoma and osteosarcoma. Nature 323, 643-646. 
Fujimura, F.K., Deininger, P.L., Friedmann, T., and Linney, E. (1981). Mutation near the 
polyoma DNA replication origin permits productive infection of F9 embryonal 
carcinoma cells. Cell 23, 809-814. 
Fung, Y.K., Murphree, A.L., T'Ang, A., Qian, J., Hinrichs, S.H., and Benedict, W.F. (1987). 
Structural evidence for the authenticity of the human retinoblastoma gene. Science 236, 
1657-1661. 
Furuse, Y., Suzuki, A., Kishi, M., Galang, H.O., Lupisan, S.P., Olveda, R.M., and Oshitani, H. 
(2010). Detection of novel respiratory viruses from influenza-like illness in the 
Philippines. J Med Virol 82, 1071-1074. 
  181 
Gardner, S.D., Field, A.M., Coleman, D.V., and Hulme, B. (1971). New human papovavirus 
(B.K.) isolated from urine after renal transplantation. Lancet 1, 1253-1257. 
Garneski, K.M., Warcola, A.H., Feng, Q., Kiviat, N.B., Leonard, J.H., and Nghiem, P. (2009). 
Merkel cell polyomavirus is more frequently present in North American than Australian 
Merkel cell carcinoma tumors. J Invest Dermatol 129, 246-248. 
Gasnault, J., Taoufik, Y., Goujard, C., Kousignian, P., Abbed, K., Boue, F., Dussaix, E., and 
Delfraissy, J.F. (1999). Prolonged survival without neurological improvement in patients 
with AIDS-related progressive multifocal leukoencephalopathy on potent combined 
antiretroviral therapy. J Neurovirol 5, 421-429. 
Gaynor, A.M., Nissen, M.D., Whiley, D.M., Mackay, I.M., Lambert, S.B., Wu, G., Brennan, 
D.C., Storch, G.A., Sloots, T.P., and Wang, D. (2007). Identification of a novel 
polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 3, e64. 
Ge, H., and Manley, J.L. (1990). A protein factor, ASF, controls cell-specific alternative 
splicing of SV40 early pre-mRNA in vitro. Cell 62, 25-34. 
Gerber, P., and Kirschstein, R.L. (1962). SV40-induced ependymomas in newborn hamsters. I. 
Virus-tumor relationships. Virology 18, 582-588. 
Germond, J.E., Hirt, B., Oudet, P., Gross-Bellark, M., and Chambon, P. (1975). Folding of the 
DNA double helix in chromatin-like structures from simian virus 40. Proc Natl Acad Sci 
U S A 72, 1843-1847. 
Gershon, D., Hausen, P., Sachs, L., and Winocour, E. (1965). On the mechanism of polyoma 
virus-induced synthesis of cellular DNA. Proc Natl Acad Sci U S A 54, 1584-1592. 
Gething, M.J., and Sambrook, J. (1992). Protein folding in the cell. Nature 355, 33-45. 
Giacherio, D., and Hager, L.P. (1979). A poly(dT)-stimulated ATPase activity associated with 
simian virus 40 large T antigen. J Biol Chem 254, 8113-8116. 
Giacherio, D., and Hager, L.P. (1980). A specific DNA unwinding activity associated with 
SV40 large T antigen. J Biol Chem 255, 8963-8966. 
Gidoni, D., Scheller, A., Barnet, B., Hantzopoulos, P., Oren, M., and Prives, C. (1982). 
Different forms of simian virus 40 large tumor antigen varying in their affinities for 
DNA. J Virol 42, 456-466. 
Gilbert, J., and Benjamin, T. (2004). Uptake pathway of polyomavirus via ganglioside GD1a. J 
Virol 78, 12259-12267. 
Gilden, R.V., Carp, R.I., Taguchi, F., and Defend, V. (1965). The Nature and Localization of 
the Sv 40-Induced Complement-Fixing Antigen. Proc Natl Acad Sci U S A 53, 684-692. 
  182 
Giraldi, C., Noto, A., Tenuta, R., Greco, F., Perugini, D., Dodaro, S., Spadafora, M., Lo Bianco, 
A.M., Savino, O., Papalia, T., et al. (2007). Prospective study of BKV nephropathy in 
117 renal transplant recipients. New Microbiol 30, 127-130. 
Girardi, A.J., Jensen, F.C., and Koprowski, H. (1965). Sv40-Induced Tranformation of Human 
Diploid Cells: Crisis and Recovery. J Cell Physiol 65, 69-83. 
Gjoerup, O., and Chang, Y. (2010). Update on human polyomaviruses and cancer. Adv Cancer 
Res 106, 1-51. 
Gjorup, O.V., Rose, P.E., Holman, P.S., Bockus, B.J., and Schaffhausen, B.S. (1994). Protein 
domains connect cell cycle stimulation directly to initiation of DNA replication. Proc 
Natl Acad Sci U S A 91, 12125-12129. 
Goodwin, E.C., Atwood, W.J., and DiMaio, D. (2009). High-throughput cell-based screen for 
chemicals that inhibit infection by simian virus 40 and human polyomaviruses. J Virol 
83, 5630-5639. 
Goorha, R., Granoff, A., Willis, D.B., and Murti, K.G. (1984). The role of DNA methylation in 
virus replication: inhibition of frog virus 3 replication by 5-azacytidine. Virology 138, 
94-102. 
Gordon-Shaag, A., Yosef, Y., Abd El-Latif, M., and Oppenheim, A. (2003). The abundant 
nuclear enzyme PARP participates in the life cycle of simian virus 40 and is stimulated 
by minor capsid protein VP3. J Virol 77, 4273-4282. 
Gotz, C., Koenig, M.G., Issinger, O.G., and Montenarh, M. (1995). A casein-kinase-2-related 
protein kinase is tightly associated with the large T antigen of simian virus 40. Eur J 
Biochem 233, 327-334. 
Graffi, A., Schramm, T., Graffi, I., Bierwolf, D., and Bender, E. (1968). Virus-associated skin 
tumors of the Syrian hamster: preliminary note. J Natl Cancer Inst 40, 867-873. 
Gray, F., Chretien, F., Vallat-Decouvelaere, A.V., and Scaravilli, F. (2003). The changing 
pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 62, 429-
440. 
Griffith, J.D. (1975). Chromatin structure: deduced from a minichromosome. Science 187, 
1202-1203. 
Gross, L. (1953). A filterable agent, recovered from Ak leukemic extracts, causing salivary 
gland carcinomas in C3H mice. Proc Soc Exp Biol Med 83, 414-421. 
Grundhoff, A., and Sullivan, C.S. (2011). Virus-encoded microRNAs. Virology 411, 325-343. 
Guerriero, C.J., Weixel, K.M., Bruns, J.R., and Weisz, O.A. (2006). Phosphatidylinositol 5-
kinase stimulates apical biosynthetic delivery via an Arp2/3-dependent mechanism. J 
Biol Chem 281, 15376-15384. 
  183 
Habel, K., Jensen, F., Pagano, J.S., and Koprowski, H. (1965). Specific Complement-Fixing 
Tumor Antigen in Sv40-Transformed Human Cells. Proc Soc Exp Biol Med 118, 4-9. 
Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks, M.W., and 
Weinberg, R.A. (1999). Creation of human tumour cells with defined genetic elements. 
Nature 400, 464-468. 
Hahn, W.C., Dessain, S.K., Brooks, M.W., King, J.E., Elenbaas, B., Sabatini, D.M., DeCaprio, 
J.A., and Weinberg, R.A. (2002). Enumeration of the simian virus 40 early region 
elements necessary for human cell transformation. Mol Cell Biol 22, 2111-2123. 
Halami, M.Y., Dorrestein, G.M., Couteel, P., Heckel, G., Muller, H., and Johne, R. (2010). 
Whole-genome characterization of a novel polyomavirus detected in fatally diseased 
canary birds. J Gen Virol 91, 3016-3022. 
Hall, C.D., Dafni, U., Simpson, D., Clifford, D., Wetherill, P.E., Cohen, B., McArthur, J., 
Hollander, H., Yainnoutsos, C., Major, E., et al. (1998). Failure of cytarabine in 
progressive multifocal leukoencephalopathy associated with human immunodeficiency 
virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338, 1345-1351. 
Harlow, E., Crawford, L.V., Pim, D.C., and Williamson, N.M. (1981). Monoclonal antibodies 
specific for simian virus 40 tumor antigens. J Virol 39, 861-869. 
Harris, K.F., Chang, E., Christensen, J.B., and Imperiale, M.J. (1998). BK virus as a potential 
co-factor in human cancer. Dev Biol Stand 94, 81-91. 
Harris, K.F., Christensen, J.B., and Imperiale, M.J. (1996). BK virus large T antigen: 
interactions with the retinoblastoma family of tumor suppressor proteins and effects on 
cellular growth control. J Virol 70, 2378-2386. 
Hartley, J.W., and Rowe, W.P. (1964). New Papovavirus Contaminating Shope Papillomata. 
Science 143, 258-260. 
Hartwell, L. (2001). Leland Hartwell - Autobiography. In Nobel Lectures, T. Frängsmyr, ed. 
(Stockholm, The Nobel Foundation). 
Hartwell, L.H., Vogt, M., and Dulbecco, R. (1965). Induction of cellular DNA synthesis by 
polyoma virus. II. Increase in the rate of enzyme synthesis after infection with polyoma 
virus in mouse kidney cells. Virology 27, 262-272. 
Haycox, C.L., Kim, S., Fleckman, P., Smith, L.T., Piepkorn, M., Sundberg, J.P., Howell, D.N., 
and Miller, S.E. (1999). Trichodysplasia spinulosa--a newly described folliculocentric 
viral infection in an immunocompromised host. J Investig Dermatol Symp Proc 4, 268-
271. 
Hein, J., Boichuk, S., Wu, J., Cheng, Y., Freire, R., Jat, P.S., Roberts, T.M., and Gjoerup, O.V. 
(2009). Simian virus 40 large T antigen disrupts genome integrity and activates a DNA 
damage response via Bub1 binding. J Virol 83, 117-127. 
  184 
Herbig, U., Weisshart, K., Taneja, P., and Fanning, E. (1999). Interaction of the transcription 
factor TFIID with simian virus 40 (SV40) large T antigen interferes with replication of 
SV40 DNA in vitro. J Virol 73, 1099-1107. 
Hermannstadter, A., Ziegler, C., Kuhl, M., Deppert, W., and Tolstonog, G.V. (2009). Wild-type 
p53 enhances efficiency of simian virus 40 large-T-antigen-induced cellular 
transformation. J Virol 83, 10106-10118. 
Hill, A.B. (1965). The Environment and Disease: Association or Causation? Proc R Soc Med 
58, 295-300. 
Hilton, R., and Tong, C.Y. (2008). Antiviral therapy for polyomavirus-associated nephropathy 
after renal transplantation. J Antimicrob Chemother 62, 855-859. 
Hinds, P., Finlay, C., and Levine, A.J. (1989). Mutation is required to activate the p53 gene for 
cooperation with the ras oncogene and transformation. J Virol 63, 739-746. 
Hinzpeter, M., and Deppert, W. (1987). Analysis of biological and biochemical parameters for 
chromatin and nuclear matrix association of SV40 large T antigen in transformed cells. 
Oncogene 1, 119-129. 
Hirsch, H.H., Knowles, W., Dickenmann, M., Passweg, J., Klimkait, T., Mihatsch, M.J., and 
Steiger, J. (2002). Prospective study of polyomavirus type BK replication and 
nephropathy in renal-transplant recipients. N Engl J Med 347, 488-496. 
Hirsch, H.H., and Randhawa, P. (2009). BK virus in solid organ transplant recipients. Am J 
Transplant 9 Suppl 4, S136-146. 
Hirsch, H.H., and Steiger, J. (2003). Polyomavirus BK. Lancet Infect Dis 3, 611-623. 
Horowitz, J.M., Yandell, D.W., Park, S.H., Canning, S., Whyte, P., Buchkovich, K., Harlow, E., 
Weinberg, R.A., and Dryja, T.P. (1989). Point mutational inactivation of the 
retinoblastoma antioncogene. Science 243, 937-940. 
Hoss, A., Moarefi, I., Scheidtmann, K.H., Cisek, L.J., Corden, J.L., Dornreiter, I., Arthur, A.K., 
and Fanning, E. (1990). Altered phosphorylation pattern of simian virus 40 T antigen 
expressed in insect cells by using a baculovirus vector. J Virol 64, 4799-4807. 
Hou, J., and Major, E.O. (1998). The efficacy of nucleoside analogs against JC virus 
multiplication in a persistently infected human fetal brain cell line. J Neurovirol 4, 451-
456. 
Houben, R., Adam, C., Baeurle, A., Hesbacher, S., Grimm, J., Angermeyer, S., Henzel, K., 
Hauser, S., Elling, R., Brocker, E.B., et al. (2011). An intact retinoblastoma protein 
binding site in merkel cell polyomavirus large T antigen is required for promoting 
growth of merkel cell carcinoma cells. Int J Cancer. 
  185 
Houben, R., Shuda, M., Weinkam, R., Schrama, D., Feng, H., Chang, Y., Moore, P.S., and 
Becker, J.C. (2010). Merkel cell polyomavirus-infected Merkel cell carcinoma cells 
require expression of viral T antigens. J Virol 84, 7064-7072. 
Huang, H., Zhao, K., Arnett, D.R., and Fanning, E. (2010). A specific docking site for DNA 
polymerase {alpha}-primase on the SV40 helicase is required for viral primosome 
activity, but helicase activity is dispensable. J Biol Chem 285, 33475-33484. 
Hubner, S., Xiao, C.Y., and Jans, D.A. (1997). The protein kinase CK2 site (Ser111/112) 
enhances recognition of the simian virus 40 large T-antigen nuclear localization 
sequence by importin. J Biol Chem 272, 17191-17195. 
Huryn, D.M., Brodsky, J.L., Brummond, K.M., Chambers, P.G., Eyer, B., Ireland, A.W., 
Kawasumi, M., Laporte, M.G., Lloyd, K., Manteau, B., et al. (2011). Organic Synthesis 
Toward Small-Molecule Probes and Drugs Special Feature: Chemical methodology as a 
source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) 
modulators. Proc Natl Acad Sci U S A 108, 6757-6762. 
Imperiale, M.J., and Major, E.O. (2007). Polyomaviruses. In Field's Virology, D.M. Knipe, 
P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, and S.E. Straus, eds. 
(Philadelphia, Lippincott Williams & Wilkins). 
Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., and Grove, J.R. 
(1999). MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability 
screening. J Pharm Sci 88, 28-33. 
Ishimi, Y., Sugasawa, K., Hanaoka, F., Eki, T., and Hurwitz, J. (1992). Topoisomerase II plays 
an essential role as a swivelase in the late stage of SV40 chromosome replication in 
vitro. J Biol Chem 267, 462-466. 
Izzedine, H., Launay-Vacher, V., and Deray, G. (2005). Antiviral drug-induced nephrotoxicity. 
Am J Kidney Dis 45, 804-817. 
Jay, G., Nomura, S., Anderson, C.W., and Khoury, G. (1981). Identification of the SV40 
agnogene product: a DNA binding protein. Nature 291, 346-349. 
Jenkins, J.R., Rudge, K., and Currie, G.A. (1984). Cellular immortalization by a cDNA clone 
encoding the transformation-associated phosphoprotein p53. Nature 312, 651-654. 
Jensen, F., Koprowski, H., and Ponten, J.A. (1963). Rapid Transformation of Human Fibroblast 
Cultures by Simian Virus. Proc Natl Acad Sci U S A 50, 343-348. 
Jiang, M., Abend, J.R., Johnson, S.F., and Imperiale, M.J. (2009a). The role of polyomaviruses 
in human disease. Virology 384, 266-273. 
Jiang, M., Abend, J.R., Tsai, B., and Imperiale, M.J. (2009b). Early events during BK virus 
entry and disassembly. J Virol 83, 1350-1358. 
  186 
Johne, R., Buck, C.B., Allander, T., Atwood, W.J., Garcea, R.L., Imperiale, M.J., Major, E.O., 
Ramqvist, T., and Norkin, L.C. (2011). Taxonomical developments in the family 
Polyomaviridae. Arch Virol. 
Johne, R., and Muller, H. (2007). Polyomaviruses of birds: etiologic agents of inflammatory 
diseases in a tumor virus family. J Virol 81, 11554-11559. 
Johne, R., Wittig, W., Fernandez-de-Luco, D., Hofle, U., and Muller, H. (2006). 
Characterization of two novel polyomaviruses of birds by using multiply primed rolling-
circle amplification of their genomes. J Virol 80, 3523-3531. 
Johnston, O., Jaswal, D., Gill, J.S., Doucette, S., Fergusson, D.A., and Knoll, G.A. (2010). 
Treatment of polyomavirus infection in kidney transplant recipients: a systematic 
review. Transplantation 89, 1057-1070. 
Johnston, S.D., Yu, X.M., and Mertz, J.E. (1996). The major transcriptional transactivation 
domain of simian virus 40 large T antigen associates nonconcurrently with multiple 
components of the transcriptional preinitiation complex. J Virol 70, 1191-1202. 
Josephson, M.A., Gillen, D., Javaid, B., Kadambi, P., Meehan, S., Foster, P., Harland, R., 
Thistlethwaite, R.J., Garfinkel, M., Atwood, W., et al. (2006a). Treatment of renal 
allograft polyoma BK virus infection with leflunomide. Transplantation 81, 704-710. 
Josephson, M.A., Williams, J.W., Chandraker, A., and Randhawa, P.S. (2006b). Polyomavirus-
associated nephropathy: update on antiviral strategies. Transpl Infect Dis 8, 95-101. 
Ju, J.S., and Weihl, C.C. (2010). Inclusion body myopathy, Paget's disease of the bone and 
fronto-temporal dementia: a disorder of autophagy. Hum Mol Genet 19, R38-45. 
Kakizuka, A. (2008). Roles of VCP in human neurodegenerative disorders. Biochem Soc Trans 
36, 105-108. 
Kalderon, D., Richardson, W.D., Markham, A.F., and Smith, A.E. (1984a). Sequence 
requirements for nuclear location of simian virus 40 large-T antigen. Nature 311, 33-38. 
Kalderon, D., Roberts, B.L., Richardson, W.D., and Smith, A.E. (1984b). A short amino acid 
sequence able to specify nuclear location. Cell 39, 499-509. 
Kalderon, D., and Smith, A.E. (1984). In vitro mutagenesis of a putative DNA binding domain 
of SV40 large-T. Virology 139, 109-137. 
Kantola, K., Sadeghi, M., Ewald, M.J., Weissbrich, B., Allander, T., Lindau, C., Andreasson, 
K., Lahtinen, A., Kumar, A., Norja, P., et al. (2010). Expression and serological 
characterization of polyomavirus WUPyV and KIPyV structural proteins. Viral 
Immunol 23, 385-393. 
  187 
Katinka, M., Yaniv, M., Vasseur, M., and Blangy, D. (1980). Expression of polyoma early 
functions in mouse embryonal carcinoma cells depends on sequence rearrangements in 
the beginning of the late region. Cell 20, 393-399. 
Katoh, H., Ogawa, H., Ohya, K., and Fukushi, H. (2010). A review of DNA viral infections in 
psittacine birds. J Vet Med Sci 72, 1099-1106. 
Kean, J.M., and Garcea, R. (2009). Polyomaviruses and Disease. In DNA Tumor Viruses, B. 
Damania, and J. Pipas, eds. (New York, NY, Springer Science+Business Media, LLC), 
pp. 53-74. 
Kean, J.M., Rao, S., Wang, M., and Garcea, R.L. (2009). Seroepidemiology of human 
polyomaviruses. PLoS Pathog 5, e1000363. 
Kelley, W.L., and Georgopoulos, C. (1997). The T/t common exon of simian virus 40, JC, and 
BK polyomavirus T antigens can functionally replace the J-domain of the Escherichia 
coli DnaJ molecular chaperone. Proc Natl Acad Sci U S A 94, 3679-3684. 
Khalili, K., White, M.K., Sawa, H., Nagashima, K., and Safak, M. (2005). The agnoprotein of 
polyomaviruses: a multifunctional auxiliary protein. J Cell Physiol 204, 1-7. 
Khanna, N., Elzi, L., Mueller, N.J., Garzoni, C., Cavassini, M., Fux, C.A., Vernazza, P., 
Bernasconi, E., Battegay, M., and Hirsch, H.H. (2009). Incidence and outcome of 
progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort 
Study. Clin Infect Dis 48, 1459-1466. 
Khopde, S., and Simmons, D.T. (2008). Simian virus 40 DNA replication is dependent on an 
interaction between topoisomerase I and the C-terminal end of T antigen. J Virol 82, 
1136-1145. 
Khoury, G., Martin, M.A., Lee, T.N., Danna, K.J., and Nathans, D. (1973). A map of simian 
virus 40 transcription sites expressed in productively infected cells. J Mol Biol 78, 377-
389. 
Kierstead, T.D., and Tevethia, M.J. (1993). Association of p53 binding and immortalization of 
primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants 
bearing internal overlapping deletion mutations. J Virol 67, 1817-1829. 
Kilham, L. (1952). Isolation in suckling mice of a virus from C3H mice harboring Bittner milk 
agent. Science 116, 391-392. 
Kim, H.Y., Ahn, B.Y., and Cho, Y. (2001). Structural basis for the inactivation of 
retinoblastoma tumor suppressor by SV40 large T antigen. EMBO J 20, 295-304. 
Kim, J.S. (1970). Treatment of Paragonimus westermani infections with bithionol. Am J Trop 
Med Hyg 19, 940-942. 
  188 
Kim, K., Son, T.G., Kim, S.J., Kim, H.S., Kim, T.S., Han, S.Y., and Lee, J. (2007). Suppressive 
effects of bisphenol A on the proliferation of neural progenitor cells. J Toxicol Environ 
Health A 70, 1288-1295. 
Kimbrough, R.D. (1973). Review of the toxicity of hexachlorophene, including its 
neurotoxicity. J Clin Pharmacol 13, 439-444. 
Kimura, G., and Dulbecco, R. (1973). A temperature-sensitive mutant of simian virus 40 
affecting transforming ability. Virology 52, 529-534. 
Kimura, G., and Itagaki, A. (1975). Initiation and maintenance of cell transformation by simian 
virus 40: a viral genetic property. Proc Natl Acad Sci U S A 72, 673-677. 
Kirschstein, R.L., and Gerber, P. (1962). Ependymomas produced after intracerebral inoculation 
of SV40 into new-born hamsters. Nature 195, 299-300. 
Kit, S., Piekarski, L.J., and Dubbs, D.R. (1967). DNA polymerase induced by Simian virus 40. J 
Gen Virol 1, 163-173. 
Klein, G., Powers, A., and Croce, C. (2002). Association of SV40 with human tumors. 
Oncogene 21, 1141-1149. 
Klockmann, U., and Deppert, W. (1983). Acylated simian virus 40 large T-antigen: a new 
subclass associated with a detergent-resistant lamina of the plasma membrane. EMBO J 
2, 1151-1157. 
Knudson, A.G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl 
Acad Sci U S A 68, 820-823. 
Kondo, M., Kojima, S., Kato, K., and Matsuyama, T. (1998). Late-onset hemorrhagic cystitis 
after hematopoietic stem cell transplantation in children. Bone Marrow Transplant 22, 
995-998. 
Koonin, E.V. (1993). A common set of conserved motifs in a vast variety of putative nucleic 
acid-dependent ATPases including MCM proteins involved in the initiation of 
eukaryotic DNA replication. Nucleic Acids Res 21, 2541-2547. 
Koprowski, H., Ponten, J., Jensen, F., Ravdin, R.G., Moorhead, P., and Saksela, E. (1963). 
Transformation of cultures of human tissue infected with simian virus SV40. Acta Unio 
Int Contra Cancrum 19, 362-367. 
Kress, M., May, E., Cassingena, R., and May, P. (1979). Simian virus 40-transformed cells 
express new species of proteins precipitable by anti-simian virus 40 tumor serum. J 
Virol 31, 472-483. 
Kress, M., Resche-Rigon, M., and Feunteun, J. (1982). Phosphorylation pattern of large T 
antigens in mouse cells infected by simian virus 40 wild type or deletion mutants. J 
Virol 43, 761-771. 
  189 
Kunisaki, K.M., and Janoff, E.N. (2009). Influenza in immunosuppressed populations: a review 
of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9, 
493-504. 
Kunitake, T., Kitamura, T., Guo, J., Taguchi, F., Kawabe, K., and Yogo, Y. (1995). Parent-to-
child transmission is relatively common in the spread of the human polyomavirus JC 
virus. J Clin Microbiol 33, 1448-1451. 
Lane, D.P., and Crawford, L.V. (1979). T antigen is bound to a host protein in SV40-
transformed cells. Nature 278, 261-263. 
Lanford, R.E., and Butel, J.S. (1984). Construction and characterization of an SV40 mutant 
defective in nuclear transport of T antigen. Cell 37, 801-813. 
Lange-Mutschler, J., and Henning, R. (1984). Cell surface binding simian virus 40 large T 
antigen becomes anchored and stably linked to lipid of the target cells. Virology 136, 
404-413. 
Lauring, A.S., and Andino, R. (2010). Quasispecies theory and the behavior of RNA viruses. 
PLoS Pathog 6, e1001005. 
Lazarus, H.M., Sporn, M.B., Smith, J.M., and Henderson, W.R. (1967). Purification of T 
antigen from nuclei of simian virus 40-induced hamster tumors. J Virol 1, 1093-1095. 
Lee, O.J., and Kim, T.H. (2006). Indirect evidence of ectopic pancreatic fascioliasis in a human. 
J Gastroenterol Hepatol 21, 1631-1633. 
Lee, S.H., Eki, T., and Hurwitz, J. (1989). Synthesis of DNA containing the simian virus 40 
origin of replication by the combined action of DNA polymerases alpha and delta. Proc 
Natl Acad Sci U S A 86, 7361-7365. 
Lee, S.H., and Hurwitz, J. (1990). Mechanism of elongation of primed DNA by DNA 
polymerase delta, proliferating cell nuclear antigen, and activator 1. Proc Natl Acad Sci 
U S A 87, 5672-5676. 
Lee, W.H., Bookstein, R., Hong, F., Young, L.J., Shew, J.Y., and Lee, E.Y. (1987). Human 
retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235, 
1394-1399. 
Leung, A.Y., Chan, M.T., Yuen, K.Y., Cheng, V.C., Chan, K.H., Wong, C.L., Liang, R., Lie, 
A.K., and Kwong, Y.L. (2005). Ciprofloxacin decreased polyoma BK virus load in 
patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect 
Dis 40, 528-537. 
Levine, A.J. (2009). The common mechanisms of transformation by the small DNA tumor 
viruses: The inactivation of tumor suppressor gene products: p53. Virology 384, 285-
293. 
  190 
Li, D., Zhao, R., Lilyestrom, W., Gai, D., Zhang, R., DeCaprio, J.A., Fanning, E., Jochimiak, 
A., Szakonyi, G., and Chen, X.S. (2003). Structure of the replicative helicase of the 
oncoprotein SV40 large tumour antigen. Nature 423, 512-518. 
Li, J.J., and Kelly, T.J. (1984). Simian virus 40 DNA replication in vitro. Proc Natl Acad Sci U 
S A 81, 6973-6977. 
Li, M., Smith, C.J., Walker, M.T., and Smith, T.J. (2009). Novel inhibitors complexed with 
glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol 
Chem 284, 22988-23000. 
Liang, H., Wu, X., Yalowich, J.C., and Hasinoff, B.B. (2008). A three-dimensional quantitative 
structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors. 
Mol Pharmacol 73, 686-696. 
Liberek, K., Marszalek, J., Ang, D., Georgopoulos, C., and Zylicz, M. (1991). Escherichia coli 
DnaJ and GrpE heat shock proteins jointly stimulate ATPase activity of DnaK. Proc Natl 
Acad Sci U S A 88, 2874-2878. 
Liddington, R.C., Yan, Y., Moulai, J., Sahli, R., Benjamin, T.L., and Harrison, S.C. (1991). 
Structure of simian virus 40 at 3.8-A resolution. Nature 354, 278-284. 
Lill, N.L., Tevethia, M.J., Eckner, R., Livingston, D.M., and Modjtahedi, N. (1997). p300 
family members associate with the carboxyl terminus of simian virus 40 large tumor 
antigen. J Virol 71, 129-137. 
Lilyestrom, W., Klein, M.G., Zhang, R., Joachimiak, A., and Chen, X.S. (2006). Crystal 
structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein 
and a cellular tumor suppressor. Genes Dev 20, 2373-2382. 
Lin, H.J., Upson, R.H., and Simmons, D.T. (1992). Nonspecific DNA binding activity of simian 
virus 40 large T antigen: evidence for the cooperation of two regions for full activity. J 
Virol 66, 5443-5452. 
Linzer, D.I., and Levine, A.J. (1979). Characterization of a 54K dalton cellular SV40 tumor 
antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. 
Cell 17, 43-52. 
Liu, X., Hein, J., Richardson, S.C., Basse, P.H., Toptan, T., Moore, P.S., Gjoerup, O.V., and 
Chang, Y. (2011a). Merkel cell polyomavirus large T antigen disrupts lysosome 
clustering by translocating human Vam6p from the cytoplasm to the nucleus. J Biol 
Chem 286, 17079-17090. 
Liu, X., Hein, J., Richardson, S.C., Basse, P.H., Toptan, T., Moore, P.S., Gjoerup, O.V., and 
Chang, Y. (2011b). Merkel cell polyomavirus large T antigen disrupts lysosome 
clustering by translocating human VAM6P to the nucleus. J Biol Chem. 
  191 
Low, J., Humes, H.D., Szczypka, M., and Imperiale, M. (2004). BKV and SV40 infection of 
human kidney tubular epithelial cells in vitro. Virology 323, 182-188. 
Low, J.A., Magnuson, B., Tsai, B., and Imperiale, M.J. (2006). Identification of gangliosides 
GD1b and GT1b as receptors for BK virus. J Virol 80, 1361-1366. 
Lowe, D.B., Shearer, M.H., Aldrich, J.F., Winn, R.E., Jumper, C.A., and Kennedy, R.C. (2010). 
Role of the innate immune response and tumor immunity associated with simian virus 
40 large tumor antigen. J Virol 84, 10121-10130. 
Luo, C., Bueno, M., Kant, J., Martinson, J., and Randhawa, P. (2009). Genotyping schemes for 
polyomavirus BK, using gene-specific phylogenetic trees and single nucleotide 
polymorphism analysis. J Virol 83, 2285-2297. 
Luo, X., Sanford, D.G., Bullock, P.A., and Bachovchin, W.W. (1996). Solution structure of the 
origin DNA-binding domain of SV40 T-antigen. Nat Struct Biol 3, 1034-1039. 
Macpherson, I., and Montagnier, L. (1964). Agar Suspension Culture for the Selective Assay of 
Cells Transformed by Polyoma Virus. Virology 23, 291-294. 
Magnuson, B., Rainey, E.K., Benjamin, T., Baryshev, M., Mkrtchian, S., and Tsai, B. (2005). 
ERp29 triggers a conformational change in polyomavirus to stimulate membrane 
binding. Mol Cell 20, 289-300. 
Mansilla-Soto, J., Yoon-Robarts, M., Rice, W.J., Arya, S., Escalante, C.R., and Linden, R.M. 
(2009). DNA structure modulates the oligomerization properties of the AAV initiator 
protein Rep68. PLoS Pathog 5, e1000513. 
Martin, R.G., and Chou, J.Y. (1975). Simian virus 40 functions required for the establishment 
and maintenance of malignant transformation. J Virol 15, 599-612. 
Marzocchetti, A., Tompkins, T., Clifford, D.B., Gandhi, R.T., Kesari, S., Berger, J.R., Simpson, 
D.M., Prosperi, M., De Luca, A., and Koralnik, I.J. (2009). Determinants of survival in 
progressive multifocal leukoencephalopathy. Neurology 73, 1551-1558. 
Mastrangelo, I.A., Hough, P.V., Wall, J.S., Dodson, M., Dean, F.B., and Hurwitz, J. (1989). 
ATP-dependent assembly of double hexamers of SV40 T antigen at the viral origin of 
DNA replication. Nature 338, 658-662. 
Maxwell, S.A., Ames, S.K., Sawai, E.T., Decker, G.L., Cook, R.G., and Butel, J.S. (1991). 
Simian virus 40 large T antigen and p53 are microtubule-associated proteins in 
transformed cells. Cell Growth Differ 2, 115-127. 
Mayer, M.P., and Bukau, B. (2005). Hsp70 chaperones: cellular functions and molecular 
mechanism. Cell Mol Life Sci 62, 670-684. 
  192 
Mazzarelli, J.M., Atkins, G.B., Geisberg, J.V., and Ricciardi, R.P. (1995). The viral 
oncoproteins Ad5 E1A, HPV16 E7 and SV40 TAg bind a common region of the TBP-
associated factor-110. Oncogene 11, 1859-1864. 
McVey, D., Brizuela, L., Mohr, I., Marshak, D.R., Gluzman, Y., and Beach, D. (1989). 
Phosphorylation of large tumour antigen by cdc2 stimulates SV40 DNA replication. 
Nature 341, 503-507. 
Meinke, G., Bullock, P.A., and Bohm, A. (2006). Crystal structure of the simian virus 40 large 
T-antigen origin-binding domain. J Virol 80, 4304-4312. 
Meinke, G., Phelan, P.J., Fradet-Turcotte, A., Bohm, A., Archambault, J., and Bullock, P.A. 
(2011). Structure-based analysis of the interaction between the simian virus 40 T-antigen 
origin binding domain and single-stranded DNA. J Virol 85, 818-827. 
Melendy, T., and Stillman, B. (1993). An interaction between replication protein A and SV40 T 
antigen appears essential for primosome assembly during SV40 DNA replication. J Biol 
Chem 268, 3389-3395. 
Mercer, W.E., Nelson, D., Hyland, J.K., Croce, C.M., and Baserga, R. (1983). Inhibition of 
SV40-induced cellular DNA synthesis by microinjection of monoclonal antibodies. 
Virology 127, 149-158. 
Miller, S.C., Huang, R., Sakamuru, S., Shukla, S.J., Attene-Ramos, M.S., Shinn, P., Van Leer, 
D., Leister, W., Austin, C.P., and Xia, M. (2010). Identification of known drugs that act 
as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem 
Pharmacol 79, 1272-1280. 
Min, H.J., Cho, I.R., Srisuttee, R., Park, E.H., Cho, D.H., Ahn, J.H., Lee, I.S., Johnston, R.N., 
Oh, S., and Chung, Y.H. (2009). Hexachlorophene suppresses beta-catenin expression 
by up-regulation of Siah-1 in EBV-infected B lymphoma cells. Cancer Lett 276, 136-
142. 
Minguez, J.M., Kim, S.Y., Giuliano, K.A., Balachandran, R., Madiraju, C., Day, B.W., and 
Curran, D.P. (2003). Synthesis and biological assessment of simplified analogues of the 
potent microtubule stabilizer (+)-discodermolide. Bioorg Med Chem 11, 3335-3357. 
Mitchell, P.J., Wang, C., and Tjian, R. (1987). Positive and negative regulation of transcription 
in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell 50, 847-
861. 
Miyata, Y., Chang, L., Bainor, A., McQuade, T.J., Walczak, C.P., Zhang, Y., Larsen, M.J., 
Kirchhoff, P., and Gestwicki, J.E. (2010). High-throughput screen for Escherichia coli 
heat shock protein 70 (Hsp70/DnaK): ATPase assay in low volume by exploiting energy 
transfer. J Biomol Screen 15, 1211-1219. 
Mogensen, T.H. (2009). Pathogen recognition and inflammatory signaling in innate immune 
defenses. Clin Microbiol Rev 22, 240-273, Table of Contents. 
  193 
Monaco, M.C., Jensen, P.N., Hou, J., Durham, L.C., and Major, E.O. (1998). Detection of JC 
virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 72, 
9918-9923. 
Montagnier, L. (2008). Luc Montagnier - Autobiography. In The Nobel Lectures, K. Grandin, 
ed. (Stockholm, The Nobel Foundation). 
Montenarh, M., and Henning, R. (1982). The binding of simian virus 40 large T antigen to the 
polyphosphate backbone of nucleic acids. Biochim Biophys Acta 697, 322-329. 
Mukherjee, S., Kler, S., Oppenheim, A., and Zlotnick, A. (2010). Uncatalyzed assembly of 
spherical particles from SV40 VP1 pentamers and linear dsDNA incorporates both low 
and high cooperativity elements. Virology 397, 199-204. 
Muller, H., and Nitschke, R. (1986). A polyoma-like virus associated with an acute disease of 
fledgling budgerigars (Melopsittacus undulatus). Med Microbiol Immunol 175, 1-13. 
Murakami, Y., Wobbe, C.R., Weissbach, L., Dean, F.B., and Hurwitz, J. (1986). Role of DNA 
polymerase alpha and DNA primase in simian virus 40 DNA replication in vitro. Proc 
Natl Acad Sci U S A 83, 2869-2873. 
Murata, H., Peden, K., and Lewis, A.M., Jr. (2008). Identification of a mutation in the SV40 
capsid protein VP1 that influences plaque morphology, vacuolization, and receptor 
usage. Virology 370, 343-351. 
Murata, H., Teferedegne, B., Lewis, A.M., Jr., and Peden, K. (2009). A quantitative PCR assay 
for SV40 neutralization adaptable for high-throughput applications. J Virol Methods 
162, 236-244. 
Myers, R.M., Kligman, M., and Tjian, R. (1981). Does simian virus 40 T antigen unwind DNA? 
J Biol Chem 256, 10156-10160. 
Nathans, D. (1978). Daniel Nathans - Autobiography. In The Nobel Lectures, W. Odelberg, ed. 
(Stockholm, The Nobel Foundation). 
Neske, F., Blessing, K., Prottel, A., Ullrich, F., Kreth, H.W., and Weissbrich, B. (2009). 
Detection of WU polyomavirus DNA by real-time PCR in nasopharyngeal aspirates, 
serum, and stool samples. J Clin Virol 44, 115-118. 
Neu, U., Stehle, T., and Atwood, W.J. (2009). The Polyomaviridae: Contributions of virus 
structure to our understanding of virus receptors and infectious entry. Virology 384, 
389-399. 
Neuwald, A.F., Aravind, L., Spouge, J.L., and Koonin, E.V. (1999). AAA+: A class of 
chaperone-like ATPases associated with the assembly, operation, and disassembly of 
protein complexes. Genome Res 9, 27-43. 
  194 
Nickeleit, V., Hirsch, H.H., Binet, I.F., Gudat, F., Prince, O., Dalquen, P., Thiel, G., and 
Mihatsch, M.J. (1999). Polyomavirus infection of renal allograft recipients: from latent 
infection to manifest disease. J Am Soc Nephrol 10, 1080-1089. 
Noah, J.W., Severson, W., Noah, D.L., Rasmussen, L., White, E.L., and Jonsson, C.B. (2007). 
A cell-based luminescence assay is effective for high-throughput screening of potential 
influenza antivirals. Antiviral Res 73, 50-59. 
Norkin, L.C., and Kuksin, D. (2005). The caveolae-mediated sv40 entry pathway bypasses the 
golgi complex en route to the endoplasmic reticulum. Virol J 2, 38. 
Oda, K., and Dulbecco, R. (1968a). Induction of cellular mRNA synthesis in BSC-1 cells 
infected by SV40. Virology 35, 439-444. 
Oda, K., and Dulbecco, R. (1968b). Regulation of transcription of the SV40 DNA in 
productively infected and in transformed cells. Proc Natl Acad Sci U S A 60, 525-532. 
OPTN (2009). Annual Report of the U.S. Organ Procurement and Transplantation Network and 
the Scientific Registry of Transplant Recipients: Transplant Data 2000-2009 (United 
Network for Organ Sharing, Richmond, VA; University Renal Research and Education 
Association, Ann Arbor, MI). 
Osborn, M., and Weber, K. (1975). Simian virus 40 gene A function and maintenance of 
transformation. J Virol 15, 636-644. 
Oudet, P., Gross-Bellard, M., and Chambon, P. (1975). Electron microscopic and biochemical 
evidence that chromatin structure is a repeating unit. Cell 4, 281-300. 
Padgett, B.L., Rogers, C.M., and Walker, D.L. (1977). JC virus, a human polyomavirus 
associated with progressive multifocal leukoencephalopathy: additional biological 
characteristics and antigenic relationships. Infect Immun 15, 656-662. 
Padgett, B.L., Walker, D.L., ZuRhein, G.M., Eckroade, R.J., and Dessel, B.H. (1971). 
Cultivation of papova-like virus from human brain with progressive multifocal 
leucoencephalopathy. Lancet 1, 1257-1260. 
Pallas, D.C., Shahrik, L.K., Martin, B.L., Jaspers, S., Miller, T.B., Brautigan, D.L., and Roberts, 
T.M. (1990). Polyoma small and middle T antigens and SV40 small t antigen form 
stable complexes with protein phosphatase 2A. Cell 60, 167-176. 
Parada, L.F., Land, H., Weinberg, R.A., Wolf, D., and Rotter, V. (1984). Cooperation between 
gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312, 649-
651. 
Pastrana, D.V., Tolstov, Y.L., Becker, J.C., Moore, P.S., Chang, Y., and Buck, C.B. (2009). 
Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog 5, 
e1000578. 
  195 
Peden, K.W., and Pipas, J.M. (1985). Site-directed mutagenesis of the simian virus 40 large T-
antigen gene: replication-defective amino acid substitution mutants that retain the ability 
to induce morphological transformation. J Virol 55, 1-9. 
Peden, K.W., and Pipas, J.M. (1992). Simian virus 40 mutants with amino-acid substitutions 
near the amino terminus of large T antigen. Virus Genes 6, 107-118. 
Peden, K.W., Pipas, J.M., Pearson-White, S., and Nathans, D. (1980). Isolation of mutants of an 
animal virus in bacteria. Science 209, 1392-1396. 
Peinemann, F., de Villiers, E.M., Dorries, K., Adams, O., Vogeli, T.A., and Burdach, S. (2000). 
Clinical course and treatment of haemorrhagic cystitis associated with BK type of 
human polyomavirus in nine paediatric recipients of allogeneic bone marrow 
transplants. Eur J Pediatr 159, 182-188. 
Pelkmans, L., Kartenbeck, J., and Helenius, A. (2001). Caveolar endocytosis of simian virus 40 
reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 3, 473-483. 
Pellikainen, J.M., and Kosma, V.M. (2007). Activator protein-2 in carcinogenesis with a special 
reference to breast cancer--a mini review. Int J Cancer 120, 2061-2067. 
Pennica, D., Goeddel, D.V., Hayflick, J.S., Reich, N.C., Anderson, C.W., and Levine, A.J. 
(1984). The amino acid sequence of murine p53 determined from a c-DNA clone. 
Virology 134, 477-482. 
Pershouse, M.A., Heivly, S., and Girtsman, T. (2006). The role of SV40 in malignant 
mesothelioma and other human malignancies. Inhal Toxicol 18, 995-1000. 
Persico-DiLauro, M., Martin, R.G., and Livingston, D.M. (1977). Interaction of Simian Virus 
40 chromatin with Simian Virus 40 T-antigen. J Virol 24, 451-460. 
Pho, M.T., Ashok, A., and Atwood, W.J. (2000). JC virus enters human glial cells by clathrin-
dependent receptor-mediated endocytosis. J Virol 74, 2288-2292. 
Pieper, A.A., Verma, A., Zhang, J., and Snyder, S.H. (1999). Poly (ADP-ribose) polymerase, 
nitric oxide and cell death. Trends Pharmacol Sci 20, 171-181. 
Pipas, J.M. (1985). Mutations near the carboxyl terminus of the simian virus 40 large tumor 
antigen alter viral host range. J Virol 54, 569-575. 
Pipas, J.M. (1992). Common and unique features of T antigens encoded by the polyomavirus 
group. J Virol 66, 3979-3985. 
Pipas, J.M. (2009). SV40: Cell transformation and tumorigenesis. Virology 384, 294-303. 
Pipas, J.M., Peden, K.W., and Nathans, D. (1983). Mutational analysis of simian virus 40 T 
antigen: isolation and characterization of mutants with deletions in the T-antigen gene. 
Mol Cell Biol 3, 203-213. 
  196 
Ponten, J., Jensen, F., and Koprowski, H. (1963). Morphological and virological investigation 
of human tissue cultures transformed with SV40. J Cell Comp Physiol 61, 145-163. 
Poulin, D.L., and DeCaprio, J.A. (2006). The carboxyl-terminal domain of large T antigen 
rescues SV40 host range activity in trans independent of acetylation. Virology 349, 212-
221. 
Poulin, D.L., Kung, A.L., and DeCaprio, J.A. (2004). p53 targets simian virus 40 large T 
antigen for acetylation by CBP. J Virol 78, 8245-8253. 
Powell, H.C., and Lampert, P.W. (1973). Bithionol: a possible substitute for hexachlorophene. 
Pediatrics 52, 859-861. 
Prelich, G., Kostura, M., Marshak, D.R., Mathews, M.B., and Stillman, B. (1987). The cell-
cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication 
in vitro. Nature 326, 471-475. 
Price, T.A., Tuazon, C.U., and Simon, G.L. (1993). Fascioliasis: case reports and review. Clin 
Infect Dis 17, 426-430. 
Provost, P.J., and Hilleman, M.R. (1979). Propagation of human hepatitis A virus in cell culture 
in vitro. Proc Soc Exp Biol Med 160, 213-221. 
Rabson, A.S., and Kirschstein, R.L. (1962). Induction of malignancy in vitro in newborn 
hamster kidney tissue infected with simian vacuolating virus (SV40). Proc Soc Exp Biol 
Med 111, 323-328. 
Randhawa, P., Shapiro, R., and Vats, A. (2005a). Quantitation of DNA of polyomaviruses BK 
and JC in human kidneys. J Infect Dis 192, 504-509. 
Randhawa, P., Vats, A., and Shapiro, R. (2005b). Monitoring for polyomavirus BK And JC in 
urine: comparison of quantitative polymerase chain reaction with urine cytology. 
Transplantation 79, 984-986. 
Randhawa, P.S. (2005). Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin 
Infect Dis 41, 1366-1367. 
Rathi, A.V., Cantalupo, P.G., Sarkar, S.N., and Pipas, J.M. (2010). Induction of interferon-
stimulated genes by Simian virus 40 T antigens. Virology 406, 202-211. 
Rathi, A.V., Saenz Robles, M.T., Cantalupo, P.G., Whitehead, R.H., and Pipas, J.M. (2009). 
Simian virus 40 T-antigen-mediated gene regulation in enterocytes is controlled 
primarily by the Rb-E2F pathway. J Virol 83, 9521-9531. 
Rathi, A.V., Saenz Robles, M.T., and Pipas, J.M. (2007). Enterocyte proliferation and intestinal 
hyperplasia induced by simian virus 40 T antigen require a functional J domain. J Virol 
81, 9481-9489. 
  197 
Reddy, V.B., Thimmappaya, B., Dhar, R., Subramanian, K.N., Zain, B.S., Pan, J., Ghosh, P.K., 
Celma, M.L., and Weissman, S.M. (1978). The genome of simian virus 40. Science 200, 
494-502. 
Richter, C.A., Birnbaum, L.S., Farabollini, F., Newbold, R.R., Rubin, B.S., Talsness, C.E., 
Vandenbergh, J.G., Walser-Kuntz, D.R., and vom Saal, F.S. (2007). In vivo effects of 
bisphenol A in laboratory rodent studies. Reprod Toxicol 24, 199-224. 
Rigby, P.W., and Berg, P. (1978). Does simian virus 40 DNA integrate into cellular DNA 
during productive infection? J Virol 28, 475-489. 
Ritchie, B.W., Latimer, K.S., Leonard, J., Pesti, D., Campagnoli, R., and Lukert, P.D. (1998a). 
Safety, immunogenicity, and efficacy of an inactivated avian polyomavirus vaccine. Am 
J Vet Res 59, 143-148. 
Ritchie, B.W., Vaughn, S.B., Leger, J.S., Rich, G.A., Rupiper, D.J., Forgey, G., Greenacre, 
C.B., Latimer, K.S., Pesti, D., Campagnoli, R., et al. (1998b). Use of an inactivated 
virus vaccine to control polyomavirus outbreaks in nine flocks of psittacine birds. J Am 
Vet Med Assoc 212, 685-690. 
Rohaly, G., Korf, K., Dehde, S., and Dornreiter, I. (2010). Simian virus 40 activates ATR-Delta 
p53 signaling to override cell cycle and DNA replication control. J Virol 84, 10727-
10747. 
Roy, R., Trowbridge, P., Yang, Z., Champoux, J.J., and Simmons, D.T. (2003). The cap region 
of topoisomerase I binds to sites near both ends of simian virus 40 T antigen. J Virol 77, 
9809-9816. 
Rubin, B.S. (2011). Bisphenol A: An endocrine disruptor with widespread exposure and 
multiple effects. J Steroid Biochem Mol Biol. 
Rundell, K., Collins, J.K., Tegtmeyer, P., Ozer, H.L., Lai, C.J., and Nathans, D. (1977). 
Identification of simian virus 40 protein A. J Virol 21, 636-646. 
Russell, J.K., and Blalock, J.E. (1984). Vitamin A inhibition of polyoma virus replication. 
Biochem Biophys Res Commun 122, 851-858. 
Sablina, A.A., and Hahn, W.C. (2008). SV40 small T antigen and PP2A phosphatase in cell 
transformation. Cancer Metastasis Rev 27, 137-146. 
Saenz-Robles, M.T., Markovics, J.A., Chong, J.L., Opavsky, R., Whitehead, R.H., Leone, G., 
and Pipas, J.M. (2007). Intestinal hyperplasia induced by simian virus 40 large tumor 
antigen requires E2F2. J Virol 81, 13191-13199. 
Safak, M., and Khalili, K. (2003). An overview: Human polyomavirus JC virus and its 
associated disorders. J Neurovirol 9 Suppl 1, 3-9. 
  198 
Sawai, E.T., and Butel, J.S. (1989). Association of a cellular heat shock protein with simian 
virus 40 large T antigen in transformed cells. J Virol 63, 3961-3973. 
Sawai, E.T., Rasmussen, G., and Butel, J.S. (1994). Construction of SV40 deletion mutants and 
delimitation of the binding domain for heat shock protein to the amino terminus of large 
T-antigen. Virus Res 31, 367-378. 
Schaffhausen, B.S., and Roberts, T.M. (2009). Lessons from polyoma middle T antigen on 
signaling and transformation: A DNA tumor virus contribution to the war on cancer. 
Virology 384, 304-316. 
Scheidtmann, K.H., Buck, M., Schneider, J., Kalderon, D., Fanning, E., and Smith, A.E. (1991). 
Biochemical characterization of phosphorylation site mutants of simian virus 40 large T 
antigen: evidence for interaction between amino- and carboxy-terminal domains. J Virol 
65, 1479-1490. 
Scheidtmann, K.H., Echle, B., and Walter, G. (1982). Simian virus 40 large T antigen is 
phosphorylated at multiple sites clustered in two separate regions. J Virol 44, 116-133. 
Schelhaas, M., Malstrom, J., Pelkmans, L., Haugstetter, J., Ellgaard, L., Grunewald, K., and 
Helenius, A. (2007). Simian Virus 40 Depends on ER Protein Folding and Quality 
Control Factors for Entry into Host Cells. Cell 131, 516-529. 
Schowalter, R.M., Pastrana, D.V., Pumphrey, K.A., Moyer, A.L., and Buck, C.B. (2010). 
Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically 
shed from human skin. Cell Host Microbe 7, 509-515. 
Scott, W.A., Brockman, W.W., and Nathans, D. (1976). Biological activities of deletion 
mutants of simian virus 40. Virology 75, 319-334. 
Scuda, N., Hofmann, J., Calvignac-Spencer, S., Ruprecht, K., Liman, P., Kuhn, J., Hengel, H., 
and Ehlers, B. (2011). A novel human polyomavirus closely related to the African green 
monkey-derived lymphotropic polyomavirus (LPV). J Virol. 
Seber, A., Shu, X.O., Defor, T., Sencer, S., and Ramsay, N. (1999). Risk factors for severe 
hemorrhagic cystitis following BMT. Bone Marrow Transplant 23, 35-40. 
Segel, I.H. (1976). Biochemical calculations : how to solve mathematical problems in general 
biochemistry, 2d edn (New York, Wiley). 
Sencer, S.F., Haake, R.J., and Weisdorf, D.J. (1993). Hemorrhagic cystitis after bone marrow 
transplantation. Risk factors and complications. Transplantation 56, 875-879. 
Seo, B.S., Lee, S.H., Hong, S.T., Hong, S.J., Kim, C.Y., and Lee, H.Y. (1982). Studies On 
Intestinal Trematodes In Korea: V. A Human Case Infected By Fibricola Seoulensis 
(Trematoda: Diplostomatidae). Korean Journal of Parasitology 20, 93-99. 
  199 
Sever, J.L. (1962). Application of a microtechnique to viral serological investigations. J 
Immunol 88, 320-329. 
Shah, K.V. (1996). Polyomaviruses. In Fields Virology, B.N. Fields, D.M. Knipe, and P.M. 
Howley, eds. (Philadelphia, Lippincott - Raven Publishers). 
Sharma, P.M., Gupta, G., Vats, A., Shapiro, R., and Randhawa, P.S. (2007). Polyomavirus BK 
non-coding control region rearrangements in health and disease. J Med Virol 79, 1199-
1207. 
Sharp, C.P., Norja, P., Anthony, I., Bell, J.E., and Simmonds, P. (2009). Reactivation and 
Mutation of Newly Discovered WU, KI, and Merkel Cell Carcinoma Polyomaviruses in 
Immunosuppressed Individuals. J Infect Dis 199, 398-404. 
Sharpe, R.M. (2010). Is it time to end concerns over the estrogenic effects of bisphenol A? 
Toxicol Sci 114, 1-4. 
Shein, H.M., and Enders, J.F. (1962). Transformation induced by simian virus 40 in human 
renal cell cultures. I. Morphology and growth characteristics. Proc Natl Acad Sci U S A 
48, 1164-1172. 
Shein, H.M., Enders, J.F., and Levinthal, J.D. (1962). Transformation induced by simian virus 
40 in human renal cell cultures. II. Cell-virus relationships. Proc Natl Acad Sci U S A 
48, 1350-1357. 
Shein, H.M., Enders, J.F., Levinthal, J.D., and Burket, A.E. (1963). Transformation induced by 
simian virus 40 in newborn Syrian hamster renal cell cultures. Proc Natl Acad Sci U S A 
49, 28-34. 
Shi, Y., Dodson, G.E., Shaikh, S., Rundell, K., and Tibbetts, R.S. (2005). Ataxia-telangiectasia-
mutated (ATM) is a T-antigen kinase that controls SV40 viral replication in vivo. J Biol 
Chem 280, 40195-40200. 
Shimazu, T., Komatsu, Y., Nakayama, K.I., Fukazawa, H., Horinouchi, S., and Yoshida, M. 
(2006). Regulation of SV40 large T-antigen stability by reversible acetylation. 
Oncogene 25, 7391-7400. 
Shivapurkar, N., Wiethege, T., Wistuba, II, Milchgrub, S., Muller, K.M., and Gazdar, A.F. 
(2000). Presence of simian virus 40 sequences in malignant pleural, peritoneal and 
noninvasive mesotheliomas. Int J Cancer 85, 743-745. 
Shivapurkar, N., Wiethege, T., Wistuba, II, Salomon, E., Milchgrub, S., Muller, K.M., Churg, 
A., Pass, H., and Gazdar, A.F. (1999). Presence of simian virus 40 sequences in 
malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem 76, 181-
188. 
  200 
Shortle, D., and Nathans, D. (1978). Local mutagenesis: a method for generating viral mutants 
with base substitutions in preselected regions of the viral genome. Proc Natl Acad Sci U 
S A 75, 2170-2174. 
Shortle, D., and Nathans, D. (1979). Regulatory mutants of simian virus 40: constructed 
mutants with base substitutions at the origin of DNA replication. J Mol Biol 131, 801-
817. 
Shuda, M., Arora, R., Kwun, H.J., Feng, H., Sarid, R., Fernandez-Figueras, M.T., Tolstov, Y., 
Gjoerup, O., Mansukhani, M.M., Swerdlow, S.H., et al. (2009). Human Merkel cell 
polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, 
lymphoid tissues and lymphoid tumors. Int J Cancer 125, 1243-1249. 
Shuda, M., Feng, H., Kwun, H.J., Rosen, S.T., Gjoerup, O., Moore, P.S., and Chang, Y. (2008). 
T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. 
Proc Natl Acad Sci U S A 105, 16272-16277. 
Simmons, D.T. (2000). SV40 large T antigen functions in DNA replication and transformation. 
Adv Virus Res 55, 75-134. 
Simmons, D.T., Chang, C., and Martin, M.A. (1979). Multiple forms of polyoma virus tumor 
antigens from infected and transformed cells. J Virol 29, 881-887. 
Smith, A.E., Kalderon, D., Roberts, B.L., Colledge, W.H., Edge, M., Gillett, P., Markham, A., 
Paucha, E., and Richardson, W.D. (1985). The nuclear location signal. Proc R Soc Lond 
B Biol Sci 226, 43-58. 
Smith, H.S., Scher, C.D., and Todaro, G.J. (1971). Induction of cell division in medium lacking 
serum growth factor by SV40. Virology 44, 359-370. 
Snider, J., Thibault, G., and Houry, W.A. (2008). The AAA+ superfamily of functionally 
diverse proteins. Genome Biol 9, 216. 
So, A.G., and Downey, K.M. (1988). Mammalian DNA polymerases alpha and delta: current 
status in DNA replication. Biochemistry 27, 4591-4595. 
Sontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M., and Mumby, M. (1993). The 
interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map 
kinase pathway and induces cell proliferation. Cell 75, 887-897. 
Soussi, T. (1986). DNA-binding properties of the major structural protein of simian virus 40. J 
Virol 59, 740-742. 
Spence, S.L., and Pipas, J.M. (1994). Simian virus 40 large T antigen host range domain 
functions in virion assembly. J Virol 68, 4227-4240. 
Srinivasan, A., McClellan, A.J., Vartikar, J., Marks, I., Cantalupo, P., Li, Y., Whyte, P., 
Rundell, K., Brodsky, J.L., and Pipas, J.M. (1997). The amino-terminal transforming 
  201 
region of simian virus 40 large T and small t antigens functions as a J domain. Mol Cell 
Biol 17, 4761-4773. 
Stahl, H., Droge, P., and Knippers, R. (1986). DNA helicase activity of SV40 large tumor 
antigen. EMBO J 5, 1939-1944. 
Stahl, H., Droge, P., Zentgraf, H., and Knippers, R. (1985). A large-tumor-antigen-specific 
monoclonal antibody inhibits DNA replication of simian virus 40 minichromosomes in 
an in vitro elongation system. J Virol 54, 473-482. 
Stahl, H., and Knippers, R. (1983). Simian virus 40 large tumor antigen on replicating viral 
chromatin: tight binding and localization on the viral genome. J Virol 47, 65-76. 
Stehle, T., Gamblin, S.J., Yan, Y., and Harrison, S.C. (1996). The structure of simian virus 40 
refined at 3.1 A resolution. Structure 4, 165-182. 
Stehle, T., Yan, Y., Benjamin, T.L., and Harrison, S.C. (1994). Structure of murine 
polyomavirus complexed with an oligosaccharide receptor fragment. Nature 369, 160-
163. 
Stewart, S.E., Eddy, B.E., and Borgese, N. (1958). Neoplasms in mice inoculated with a tumor 
agent carried in tissue culture. J Natl Cancer Inst 20, 1223-1243. 
Stoner, G.L., Alappan, R., Jobes, D.V., Ryschkewitsch, C.F., and Landry, M.L. (2002). BK 
virus regulatory region rearrangements in brain and cerebrospinal fluid from a leukemia 
patient with tubulointerstitial nephritis and meningoencephalitis. Am J Kidney Dis 39, 
1102-1112. 
Stratton, K., Almario, D.A., and McCormick, M.C. (2003). Immunization Safety Review: SV40 
Contamination of Polio Vaccine and Cancer (Washington D.C., The National 
Academies Press). 
Subramanian, K.N. (1982). Effect of in vitro methylation at CpG sites on gene expression in a 
genome functioning autonomously in a vertebrate host. Nucleic Acids Res 10, 3475-
3486. 
Sullivan, C.S., Baker, A.E., and Pipas, J.M. (2004). Simian virus 40 infection disrupts p130-
E2F and p107-E2F complexes but does not perturb pRb-E2F complexes. Virology 320, 
218-228. 
Sullivan, C.S., Cantalupo, P., and Pipas, J.M. (2000). The molecular chaperone activity of 
simian virus 40 large T antigen is required to disrupt Rb-E2F family complexes by an 
ATP-dependent mechanism. Mol Cell Biol 20, 6233-6243. 
Sullivan, C.S., Grundhoff, A.T., Tevethia, S., Pipas, J.M., and Ganem, D. (2005). SV40-
encoded microRNAs regulate viral gene expression and reduce susceptibility to 
cytotoxic T cells. Nature 435, 682-686. 
  202 
Sweet, B.H., and Hilleman, M.R. (1960). The vacuolating virus, S.V. 40. Proc Soc Exp Biol 
Med 105, 420-427. 
Takemoto, K.K., and Segawa, K. (1983). A new monkey lymphotropic papovavirus: 
characterization of the virus and evidence of a related virus in humans. Prog Clin Biol 
Res 105, 87-96. 
Takeuchi, T., Kobayashi, S., Tanabe, M., and Fujiwara, T. (1985). In vitro inhibition of Giardia 
lamblia and Trichomonas vaginalis growth by bithionol, dichlorophene, and 
hexachlorophene. Antimicrob Agents Chemother 27, 65-70. 
Talos, F., and Moll, U.M. (2010). Role of the p53 family in stabilizing the genome and 
preventing polyploidization. Adv Exp Med Biol 676, 73-91. 
Tan, C.S., and Koralnik, I.J. (2010). Progressive multifocal leukoencephalopathy and other 
disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9, 425-
437. 
Tan, Y., Sangfelt, O., and Spruck, C. (2008). The Fbxw7/hCdc4 tumor suppressor in human 
cancer. Cancer Lett 271, 1-12. 
Tanaka, Y., Yoshihara, K., Tohno, Y., Kojima, K., Kameoka, M., and Kamiya, T. (1995). 
Inhibition and down-regulation of poly(ADP-ribose) polymerase results in a marked 
resistance of HL-60 cells to various apoptosis-inducers. Cell Mol Biol (Noisy-le-grand) 
41, 771-781. 
Tegtmeyer, P. (1972). Simian virus 40 deoxyribonucleic acid synthesis: the viral replicon. J 
Virol 10, 591-598. 
Tegtmeyer, P., Lewton, B.A., DeLucia, A.L., Wilson, V.G., and Ryder, K. (1983). Topography 
of simian virus 40 A protein-DNA complexes: arrangement of protein bound to the 
origin of replication. J Virol 46, 151-161. 
Tei, S., Saitoh, N., Funahara, T., Iida, S., Nakatsu, Y., Kinoshita, K., Kinoshita, Y., Saya, H., 
and Nakao, M. (2009). Simian virus 40 large T antigen targets the microtubule-
stabilizing protein TACC2. J Cell Sci 122, 3190-3198. 
Templeton, D., and Eckhart, W. (1984). Characterization of viable mutants of polyomavirus 
cold sensitive for maintenance of cell transformation. J Virol 49, 799-805. 
Testa, J.R., and Giordano, A. (2001). SV40 and cell cycle perturbations in malignant 
mesothelioma. Semin Cancer Biol 11, 31-38. 
Todaro, G.J., and Green, H. (1964). An assay for cellular transformation by SV40. Virology 23, 
117-119. 
Todaro, G.J., and Green, H. (1966). High frequency of SV40 transformation of mouse cell line 
3T3. Virology 28, 756-759. 
  203 
Todaro, G.J., Green, H., and Swift, M.R. (1966). Susceptibility of human diploid fibroblast 
strains to transformation by SV40 virus. Science 153, 1252-1254. 
Tonegawa, S. (1987). Susumu Tonegawa - Autobiography. In The Nobel Prizes 1987, W. 
Odelberg, ed. (Stockholm, The Nobel Foundation). 
Tornow, J., and Cole, C.N. (1983a). Intracistronic complementation in the simian virus 40 A 
gene. Proc Natl Acad Sci U S A 80, 6312-6316. 
Tornow, J., and Cole, C.N. (1983b). Nonviable mutants of simian virus 40 with deletions near 
the 3' end of gene A define a function for large T antigen required after onset of viral 
DNA replication. J Virol 47, 487-494. 
Trowbridge, P.W., and Frisque, R.J. (1995). Identification of three new JC virus proteins 
generated by alternative splicing of the early viral mRNA. J Neurovirol 1, 195-206. 
Tsai, B., Gilbert, J.M., Stehle, T., Lencer, W., Benjamin, T.L., and Rapoport, T.A. (2003). 
Gangliosides are receptors for murine polyoma virus and SV40. EMBO J 22, 4346-
4355. 
Tsukamoto, H., Kawano, M.A., Inoue, T., Enomoto, T., Takahashi, R.U., Yokoyama, N., 
Yamamoto, N., Imai, T., Kataoka, K., Yamaguchi, Y., et al. (2007). Evidence that SV40 
VP1-DNA interactions contribute to the assembly of 40-nm spherical viral particles. 
Genes Cells 12, 1267-1279. 
Tsurimoto, T., Fairman, M.P., and Stillman, B. (1989). Simian virus 40 DNA replication in 
vitro: identification of multiple stages of initiation. Mol Cell Biol 9, 3839-3849. 
Tsurimoto, T., Melendy, T., and Stillman, B. (1990). Sequential initiation of lagging and 
leading strand synthesis by two different polymerase complexes at the SV40 DNA 
replication origin. Nature 346, 534-539. 
Tsurimoto, T., and Stillman, B. (1989). Multiple replication factors augment DNA synthesis by 
the two eukaryotic DNA polymerases, alpha and delta. EMBO J 8, 3883-3889. 
Udall, V. (1972). Drug-induced blindness in some experimental animals and its relevance to 
toxicology. Proc R Soc Med 65, 197-200. 
Unterholzner, L., and Bowie, A.G. (2008). The interplay between viruses and innate immune 
signaling: recent insights and therapeutic opportunities. Biochem Pharmacol 75, 589-
602. 
van der Meijden, E., Janssens, R.W., Lauber, C., Bouwes Bavinck, J.N., Gorbalenya, A.E., and 
Feltkamp, M.C. (2010). Discovery of a new human polyomavirus associated with 
trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog 6, e1001024. 
van Roy, F., Fransen, L., and Fiers, W. (1983). Improved localization of phosphorylation sites 
in simian virus 40 large T antigen. J Virol 45, 315-331. 
  204 
Vats, A., Randhawa, P.S., and Shapiro, R. (2006). Diagnosis and treatment of BK virus-
associated transplant nephropathy. Adv Exp Med Biol 577, 213-227. 
Vogt, M., and Dulbecco, R. (1960). Virus-Cell Interaction with a Tumor-Producing Virus. Proc 
Natl Acad Sci U S A 46, 365-370. 
vom Saal, F.S., Akingbemi, B.T., Belcher, S.M., Birnbaum, L.S., Crain, D.A., Eriksen, M., 
Farabollini, F., Guillette, L.J., Jr., Hauser, R., Heindel, J.J., et al. (2007). Chapel Hill 
bisphenol A expert panel consensus statement: integration of mechanisms, effects in 
animals and potential to impact human health at current levels of exposure. Reprod 
Toxicol 24, 131-138. 
Waga, S., Bauer, G., and Stillman, B. (1994). Reconstitution of complete SV40 DNA 
replication with purified replication factors. J Biol Chem 269, 10923-10934. 
Waga, S., and Stillman, B. (1994). Anatomy of a DNA replication fork revealed by 
reconstitution of SV40 DNA replication in vitro. Nature 369, 207-212. 
Walczak, C.P., and Tsai, B. (2011). A PDI family network acts distinctly and coordinately with 
ERp29 to facilitate polyomavirus infection. J Virol 85, 2386-2396. 
Walsh, P., Bursac, D., Law, Y.C., Cyr, D., and Lithgow, T. (2004). The J-protein family: 
modulating protein assembly, disassembly and translocation. EMBO Rep 5, 567-571. 
Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M., and Barton, G.J. (2009). Jalview 
Version 2--a multiple sequence alignment editor and analysis workbench. 
Bioinformatics 25, 1189-1191. 
Wattier, R.L., Vazquez, M., Weibel, C., Shapiro, E.D., Ferguson, D., Landry, M.L., and Kahn, 
J.S. (2008). Role of human polyomaviruses in respiratory tract disease in young 
children. Emerg Infect Dis 14, 1766-1768. 
Weinberg, D.H., and Kelly, T.J. (1989). Requirement for two DNA polymerases in the 
replication of simian virus 40 DNA in vitro. Proc Natl Acad Sci U S A 86, 9742-9746. 
Weinberg, G.A., and Mian, A.N. (2010). BK virus nephropathy and other polyoma virus 
infections. Pediatr Infect Dis J 29, 257-260. 
Weisshart, K., Bradley, M.K., Weiner, B.M., Schneider, C., Moarefi, I., Fanning, E., and 
Arthur, A.K. (1996). An N-terminal deletion mutant of simian virus 40 (SV40) large T 
antigen oligomerizes incorrectly on SV40 DNA but retains the ability to bind to DNA 
polymerase alpha and replicate SV40 DNA in vitro. J Virol 70, 3509-3516. 
Weisshart, K., Friedl, S., Taneja, P., Nasheuer, H.P., Schlott, B., Grosse, F., and Fanning, E. 
(2004). Partial proteolysis of simian virus 40 T antigen reveals intramolecular contacts 
between domains and conformation changes upon hexamer assembly. J Biol Chem 279, 
38943-38951. 
  205 
Weisshart, K., Taneja, P., and Fanning, E. (1998). The replication protein A binding site in 
simian virus 40 (SV40) T antigen and its role in the initial steps of SV40 DNA 
replication. J Virol 72, 9771-9781. 
Welcker, M., and Clurman, B.E. (2005). The SV40 large T antigen contains a decoy 
phosphodegron that mediates its interactions with Fbw7/hCdc4. J Biol Chem 280, 7654-
7658. 
Westphal, H., and Dulbecco, R. (1968). Viral DNA in polyoma- and SV40-transformed cell 
lines. Proc Natl Acad Sci U S A 59, 1158-1165. 
Wheeler, D.L., Barrett, T., Benson, D.A., Bryant, S.H., Canese, K., Chetvernin, V., Church, 
D.M., DiCuccio, M., Edgar, R., Federhen, S., et al. (2007). Database resources of the 
National Center for Biotechnology Information. Nucleic Acids Res 35, D5-12. 
White, M.K., and Khalili, K. (2006). Interaction of retinoblastoma protein family members with 
large T-antigen of primate polyomaviruses. Oncogene 25, 5286-5293. 
WHO (2008). Annex 1: HIV and AIDS estimates and data, 2007 and 2001. In 2008 Report on 
the Global AIDS epidemic (Geneva, Switzerland, World Health Organization). 
Wickramasinghe, S.R., Inglis, K.A., Urch, J.E., Muller, S., van Aalten, D.M., and Fairlamb, 
A.H. (2006). Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from 
Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. Biochem J 393, 447-
457. 
Williams, G.L., Roberts, T.M., and Gjoerup, O.V. (2007). Bub1: escapades in a cellular world. 
Cell Cycle 6, 1699-1704. 
Wisen, S., Androsavich, J., Evans, C.G., Chang, L., and Gestwicki, J.E. (2008). Chemical 
modulators of heat shock protein 70 (Hsp70) by sequential, microwave-accelerated 
reactions on solid phase. Bioorg Med Chem Lett 18, 60-65. 
Wisen, S., Bertelsen, E.B., Thompson, A.D., Patury, S., Ung, P., Chang, L., Evans, C.G., 
Walter, G.M., Wipf, P., Carlson, H.A., et al. (2010). Binding of a small molecule at a 
protein-protein interface regulates the chaperone activity of hsp70-hsp40. ACS Chem 
Biol 5, 611-622. 
Wisen, S., and Gestwicki, J.E. (2008). Identification of small molecules that modify the protein 
folding activity of heat shock protein 70. Anal Biochem 374, 371-377. 
Wobbe, C.R., Weissbach, L., Borowiec, J.A., Dean, F.B., Murakami, Y., Bullock, P., and 
Hurwitz, J. (1987). Replication of simian virus 40 origin-containing DNA in vitro with 
purified proteins. Proc Natl Acad Sci U S A 84, 1834-1838. 
Wold, M.S., and Kelly, T. (1988). Purification and characterization of replication protein A, a 
cellular protein required for in vitro replication of simian virus 40 DNA. Proc Natl Acad 
Sci U S A 85, 2523-2527. 
  206 
Wold, M.S., Li, J.J., and Kelly, T.J. (1987). Initiation of simian virus 40 DNA replication in 
vitro: large-tumor-antigen- and origin-dependent unwinding of the template. Proc Natl 
Acad Sci U S A 84, 3643-3647. 
Wold, M.S., Weinberg, D.H., Virshup, D.M., Li, J.J., and Kelly, T.J. (1989). Identification of 
cellular proteins required for simian virus 40 DNA replication. J Biol Chem 264, 2801-
2809. 
Wright, C.M., Chovatiya, R.J., Jameson, N.E., Turner, D.M., Zhu, G., Werner, S., Huryn, D.M., 
Pipas, J.M., Day, B.W., Wipf, P., et al. (2008). Pyrimidinone-peptoid hybrid molecules 
with distinct effects on molecular chaperone function and cell proliferation. Bioorg Med 
Chem 16, 3291-3301. 
Wright, C.M., Seguin, S.P., Fewell, S.W., Zhang, H., Ishwad, C., Vats, A., Lingwood, C.A., 
Wipf, P., Fanning, E., Pipas, J.M., et al. (2009). Inhibition of Simian Virus 40 
replication by targeting the molecular chaperone function and ATPase activity of T 
antigen. Virus Res 141, 71-80. 
Wu, J.K., and Harris, M.T. (2008). Use of leflunomide in the treatment of polyomavirus BK-
associated nephropathy. Ann Pharmacother 42, 1679-1685. 
Wu, X., Avni, D., Chiba, T., Yan, F., Zhao, Q., Lin, Y., Heng, H., and Livingston, D. (2004). 
SV40 T antigen interacts with Nbs1 to disrupt DNA replication control. Genes Dev 18, 
1305-1316. 
Wu, X., and Levine, A.J. (1994). p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl 
Acad Sci U S A 91, 3602-3606. 
Wun-Kim, K., and Simmons, D.T. (1990). Mapping of helicase and helicase substrate-binding 
domains on simian virus 40 large T antigen. J Virol 64, 2014-2020. 
Wyatt, A.J., Sachs, D.L., Shia, J., Delgado, R., and Busam, K.J. (2005). Virus-associated 
trichodysplasia spinulosa. Am J Surg Pathol 29, 241-246. 
Xiao, C.Y., Hubner, S., and Jans, D.A. (1997). SV40 large tumor antigen nuclear import is 
regulated by the double-stranded DNA-dependent protein kinase site (serine 120) 
flanking the nuclear localization sequence. J Biol Chem 272, 22191-22198. 
Yang, L., Wold, M.S., Li, J.J., Kelly, T.J., and Liu, L.F. (1987). Roles of DNA topoisomerases 
in simian virus 40 DNA replication in vitro. Proc Natl Acad Sci U S A 84, 950-954. 
Ye, Y., Shibata, Y., Kikkert, M., van Voorden, S., Wiertz, E., and Rapoport, T.A. (2005). 
Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at 
the endoplasmic reticulum membrane. Proc Natl Acad Sci U S A 102, 14132-14138. 
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W.C., 
Stukenberg, P.T., Shenolikar, S., Uchida, T., et al. (2004). A signalling pathway 
  207 
controlling c-Myc degradation that impacts oncogenic transformation of human cells. 
Nat Cell Biol 6, 308-318. 
Yoneda, Y., Arioka, T., Imamoto-Sonobe, N., Sugawa, H., Shimonishi, Y., and Uchida, T. 
(1987). Synthetic peptides containing a region of SV 40 large T-antigen involved in 
nuclear localization direct the transport of proteins into the nucleus. Exp Cell Res 170, 
439-452. 
Yu, J., Boyapati, A., and Rundell, K. (2001). Critical role for SV40 small-t antigen in human 
cell transformation. Virology 290, 192-198. 
Yu, Y., and Alwine, J.C. (2008). Interaction between simian virus 40 large T antigen and insulin 
receptor substrate 1 is disrupted by the K1 mutation, resulting in the loss of large T 
antigen-mediated phosphorylation of Akt. J Virol 82, 4521-4526. 
Zhai, W., Tuan, J.A., and Comai, L. (1997). SV40 large T antigen binds to the TBP-TAF(I) 
complex SL1 and coactivates ribosomal RNA transcription. Genes Dev 11, 1605-1617. 
Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A Simple Statistical Parameter for Use 
in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 
67-73. 
Zhao, L., Qian, Y., Zhu, R., Deng, J., Wang, F., Sun, Y., and Ding, Y. (2010). Identification of 
WU polyomavirus from pediatric patients with acute respiratory infections in Beijing, 
China. Arch Virol 155, 181-186. 
Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W.H., Tom, E., Mack, D.H., 
and Levine, A.J. (2000). The transcriptional program following p53 activation. Cold 
Spring Harb Symp Quant Biol 65, 475-482. 
Zheng, H.Y., Kitamura, T., Takasaka, T., Chen, Q., and Yogo, Y. (2004). Unambiguous 
identification of JC polyomavirus strains transmitted from parents to children. Arch 
Virol 149, 261-273. 
zur Hausen, H. (2008). Harald zur Hausen - Autobiography. In Nobel Lectures, K. Grandin, ed. 
(Stockholm, The Nobel Foundation). 
zur Hausen, H., and Gissmann, L. (1979). Lymphotropic papovaviruses isolated from African 
green monkey and human cells. Med Microbiol Immunol 167, 137-153. 
 
 
